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Chapter 1: Introduction 
1.1. Epidemiology and Diagnosis  
Rheumatoid arthritis (RA) and Axial Spondyloarthritis (SpA) are chronic systemic inflammatory disorders 
that affect the peripheral joints and the spine respectively.  
About 0.5% to 1% of the population has RA [1]. Patients are mostly females and onset is usually 
between 35 and 50 years old [1]. It is typically a poly-articular disease (i.e. 5 or more joints affected) and 
primarily involves the smaller peripheral joints (e.g. wrists, inter-phalangeal joints and the metacarpo- & 
metatarso-phalangeal joints) which are inflamed due to proliferation of the synovium. Persistent 
synovitis leads to progressive destruction of articular structures due to cartilage destruction and 
erosions of the sub-chondral bone resulting in irreversible function loss and disability; Figure 1 [2-4].  
 
FIG. 1: Association of joint damage & inflammation with disability. Adapted from Kirwan JR. J 
Rheumatol. 2001;28:881-886. 
Axial SpA is primarily seen in men and usually starts in the second or third decade. It has a reported 
prevalence ranging from 0.6% to 1.2% of the population and primarily affects the joints of the axial 
skeleton but may also affect some peripheral, large joints such as hips and knees (usually less than 5 
joints affected) and the entheses of the Achilles tendon and plantar fascia [5-7]. The hallmark 
characteristic of AS is sacroiliitis and ankylosis of the spine which can be visualized on conventional X-
rays. This leads to irreversible reduction in the range of motion of the axial skeleton which results in loss 
of function; Figure 2 [8].  
 
FIG. 2: Relationship between imaging findings, range of motion of the axial spine and function. From the 
ASPECT study, unpublished data. 
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For both diseases there have recently been important efforts towards improvement of the criteria for 
diagnosis. The purpose of these revised criteria is to increase sensitivity and specificity to diagnose and 
treat RA and Axial SpA in an early phase of disease. In RA emerging evidence has highlighted a window 
of opportunity during which effective therapy can lead to long-term benefits in outcomes including 
limiting or preventing occurrence of radiographic progression which can no longer be achieved once the 
disease is more established [9]. As such, where the 1987 ACR classification criteria for RA helped to 
correctly identify patients with RA and to minimize misclassification in clinical or epidemiological studies, 
the 2010 diagnostic criteria allow doctors to diagnose an RA patient in the clinic at a time when early 
DMARD therapy is prompted to modify the disease course on the long run; Table 1 [10, 11].  
 
TABLE 1 1987 American College of 
Rheumatology (ACR) Classification 
criteria for rheumatoid arthritis (10) 
2010 ACR/European League Against 
Rheumatism (EULAR) classification criteria for 
early rheumatoid arthritis (11) 
Criteria  1. Morning stiffness (at least 1 hour) 
2. Arthritis in 3 or more joint areas 
3. arthritis of hand joints (>=1 
swollen joints) 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Serum Rheumatoid Factor positive 
7. Radiographic Changes (erosions) 
on X-rays of hands 
1. Joint involvement (score 0 to 5) 
• 1 medium large joint (0) 
• 2 to 10 large joints (1) 
• 1 to 3 small joints (with or without 
involvement of large joints) (2) 
• 4 to10 small joints (with or without 
involvement of large joints) (3) 
• >10 joints (at least 1 small joint) (5) 
2. Serology (score 0-3) 
• Negative Rheumatoid Factor (RF) and 
negative Anti-Citrillunated Protein 
Antigen (ACPA) (0) 
• Low-positive RF or low-positive ACPA (2) 
• High-positive RF or high-positive ACPA 
(3) 
3. Acute-phase reactants (sore 0-1) 
• Normal C-Reactive Protein (CRP) and 
normal Erythrocyte Sedimentation Rate 
(ESR) (0) 
• Abnormal CRP or abnormal ESR (1) 
4. Duration of symptoms (score 0-1) 
• <6 weeks (0) 
• >=6 weeks (1) 
Target All arthritis patients Undifferentiated Arthritis patients  
Results in Classification of RA (yes/no) Classification of early RA (yes/no) 
Positive in 
case 
Four of 7 criteria must be present. 
Criteria 1 through 4 must have been 
present for at least 6 weeks. 
Scoring >=6 points. In the presence of 
erosiveness seen in light of inflammatory 
disorder, no other points need to be obtained for 
the classification of RA. 
Test 
Characte-
ristics 
Sensitivity: 79%-80%, specificity: 
90%-93% for established RA. 
Sensitivity: 77%-80%, specificity 33%-
77% for early RA. 
Sensitivity and specificity for established RA and 
early RA unknown. 
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Similarly, according to the 1984 modified New York criteria for Ankylosing Spondylitis (AS), definite 
disease can only be diagnosed when sacroiliitis is observed on conventional X-rays [12]. Patients without 
X-ray damage but with clinical features have probable AS [12]. X-ray signals only become visible at an 
advanced stage of the disease and usually manifest several years after symptom onset. This frequently 
leads to a long delay in diagnosis and appropriate treatment which prompted the development of new 
classification criteria for Axial SpA allowing earlier recognition and treatment it in clinical practice [13, 
14]. Unlike RA where the need for imaging techniques has been abandoned, imaging with either X-rays 
or Magnetic Resonance remains a diagnostic criterion in Axial SpA, albeit not a mandatory one. See 
Table 2 below. 
 
TABLE 2 1984 Modified New York Criteria for 
Ankylosing Spondylitis (12) 
2009 ASAS Criteria for Axial Spondyloarthritis 
(13, 14) 
Criteria  Clinical criteria: 
• Low back pain and stiffness for 
more than 3 months which 
improves with exercise, but is 
not relieved by rest. 
• Limitation of motion of the 
lumbar spine in the sagittal and 
frontal planes. 
• Limitation of chest expansion 
relative to normal values 
corrected for age and sex. 
Radiological criterion: 
• Sacroiliitis grade >2 bilaterally 
or grade 3–4 unilaterally. 
 
Spondylo-Arthritis features: 
• Inflammatory back pain 
• Arthritis 
• Enthesitis of the heel 
• Uveitis 
• Dactylitis 
• Psoriasis 
• Crohn’s disease or Ulcerative Colitis 
• Good response to Non-Steroidal Anti-
Inflammatory Drugs 
• Family history of SpA 
• Human Leucocyte Antigen-B27 
genotype 
• Elevated CRP (in context of back pain) 
Sacroiliitis on imaging: 
• Active inflammation on MRI highly 
suggestive of sacroiliitis associated 
with SpA  - OR 
• Definite radiographic sacroiliitis 
according to the modified New York 
Criteria 
Target General population Patients with back pain >=3 months and age at 
onset <45 years old. 
Results in Classification of Definite AS (yes/no) or 
Probable AS (yes/no) 
Classification of Axial SpA (yes/no) 
Positive in 
case 
Definite AS if the radiological criterion 
is associated with at least one clinical 
criterion.  
Probable AS if 3 clinical criteria are 
present or the radiological criterion is 
present without any signs or symptoms 
satisfying the clinical criteria. 
Sacroiliitis on imaging plus at least one of the 
above SpA features 
OR 
HLA-B27 genotype positive and at least 2 of 
the SpA features. 
Test Char-
acteristics 
Specificity 83% in healthy controls. Sensitivity of 82.9%, specificity 84.4%. Imaging 
alone: sensitivity 66.2%, specificity 97.3%. 
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In the most recent ASAS classification setting, Axial SpA encompasses both patients with chronic back 
pain in whom radiological signs of sacroiliitis can be measured with conventional X-rays (radiographic 
Axial SpA or AS) and those in whom damage on radiographs cannot be observed (non-radiographic Axial 
SpA). Patients who do not have sacroiliitis nor signs of inflammation of the spine on MRI can still be 
diagnosed with Axial SpA if Human Leucocyte Antigen B27 is present  [13, 14]. 
1.2. Signs, Symptoms and Clinical Disease Assessment  
For both diseases, onset tends to be insidious and the articular (RA) and axial skeletal (Axial SpA) 
symptoms are usually accompanied by systemic symptoms such as fatigue and malaise [15].  
Rheumatoid arthritis 
In RA the hallmark disease feature is synovitis of the peripheral joints and symptoms include early 
morning stiffness of the joints which are tender or painful, red, warm, swollen, and stiff. Stiffness 
frequently lasts more than 60 min after rising in the morning and may also occur after prolonged 
inactivity, resulting in typical nocturnal pain. The pattern of peripheral joint affection is symmetric and 
virtually any joint can be involved but especially the small joints of the hands and feet, wrist, elbows, 
shoulders, knees and ankles tend to be affected. Synovitis of the distal inter-phalangeal (DIP) joints and 
the axial skeleton are rarely seen with exception of the upper cervical spine [16]. In different validated 
assessments of disease activity up to 66 joints are measured for swelling and up to 68 for tenderness. 
The 44 joint count in which the joints of the feet are also assessed is frequently used in studies but as 
with the 66 / 68 joint counts this is more time consuming and cumbersome to perform. The 28 joint 
count is the most frequently used joint count in clinical practice and the below figure highlights which 
joints are then assessed for swelling and tenderness [17]. This is shown in Figure 3. 
 
FIG. 3: Joints that are assessed for swelling and tenderness in the 28 joint counts (modified from 
hindawi.com). 
The number of tender and swollen joints combined with the patient’s global assessment of disease 
activity (PG) measured on a Visual Analogue Scale (VAS) of 100 mm, and the erythrocyte sedimentation 
rate (ESR) or C-reactive protein (CRP) are combined in a composite disease activity assessment 
instrument called the Disease Activity Score (DAS or DAS28, in which the 44 and 28 joint counts are used 
respectively). Patients who have a DAS28 more than 5.1 have high disease activity, those with DAS28 
between 3.2 and 5.1 have moderate disease activity, those with DAS28 between 2.6 and 3.2 have low 
disease activity and those with a score less than 2.6 are in remission (17-20).  
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In the EULAR response criteria both the change in the DAS28 score and the disease state in which a 
patient is brought with therapy are needed to determine whether a patient has good or moderate 
response or no response [19]. See Table 3 below. 
DAS28 Improvement  
 
 
Present DAS28 
 
>1.2 
 
0.6 - 1.2 
 
<0.6 
 
<3.2 good response moderate response no response 
3.2 - 5.1 moderate response moderate response no response 
>5.1 moderate response no response no response 
TABLE 3: European League against Rheumatism response criteria. 
Joints are often held in flexion to minimize pain and this may lead to fixed deformities like flexion 
contractures resulting in the very typical swan-neck and boutonniere deformities. Tendon rupture due 
to inflammation also occurs. Joint instability due to stretching of the joint capsule can also occur [8, 16]. 
These changes and the tenderness and swelling of the joints and surrounding tendons itself lead to 
disability which is measured with patient reported outcomes (PRO) questionnaires that assess quality of 
life (QoL) and function. The most frequently used PRO questions used for the assessment of function in 
RA are the disability scales of the Health Assessment Questionnaire (HAQ). In the HAQ score, disability is 
assessed by eight categories (dressing, arising, eating, walking, hygiene, reach, grip, and common 
activities). The score for the disability index ranges from 0 to 3 and is the mean of the eight category 
scores which are individually scored from 0 (without any difficulty) to 3 (unable to do). As such patients 
with a high score have severe disability and those with a low score have limited disability [21, 22]. 
Extra-articular manifestations are not so common anymore in RA. Subcutaneous rheumatoid nodules 
are the most known and develop in up to 30% of patients, usually at sites of pressure and chronic 
irritation. Pulmonary nodules may occur in severe RA and are usually asymptomatic. Other extra-
articular signs include symptoms of vasculitis such as leg ulcers, mononeuritis multiplex, pleural or 
pericardial effusions, pulmonary infiltrates or fibrosis, pericarditis, myocarditis, lymphadenopathy, Felty 
syndrome, Sjögren syndrome, scleromalacia, and episcleritis [8, 16]. 
Axial Spondyloarthritis 
Axial SpA affects the axial skeleton and inflammatory back pain is the main symptom of this disease. 
Patients may wake up in the second half of the night because of pain and usually have morning stiffness 
of the back that lasts more than 30 minutes and improves with exercise. Morning pain and improvement 
with exercise and not with rest are important characteristics which allow to distinct the pain pattern of 
inflammatory back pain from that of mechanical back pain. The latter tends to improve with rest and 
usually appears after exercise (e.g. in the evening). The involvement of the sacroiliac joints in Axial SpA 
may result in alternating buttock pain. Patients are relieved of the pain in the lower back and the 
associated muscle spasms when they bend forward and this is a posture that is very typical for the 
disease. If the joints of the ribs are inflamed, the pain may limit the ability to expand the chest to take a 
deep breath. Stiffness (fusion) of the spine can restrict the ability to expand the chest wall as well and 
may lead to an irreversibly bent over posture [16, 23].  
When peripheral joints are affected in Axial SpA, symptoms are similar to those in RA (i.e. swelling, 
tenderness, redness, stiffness) but the pattern differs as usually only few and large joints (hip or knee) 
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are affected in a non-symmetric fashion. Dactylitis or ‘sausage finger or toe’ is often seen and consists of 
diffuse swelling and redness of the entire digit.  
Enthesitis is also a frequent disease characteristic and leads to tenderness and swelling, redness and 
stiffness of the affected site [24]. The most frequent sites where enthesitis presents itself in Axial SpA 
patients are at the insertion of the Achilles tendon and the tendon of the fascia plantaris of the heel. Yet 
also other sites such as the costo-chondral sites, the iliac crest and the processsus spinosus L5 can be 
assessed for tenderness suggesting enthesitis. The Maastricht Enthesitis Ankylosing Spondylitis 
Enthesitis Score, the Berlin and the San Francisco scores for enthesitis have all been validated and have 
different counts for enthesitis based on different enthesial sites and differences in the total number of 
points where pressure needs to be applied to evaluate tenderness [25, 26]. Pressure points are also 
used to diagnose fibromyalgia and the differential diagnosis between enthesitis and fibromyalgia may be 
difficult in the absence of more objective signs of inflammation at the affected sites (e.g. redness or 
swelling). Echography may also be useful to determine whether inflammatory processes are at the origin 
of the tenderness if swelling or other clinical symptoms are not obvious [27]. 
The back is not as accessible as joints are and, assessment of disease activity in AS is therefore mostly 
based on patient reported outcomes. The Bath ankylosing spondylitis disease activity index (BASDAI) 
score measures disease activity based on six questions on fatigue, spinal pain, joint pain/swelling, areas 
of localized tenderness and morning stiffness. The BASDAI score ranges from 0 to 10 with a higher score 
corresponding to higher disease activity [28]. Function is also assessed through PRO in AS and one of the 
most frequently used assessment instruments for function in AS is the Bath ankylosing spondylitis 
functional index (BASFI). The BASFI has ten questions of which 8 evaluate activities related to functional 
anatomical limitations due to the course of this inflammatory disease and 2 evaluate the patients’ ability 
to cope with everyday life [29]. As with BASDAI it rates function with a score from 0 to 10 and patients 
with a higher score are more functionally impaired. 
 
FIG. 4: BASDAI and BASFI score across the ASPECT study population for patients with AS. From the 
ASPECT study, unpublished data. 
The range of motion of the axial skeleton is most frequently assessed through measurement of chest 
expansion, cervical rotation, lateral and frontal spinal flexion of the spine, the occiput to wall distance 
and abduction of the hips. The 5 latter measurements can be combined into the Bath AS metrology 
index which ranges from 0 to 10 with a higher score meaning less range of motion [30-32]. 
 14  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
Extra-articular manifestations are more common in Axial SpA than in RA and are important to establish 
the diagnosis early in this disease. More than 50% of patients with ankylosing spondylitis will have 
uveitis, psoriasis or inflammatory bowel disease at one time of their disease [33, 34]. One third of the 
people have recurring attacks of mild eye inflammation (uveitis), which usually does not impair vision if 
treated promptly [35].  
 
FIG. 5: Proportion of AS patients with a history of extra-articular manifestations over time in the ASPECT 
study population. From the ASPECT study, unpublished data. 
1.3. Imaging techniques  
Imaging techniques such as conventional X-rays and, more recently frequently magnetic resonance 
imaging (MRI) have been used in clinical practice and in clinical studies as tools to assess progression 
and prognosis of both diseases.  
Rheumatoid arthritis 
In RA, aside from soft-tissue swelling, X-rays show periarticular osteoporosis, joint space narrowing 
(caused by destruction of the articular cartilage) and erosions (caused by synovial invasion of the bone, 
typically occurring at the osteo-chondral junction). Erosions often develop within the first year but may 
occur at any time. Driven by persistent, severe and long-standing inflammation of the synovia of the 
joints, severely disabled rheumatoid arthritis (RA) patients with completely destructed wrists and hands 
were seen in every rheumatology practice until not so long ago [37-41].  The most frequently used 
method to measure joint damage is through the modified Sharp van der Heijde (SvH) method for which 
16 areas for erosions and 15 areas for joint space narrowing in each hand are combined with 6 areas for 
erosions and 6 areas for joint space narrowing in the feet. The maximum score for erosion and joint-
space narrowing in a single joint of the hand is 5 and 4 for the foot and the total SvH score ranges from 0 
to 448 [42, 43].  
MRI is more sensitive than X-rays to detect inflammatory signals (e.g., bone marrow lesions, bone 
marrow edema) and erosive changes in the bone which cannot be visualized with X-rays. It can also 
identify and quantify articular inflammation in a way that is not possible with clinical joint assessment. In 
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spite of these advantages of MRI there are also disadvantages like availability and cost which place this 
imaging technique in the research setting much more than in clinical practice [44].  
Axial Spondyloarthritis 
In Axial SpA, conventional X-rays are still used to stage the disease and allow to distinct non-
radiographic disease from ankylosing spondylitis through measurement of the sacroiliac joints (see 
classification of AS) [13, 14]. In the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), lateral 
cervical and lumbar spine X-rays allow to score 24 vertebral corners from 0 to 3 resulting in a range from 
0 to 72 for the total score [45]. The typical lesions that can be visualized on X-rays are syndesmophytes 
(i.e. bone growth at the anterior corner of a vertebra, corresponding with an mSASSS score of 2) and 
bony bridges between 2 vertebras which are also called ankylosis (score 3) and are more frequently seen 
in men than in women [45]. Progression of ankylosis is slow and it usually takes several years for 
syndesmophytes and bridging to occur. 
 
FIG. 6: Radiographic signals according to gender and disease duration in the AS population of the ASPECT 
study. From Boonen et al. J Rheumatol. 2009;36(6):1249-55.  
In contrast to X-rays, MRI can also detect inflammation which is thought to be the underlying 
mechanism of ankylosis. This method is therefore more useful in the early stages of the disease at which 
time changes on X-rays may not be visible yet. Both imaging techniques are still used to determine 
whether there is sacroiliitis on imaging in the ASAS classification for Axial SpA.  Active inflammatory 
lesions of the SI joints and located in the typical anatomical areas (subchondral or peri-articular bone 
marrow (reflecting active sacroiliitis) are required for the definition of ‘‘sacroiliitis on MRI’’ (46-49). 
Several scoring methods for assessing inflammatory activity in the spine and sacroiliac joints are used 
and further explored and established. This is still a rapidly evolving field and is not further described.  
1.4. Management of patients diagnosed with RA or Axial SpA 
Both the EULAR recommendations for management of RA and the ASAS/EULAR recommendations for 
management and treatment of Axial SpA introduce the importance of non-pharmacological measures, 
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such as physical, occupational and psychological therapeutic approaches which may help lead to 
therapeutic success [49, 50]. Even though the management of these diseases thus rests on more than 
only the principle of pharmacological treatment, application of drugs is arguably the most important 
aspect of therapy. Medicinal treatment in patients with RA and SpA is mostly situated in the secondary 
prevention (diagnose and treat existing disease early before it causes significant morbidity), tertiary 
prevention (reduce negative impact of existing disease by restoring function and reducing disease 
related complications) and palliative care setting (relieving and preventing the suffering of patients) 
[16]. Cure has not been shown to be achievable with the currently available therapeutic armamentarium 
and occasional prolonged drug-free disease control that has been reported in selected patients with 
these diseases is arguably the closest achievable proxy to cure.  
Rheumatoid arthritis 
Disease-modifying anti-rheumatic drugs (DMARDs), with as anchor drug methotrexate (MTX) are used to 
reduce and control RA symptoms and modify the disease course (i.e. preserve normal architecture and 
function of the joints) [37-41]. As soon as the diagnosis of RA is made, MTX can be used alone or in 
combination with other DMARD (when there are no contraindications). The goal for every patient 
should be to establish remission or low disease activity and if no improvement is measured within 3 
months or the target is not achieved at 6 months, therapy should be adjusted. If the treatment target is 
not achieved with the first DMARD strategy, in the absence of poor prognostic factors, change to 
another DMARD strategy should be considered. When poor prognostic factors are present, addition of a 
biological agent should be considered and biologicals should also be considered when MTX and DMARD 
strategies fail. Upon failure of a first biological subsequent biologicals with the same or a different 
mechanism of action can be tried and new oral treatments like tofacitinib are reserved for patients 
failing multiple biologics [49]. 
If an RA patient is in persistent remission after having tapered glucocorticoids, physicians are 
recommended to consider tapering biological agents, especially if this treatment is combined with a 
DMARD. In cases of sustained long-term remission, cautious reduction of the DMARD dose could also be 
considered, as a shared decision between patient and physician [49]. 
Axial Spondyloarthritis 
In Axial SpA non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first line drug 
treatment for patients with pain and stiffness. Analgesics, such as paracetamol and opioids, might be 
considered for pain control in patients in whom NSAIDs are insufficient, contraindicated and/or poorly 
tolerated. Sulfasalazine (SSZ) may be considered in patients with peripheral arthritis but there is no 
evidence for the efficacy of DMARDs (including SSZ and MTX) for the treatment of axial disease [51]. All 
patients should have tried a minimum of two NSAIDs (at the maximally tolerated dose) for a minimum of 
4 weeks in total before Anti-TNFα treatment is recommended for patients with persistently high disease 
activity (BASDAI score >= 4/10) despite conventional treatments. Treatment with an anti-TNFα agent 
should be installed by a doctor, usually a rheumatologist, with expertise in Axial SpA and the use of 
biological agents. The expert should consider clinical features (history and examination), serum acute 
phase reactant levels and/or imaging results, such as radiographs demonstrating rapid progression or 
MRI indicating ongoing inflammation. Treatment effect should be assessed after at least 12 weeks of 
continued treatment with an anti-TNFα agent at which time the BASDAI should have had a 50% relative 
improvement or an absolute improvement of 2 which should allow the expert to decide upon the 
desirability to continue treatment or not [51].  
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TABLE 4 EULAR recommendations for the treatment 
of RA (49) 
ASAS/EULAR recommendations for the 
treatment of Axial SpA (51) 
Indication  As soon as diagnosis of RA is made In Axial SpA patients with pain & stiffness 
Treatment 
Goal 
Remission or Low Disease Activity in every 
RA patient 
Not specified for NSAID treatment. 
50% or 2 units improvement in the 
BASDAI score for anti-TNFα treatment and 
expert in favor of continuing. 
Monitoring 
frequency 
& 
treatment 
adjustment 
Every 1 to 3 months; therapy should be 
adjusted if there is no improvement by at 
most 3 months after the start of treatment 
or the target has not been reached by 6 
months. 
Assessment of effectiveness 2 weeks after 
initiation of an NSAID. 
Assessment at least 12 weeks after 
initiation of an anti-TNFα agent.  
1st Line  First DMARD strategy including MTX with or 
without other DMARD(s). In case MTX is not 
tolerated or contraindicated start with 
another DMARD. 
First NSAID (Cox-specific NSAID as 
indicated) 
2nd Line Second DMARD strategy if poor prognostic 
factors are not present. ¹ 
Addition of a biological agent when poor 
prognostic factors are present. 
Second NSAID 
3rd Line Biological agent if patients respond 
insufficiently to MTX and/or other DMARD 
strategies 
Anti-TNFα agent for patients with high 
disease activity (BASDAI score >= 4/10) for 
more than 4 weeks despite conventional 
treatment and as indicated by an expert. ² 
In case of 
biologic 
failure 
New biological agent. This may be a second 
anti-TNFα agent or an agent with a different 
mode of action. 
Limited information available for switch 
from a first to a second anti-TNFα agent. 
Biologic 
failures 
Tofacitinib Not specified. 
Treatment 
titration 
Taper biologic in case of persistent 
remission. Cautious reduction of DMARD 
therapy in case of sustained long-term 
remission. 
Not specified. 
Cortico-
steroids 
Low to moderately high GCs doses added 
doses to DMARD(s) provide benefit and 
should be tapered rapidly. 
Local injections for enthesitis or arthritis. 
Systemic CS not active. 
¹ These risks have been well defined over the years and include a high disease activity state, 
autoantibody positivity (rheumatoid factor and/or antibodies to citrullinated proteins) and the early 
presence of joint damage [49].  
² In the 2003 recommendations which was the basis for the 2010 revisions, expert opinion should 
include clinical features, acute phase reactants, and imaging modalities. To make an informed decision, 
the expert should have available clinical features (history and examination), as well as either serum 
acute phase reactant levels or imaging results and should assess the likelihood of response to treatment. 
At the time it was concluded that most patients will benefit from anti-TNFα therapy and it was 
recognized that there are no good predictors for treatment response [52]. 
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Treatment of RA and Axial SpA must be based on a shared decision between patient and 
rheumatologist. This includes the need to inform the patient on the risks of the disease and the benefits 
& risks of its therapies. As the presence of comorbidity or of disease manifestations may have an 
important impact on the choice of the management strategy, multidisciplinary treatment may be 
required. The perturbation of the immune-system causing RA & Axial SpA may also lead to other 
immune-mediated disorders (e.g. uveitis, vasculitis, Crohn’s disease) and high disease activity on itself is 
associated with some typical comorbidities such as cardiovascular disease, osteoporosis and even 
lymphoma  which activity control with effective therapeutic intervention may prevent [49, 51]. 
Adequate anti-conceptive measures should be taken before initiating agents like MTX and alternatives 
like SSZ or anti-malarials may be chosen in case there is a pregnancy wish. Contraindications to any 
therapeutic option should be considered before initiation of any therapy. Screening measures before 
start and during use of a specific therapy may be required. For anti-TNF, preventive screening and 
treatment of latent tuberculosis has led to a sharp decrease of the incidence of tuberculosis in treated 
patients. Since reactivation of Hepatitis B virus may occur, latent carriers should be identified. 
Throughout the treatment patients should be carefully monitored for (serious) adverse events. Due to 
the elevated risk of infections with anti-TNF agents (including opportunistic infections for which 
symptoms may be a-specific) this includes careful evaluation of any signs and symptoms that signal 
infection. The association of anti-TNF agents with no signals have been of concern this far. Occurrence 
of adverse events and/or intolerance to an agent may require change of therapy. 
1.5. Socio-economic aspects of the management of RA and Axial SpA 
Since they have been introduced in markets around the world in the beginning of the millennium, anti-
Tumor Necrosis Factor alpha (anti-TNFα) agents and subsequently other biologics have had a large 
impact on the management of rheumatologic conditions. The suppressive effects on inflammation of 
these agents in RA leads to better control of disease activity and thus also halted further deterioration of 
joint destruction which allows stabilizing functional capacity of patients [37-41, 53-56]. The availability 
of anti-TNFα agents has also led to a significant improvement in the use of the available therapeutic 
DMARD armamentarium in RA, especially MTX [57]. Earlier diagnosis and referral, earlier and more 
aggressive DMARD treatment strategies before biologics and availability of better treatments – anti-
TNFα agents initially but subsequently also other biologics - have thus changed the RA population 
characteristics to the extent where researchers are evaluating whether management of RA patients has 
improved or whether RA as a disease has become milder instead [58]. Coinciding with the increase in 
use of MTX and TNF inhibitors, elective musculoskeletal surgical procedures for RA patients have almost 
halved and RA inpatient bed days have halved over the past 15 years [59]. For Axial SpA patients the 
impact of anti-TNFα agents has been as dramatic as for RA patients, yet the success of bringing 
pharmacological treatment innovation to this disease population has been more limited than in RA as 
this far biological agents with another mechanism of action than anti-TNFα are not yet available outside 
the experimental setting. 
Health care systems and society has recognized the considerable costs associated with the care of RA 
and AS. Several economic evaluations have been published and differ substantially in their objectives, 
methods, study populations, health care setting which is very different from one country to another [60-
66].  It is not really possible to compare the studies but they all seem to agree in their general findings: 
the inflammatory activity and gradual physical impairment associated with RA and AS leads to 
substantially increased health care costs, severe limitations in the ability to work and reduced quality of 
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life. Functional disability has been identified as by far the strongest predictor of costs, while disease 
activity appears to play a minor role as well [67-74].  
The association of disease activity as measured with the BASDAI score and functionality measured with 
BASFI is shown in Figure 7 [73]. Figure 8 shows that the increase in cost does not only relate to 
treatment but that also indirect costs such as that of early retirement and hospital services increase in 
patients with higher BASDAI combined with BASFI. 
 
 
FIG. 7 and 8: Influence of disease severity as measured by BASDAI and BASFI scores on cost of care in 
ankylosing spondylitis patients. From Kobelt G et al. Rheumatology. 2004; 45:1158-1166.  
The annual cost of RA management according to health state and disease activity state are summarized 
in Table 5 [68-72, 74, 75]. This highlights how also indirect costs, which do not include medicine, have a 
tremendous impact especially in patients who are not in a controlled disease state. 
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TABLE 5: Mean annual cost of RA according to disease severity as measured by DAS28 and HAQ scores. 
From Vastesaeger et al., submitted manuscript. 
 21  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
Use of medicine and combination of drugs – NSAIDs, DMARDs and biologics – requires physicians to 
balance the anticipated benefits with the risks and cost. More intensive treatment strategies in which 
combination of immune-modulator agents is used tends to be more effective and induces remission 
more frequently than treatment strategies that do not include immune-modulators or use only one 
DMARD agent in RA [53-56]. Since NSAIDs may have effects on progression of ankylosis In Axial SpA 
whereas solid proof of such effect from anti-TNFα agents currently does not exist, there is a scientific 
and clinical basis to use combination of these 2 therapies also in this disease. If peripheral arthritis is 
present, also sulphasalzine is frequently combined with an anti-TNFα agent with or without an NSAID 
[77-80]. RA and AS are chronic diseases and in the absence of a possibility to cure, biologic agents are 
frequently continued for many years and even life-long after they are started. This results in a large 
increase of costs to manage these disorders.  
In the EULAR recommendations for the management of RA, the individual, societal and medical costs of 
RA patient management should be considered by the treating rheumatologist when selecting a 
treatment strategy. The high cost of modern therapies including anti-TNFα should be considered 
specifically [49] and are a reason why DMARDs are recommended before biologics are used. Biologic use 
in immune-modulator naïve RA patients with inflammatory pathology is however approved per label 
(approved labels for various biologics are available on http://www.ema.europa.eu/ema/). 
Reimbursement and consequently use of biologic agents in clinical practice is usually also restricted to 
the more severely ill patients and those in whom one or more previous DMARDs have failed. As such, 
disease control at a population level is achieved through ‘trial and error strategy’ of a predefined 
sequence of medicine (i.e. step up therapy) in which more effective and expensive agents are reserved 
to patients with longer disease duration and in those who are refractory to several previous agents. 
However, also the likelihood of these agents to achieve profound disease control or remission goes 
down in patients with longstanding and refractory disease [81, 82]. In addition, a prolonged state of 
non-controlled synovitis leads to continued progression of radiographic damage and irreversible 
disability.  
In 2013 the therapeutic area of rheumatology was the 2nd largest worldwide drug market (after 
oncology) with sales of anti-rheumatic agents being worth $ 44.9 billon. Analysts predict it will continue 
to grow over the next 6 years towards 57.1 billion USD market in 2020, only surpassed by oncology and 
anti-diabetic agents [83]. These numbers reflect the widespread use of the biological drugs which is a 
testimony to the benefits they bring to individual patients and explains the willingness of society to pay 
or reimburse. At the same time, in an era of financial crisis physicians, hospital management and 
governments need to keep the increasing health care costs under control. Beyond the already described 
treatment recommendations and reimbursement conditions, price reductions mandated by regulators 
and payers and price competition with other biological agents and biosimilar agents are ways to control 
cost as the number of patients treated with these agents continues to increase.   
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Chapter 2: Research aims 
 
Persistence of elevated disease activity and subsequent destruction of peripheral joints for Rheumatoid 
Arthritis (RA) and ankylosis of the axial joints & spine for Axial Spondyloarthritis (SpA) lead to functional 
impairment and disability, which may be irreversible.  
The 2 outcomes that RA treatment recommendations focus on are avoidance of poor prognosis and 
achievement of a controlled disease activity state. The therapeutic goal for treatment of RA is to achieve 
remission or low disease activity and when that is not achieved with non-biologic Disease Modifying 
Anti-Rheumatic Drugs (DMARDs); rheumatologists should use presence of poor prognostic factors to 
decide whether or not to add a more expensive biological agent. Once persistent disease activity control 
is then installed, tapering and/or discontinuation of that biologic can be considered.  
A treatment goal has not been adopted in the management guidelines of Axial SpA and use of outcome-
predictors to guide treatment choice is not recommended at this time either. Biological agents should 
be used as second-line agents in this disease when elevated disease activity persists in spite of repeated 
trial with Non-Steroidal Anti-Inflammatory drugs (NSAIDs).  
There is limited understanding of what really drives clinical decision for these diseases in daily practice. 
In addition, even if there has been a lot of research to identify outcome-predictors, it is not well 
understood how they should be used in treatment recommendations and in the clinic to ensure that the 
appropriate anti-TNF treatment candidates are selected for treatment. Both aspects have been 
investigated as part of this thesis. 
In light of this, the research questions in this thesis were: 
• What are the characteristics of RA and Axial SpA patients that rheumatologists select for 
treatment with an anti-TNF agent? 
• How can disease characteristics that predict treatment outcome be used to decide when to start 
anti-TNF in clinical practice? 
• Can anti-TNF treatment be stopped for early Axial Spondyloarthritis patients who are in 
remission?   
In Chapter 3, two studies that coincided with the introduction of biological therapy in RA and Axial SpA 
in Belgium, and that help understand what characteristics are relevant to clinicians who are making anti-
TNF treatment decisions, are reported.  
According to the protocol of the Expanded Access Program (EAP) in RA, physicians could decide whether 
there was a need to increase the dose of infliximab 22 weeks after treatment initiation.  
In the AS project, for each patient included in the Ankylosing Spondylitis Patients Epidemiological Cross-
sectional Trial (ASPECT), rheumatologists were asked whether or not an anti-TNF agent had been 
initiated. 
There were no requirements per protocol to adjust or initiate anti-TNF therapy in either study; this 
decision was at the discretion of the treating physician. The associations of a large number of 
demographic, disease specific, laboratory and imaging characteristics with the clinical decision to start 
(ASPECT) or adjust (EAP) anti-TNF therapy were used to discriminate the discretionary/intuitive 
treatment decision of a rheumatologist in clinical practice. 
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In Chapter 4, four studies that had as aim to investigate for which patients anti-TNF treatment would be 
most valuable as determined by the likelihood of achieving a desired outcome are reported.   
Inspired by a model of poor prognosis of cardiovascular disease (SCORE), a post-hoc analysis of the 
Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of 
Early Onset (ASPIRE) and the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant 
Therapy (ATTRACT) studies was initiated with the goal to create a model that can assist rheumatologists 
to make an informed treatment choice based on the risk of poor prognosis associated with a potential 
treatment choice. A number of research groups were approached to further explore the value and 
validity of our preliminary model in other RA databases. These data are briefly described in this chapter 
as well.  
Since disease activity control is the goal of treatment in RA, prediction of this outcome and creating a 
similar model allowing to identify patients in whom anti-TNF treatment can install remission or low 
disease activity was included as secondary objective of the GO-MORE study. The report of this analysis is 
a second key paper on RA outcome prediction included in this thesis. Comparison of the analyses 
resulting from ASPIRE / ATTRACT with that of GO-MORE gives insight on what the consequences are of 
aiming for remission while selecting based on prognosis in RA.   
The treatment objectives for Axial SpA are less clear and a lot of work is ongoing to refine the outcome 
instruments and to define treatment goals in this disease. Rather than focusing on one specific outcome 
at one specific time-point, a post-hoc analysis aimed at identifying baseline predictors of response 3 
months after AND good disease activity state 6 months after initiation of anti-TNF therapy was done in 
the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) and GO-
RAISE studies. This approach was chosen in order to obtain one model allowing the prediction of 
multiple outcomes of this disease. This is reported shown in the 3rd publication included in this chapter.  
C-Reactive Protein (CRP) was retained as predictor in the work described above and it is a component of 
the Ankylosing Spondylitis Disease Activity Score (ASDAS) but not of the Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI; this is the most frequently used tool to select patients in clinical trials 
and for treatment with anti-TNF in clinical practice). The objective for the last paper presented in this 
chapter was to investigate the population profile (including CRP) of patients selected with ASDAS versus 
that of those selected with BASDAI. The hypothesis is that a better profile of selected population in 
terms of outcome predictors will lead to better outcomes in that population when treated with an anti-
TNF agent. 
Chapter 5 includes 3 publications from the Infliximab as First Line Therapy in Patients with Early Active 
Axial Spondyloarthritis Trial (INFAST). Part 1 of this study was a randomized comparison to understand 
whether patients with Axial SpA treated with infliximab plus naproxen have a higher likelihood to 
achieve remission than similar patients treated with placebo plus naproxen. In part 2, for patients 
achieving remission, a randomized withdrawal design to understand if disease control could be 
maintained without continued use of the anti-TF agent was chosen, and the role of NSAIDs (naproxen) in 
maintenance of biologic free-remission was explored. Hypothesizing that treatment discontinuation 
would be possible in case of a controlled disease state in early Axial SpA, prediction of which patients 
would achieve remission was an objective of this study and this is the 3rd manuscript in this chapter.  
In Chapter 6 a critical review of the RA and Axial SpA management recommendations is done. Specific 
proposals on how the clinical tools and data presented in Chapter 4 and Chapter 5 may help refine 
guidelines are formulated. 
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Chapter 3: Intuitive Anti-TNF alpha 
Treatment Decisions in Clinical Practice 
Two studies that coincided with the introduction of biological therapy in RA and Axial SpA in Belgium, 
and that help understand what characteristics are relevant to clinicians who are making anti-TNF 
treatment decisions, are reported. 
 
 
 
 
The epidemiology of ankylosing spondylitis and the 
commencement of anti-TNF therapy in daily rheumatology 
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Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, Steinfeld S, Van den 
Bosch F, Dewulf L, Vastesaeger N. 
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DAS28 best reflects the physician's clinical judgment of 
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patients: validation of the DAS28 score in patients under 
infliximab treatment. 
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 29  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
 30  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
3.1. The epidemiology of ankylosing spondylitis and the 
commencement of anti-TNF therapy in daily rheumatology practice 
3.1.1. Abstract  
Objectives 
This study aimed to describe the epidemiology of ankylosing spondylitis (AS) in rheumatology practice at 
the beginning of the anti-TNF (tumor necrosis factor) era, and to evaluate the initiation of anti-TNF 
therapy in a clinical setting where prescription is regulated by the authority’s imposed reimbursement 
criteria.  
Methods 
Between February 2004 and February 2005, all Belgian rheumatologists in academic and non-academic 
outpatient settings were invited to register all AS patients who visited their practice. A random sample 
of these patients was further examined by an in-depth clinical profile. In a follow-up investigation, we 
recorded whether patients initiated anti-TNF therapy and compared this to their eligibility at baseline 
evaluation.  
Results 
89 rheumatologists participated and registered 2141 patients; 1023 patients were clinically evaluated. 
These 847 fulfilled the New York modified criteria for definite AS and 176 for probable AS. The profile of 
AS in rheumatology practice is characterized by longstanding and active disease with a high frequency of 
extra-articular manifestations and metrological and functional impairment. At a median of 2 months 
after the clinical evaluation, anti-TNF therapy was initiated in 263 of 603 (44%) evaluable patients with 
definite AS and in 22 of 138 (16%) evaluable patients with probable AS (total 38%). More than 85% of 
the patients who started anti-TNF therapy had an increased Bath Ankylosing Spondylitis Disease Activity 
Index despite previous NSAID (non-steroidal anti-inflammatory drug) use.  
Conclusions 
Of a representative cohort of 1023 Belgian AS patients seen in daily rheumatology practice, about 40% 
commenced anti-TNF therapy. Decision factors to start anti-TNF therapy may include disease activity 
and severity.  
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3.1.2. Introduction  
Ankylosing spondylitis (AS) is the prototype of spondyloarthropathy (SpA) characterized by sacroiliitis 
and may lead to a completely ankylosed spine in a substantial number of patients. In addition, 
peripheral arthritis and different extra-articular manifestations, such as gut inflammation and eye 
involvement, are common features that add to the burden of the disease.  
Until recently, the therapeutic options for AS have been limited to non-steroidal anti-inflammatory 
drugs (NSAIDs), alongside education and physiotherapy (which remain the cornerstone of the 
treatment) [1, 2]. Disease modifying anti-rheumatic drugs (DMARDs) such as sulphasalazine and 
methotrexate (MTX), demonstrated little or no effect on axial disease and are recommended only in 
patients with peripheral arthritis [2–5]. However, tumor necrosis factor (TNF) inhibitors have recently 
been introduced in AS and have been shown to be effective drugs, improving the signs and symptoms of 
AS with a good benefit-risk profile [6–9]. With the aim of treating a population most likely to benefit 
(thus limiting widespread use of these expensive agents), recommendations on TNF agent use have 
been formulated by national [10] and international experts (for example, ASAS) [2, 11, 12] and served 
for prescription/reimbursement laws and guidelines in different countries. The aims of the present study 
were (1) to elucidate a profile of the Belgian AS population followed in daily clinical practice by 
rheumatologists in secondary and tertiary care centers at the time anti-TNF therapy was introduced for 
treating AS, and (2) to evaluate the proportion of AS patients starting anti-TNF therapy during the first 
year that these agents became available and determine the clinical characteristics of the patients who 
received them.  
3.1.3. Methods 
3.1.3.1. Rheumatologist selection 
All Belgian rheumatology centers were contacted and asked to participate in this study. 
In order to assure a representative sample, demographic data of the participants were collected and 
were compared with demographic data of the total Belgian rheumatologist population provided by the 
Royal Belgian Society of Rheumatology (KBVR-SRBR).  
3.1.3.2. Patient selection 
Rheumatologists registered, in a confidential logbook, the birth dates and initials of all AS patients 
visiting their outpatient clinic during the study period. The number of registered patients in the logbook 
served as a denominator for a random selection of AS patients in whom the disease was documented 
further. For the in-depth clinical evaluation, every week’s first and fourth registered patient was 
evaluated using the study’s case report form. If a patient was already included or refused to participate, 
the next consecutive patient of the same week was evaluated. This selection method was preferred over 
inclusion of consecutive patients as it allowed for time distribution of the amount of study related work, 
especially in academic centers. The maximum number of patients included per rheumatologist was 
limited to 20, thereby ensuring the study population was distributed between the participating 
rheumatologists’ sites. All patients were informed about the study before inclusion and gave written 
informed consent with regard to data privacy.  
3.1.3.3. Study parameters 
The following data were collected in all patients who were randomly selected for epidemiological 
profiling: demographic data, previous and current pain patterns, peripheral disease, previous and 
current clinical extra-articular disease (psoriasis, inflammatory bowel disease, uveitis), surgery, and 
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comorbidities (arthroplasty, osteoporosis, spinal fracture). The following composite indices were 
evaluated: Bath Ankylosing Spondylitis Functionality Index (BASFI: 0–10 rated on a numerical rating 
scale), [13] Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: 0–10 rated on a numerical rating 
scale) [14] numerical scale and the components of the Bath Ankylosing Spondylitis Metrology Index 
(BASMI) [15] Laboratory testing included available HLA-B27 status and latest available C reactive protein 
(CRP) value. Available radiographic data assessed were as follows: grading of the individual sacroiliac 
joints, presence of syndesmophytes, or presence of an ankylosis on latest available x rays. Patient 
history was also documented, including first degree family history of inflammatory diseases collected for 
AS, inflammatory bowel disease (IBD), uveitis, psoriasis, psoriatic arthritis, as well as current and 
previous treatment included physiotherapy, NSAIDS (including duration and types of NSAIDs), 
corticosteroids, sulphasalazine, methotrexate, azathioprine, TNF blockers. For further analyses, patients 
who fulfilled the New York modified criteria for AS were categorized as having definite AS or probable 
AS [16] (Table 16). Also, for each patient, fulfilment of ASAS recommendations to start anti-TNF therapy 
was computed. For this study, this implied that AS patients should have tried at least two NSAIDs and 
have a BASDAI ⩾4 before starting anti-TNF therapy [2, 11, 12, 17]. 
(1) Low back pain with inflammatory characteristics 
(2) Limitation of lumbar spine motion in sagittal and frontal planes 
(3) Decreased chest expansion 
(4) Bilateral sacroiliitis grade 2 or higher 
(5) Unilateral sacroiliitis grade 3 or higher 
*Definite AS when the fourth or fifth criterion mentioned presents with any clinical criteria 
TABLE 16: New York modified criteria (1984) for ankylosing spondylitis* 
During an inquiry, approximately one year after the collection of all the above information, 
rheumatologists were asked to indicate whether anti-TNF therapy was initiated in their patients. 
Rheumatologists were not informed beforehand that that this query would take place.  
3.1.3.4. Quality assurance 
The protocol and file were developed by collaboration of a board of academic and non-academic 
rheumatologists and the study sponsor (Schering Plough). The protocol was designed to allow the 
maximum amount of data to be captured in a minimum amount of time during daily clinical practice. 
The CRF was tested in a peripheral Centre (JL) on five patients and adapted according to the suggestions 
before its use in the protocol. The protocol was approved by the Belgian national license bureau for non-
interventional research (Pharma.be) for good clinical practice and ethical approval.  
In order to ensure data quality, two independent data nurses were assigned to the project and checked 
informed consents of all patients, logbooks, and CRF completeness.  
3.1.3.5. Time frame 
In-depth profiling of patients occurred at one visit between February 2004 and February 2005. Between 
December 2005 and January 2006, rheumatologists were retrospectively asked whether anti-TNF 
therapy was initiated since that in-depth profile.  
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3.1.3.6. Study era and background 
At that time infliximab (March 2003) and etanercept (November 2003) were registered but are 
reimbursed from March 2004 and September 2004, respectively. Between December 2005 and January 
2006, rheumatologists were asked whether patients had started anti-TNF therapy since that clinical 
evaluation. The reimbursement of anti-TNF therapy in Belgium is similar for both drugs. To satisfy 
conditions set by the authorities. patients must fulfil the modified New York criteria for AS, insufficiently 
respond to conventional therapy, and present with the following: (1) severe axial symptoms reflected by 
a BASDAI ⩾4; (2) a CRP value higher than the upper limit of normal for the applicable laboratory 
(without specification about the time point that CRP must be elevated); (3) unless contraindicated, an 
insufficient response to previous optimal use of at least two NSAIDs at anti-inflammatory doses for at 
least three months; and (4) an absence of active or latent tuberculosis. Furthermore, anti-TNF treatment 
can only be prescribed by a board certified rheumatologist.  
3.1.3.7. Statistical analyses 
Consistent with the epidemiological objective of the study, descriptive statistics were used for the data. 
Differences between subgroups were compared by means of a Mann-Whitney test for continuous 
variables and χ2 statistics for dichotomous data. Logistic regression models were fitted using the 
significant variables of a univariate analysis and after backward elimination using p values of 0.05 for 
removal. Different interaction terms were initially added to the models (but none remained in the final 
models). Analyses were performed by the commercially available statistical package SPSS 12.0 (Chicago, 
IL, USA).  
 
3.1.4. Results 
3.1.4.1. Enrolment of rheumatologists 
Eighty-nine of all 204 (44%) board certified Belgian rheumatologists from 57 centers agreed to 
participate in the study. The majority of those rheumatologists (75%) worked in non-academic centers; 
45 of them worked in the French speaking part and 44 in the Dutch speaking part of Belgium; 40/49 
rheumatologists were female/male. When comparing these rheumatologist demographics with the data 
provided by the Belgian rheumatologists’ society, KBVR-SRBR, there were no significant differences with 
regard to sex, type of practice, and geographical distribution. The mean study participation of the 
rheumatologists was 15 weeks (SD 7.4). Each week, the rheumatologists saw a mean of 2.2 AS patients 
(range 1–7, interquartile range 1.4).  
3.1.4.2. Evaluation of the patients’ sampling 
In the logbooks, 2141 AS patients were registered. The planned in-depth profiling was further conducted 
in 1023 patients. All patients fulfilled modified New York classification criteria [16] 647 (83%) patients 
were classified as definite AS and 176 remained as probable AS (Figure 9). The lag time between CRP 
measurement and the clinical evaluation was median 0 months (interquartile range 0.6 months). The lag 
time between radiology and the clinical evaluation was median 0.5 year (interquartile range 1.8).  
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FIG. 9: Patient flow chart. AS, ankylosing spondylitis; TNF, tumor necrosis factor. 
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3.1.4.3. Comparison of patients with definite and probable AS 
Table 7 describes the baseline characteristics of the AS patients. An important difference between 
patients with definite AS and patients with probable AS is the difference of symptom duration, which is 
significantly higher in patients with definite AS (p<0.001). Patients with definite AS also had a higher 
disease activity (higher BASDAI, BASFI, and elevated CRP) and disease severity (higher BASMI, more 
syndesmophytes, bamboo spine, and hip involvement).  
Baseline evaluation Definite AS (n = 847) Probable AS (n = 176) p Value 
Male sex 68% 49% <0.001 
HLA-B27 (n = 816) 83% 77% 0.074 
Ever arthritis 58% 56% 0.576 
Ever enthesitis 50% 52% 0.573 
Elevated CRP 37% 18% <0.001 
Syndesmophytes 49% 15% <0.001 
Bamboo spine 21% 0% <0.001 
Hip involvement 27% 15% <0.001 
BASDAI* 5.3 (2.1) 4.7 (2.0) <0.001 
BASDAI ⩾4 75% 66% 0.014 
BASFI* 5.1 (2.5) 3.6 (2.4) <0.001 
BASMI* 3.6 (2.4) 2.4 (1.7) <0.001 
Symptom duration* 18.0 (12) 9.3 (9) <0.001 
Disease duration* 12.0 (66) 5.8 (40) <0.001 
Disease duration <1 month 6% 12% 0.003 
Age* 45 (11) 40 (12) <0.001 
Psoriasis 11% 11% 0.846 
Uveitis (ever) 27% 17% 0.002 
Crohn’s disease 8% 7% 0.854 
Ulcerative colitis 3% 2% 0.678 
Ever MTX 19% 18% 0.616 
Ever SSZ 61% 53% 0.056 
Ever azathioprine 4% 7% 0.102 
At least 2 NSAIDs used 92% 82% 0.001 
Current NSAIDs 72% 63% 0.020 
TABLE 7: Description of patients at baseline. Definite AS and probable AS are defined according to the 
New York modified criteria [16]. Percentages are given, except for continuous data: *mean (SD). 
3.1.4.4. Anti-TNF therapy in AS patients 
At the time of the clinical evaluation (between February 2004 and February 2005), 90 (11%) patients 
with definite AS and six (3%) patients with probable AS were already being treated with anti-TNF 
therapy. Most of these patients received anti-TNF therapy in the context of studies or medical need 
programs. These patients were further excluded from the analysis.  
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Of the remaining patients, 603 were evaluable for the inquiry into anti-TNF treatment (between 
December 2005 and January 2006); 263 of those patients with definite AS started anti-TNF therapy. The 
lag time between the clinical evaluation of the patient and the start of anti-TNF therapy was estimated 
as median 2 months (range 0–23 months, interquartile range 5 months). In 121 patients, this lag time 
was less than 1 month. Table 8 describes the differences in baseline characteristics in function of the 
initiation of anti-TNF treatment.  
Baseline evaluation 
Definite AS Probable AS 
Without 
anti-TNF 
at query 
(n = 340) 
With anti-
TNF at 
query    
(lag time 
<1 month) 
(n = 121) 
With anti-
TNF at 
query     
(all 
patients) 
(n = 263) 
p 
Value 
Without 
anti-TNF 
at query 
(n = 116) 
With 
anti-TNF 
at query 
(n = 22) 
p 
Value 
MALE 60% 73% 73% 0.001 46% 64% 0.123 
HLA-B27 77% 92% 88% 0.001 76% 68% 0.451 
Arthritis 22% 27% 29% 0.029 28% 46% 0.114 
Enthesitis 17% 17% 21% 0.206 24% 27% 0.754 
Elevated CRP 26% 56% 48% <0.001 16% 18% 0.840 
Syndesmophytes 38% 57% 45% <0.001 16% 15% 0.920 
Bamboo spine 16% 25% 24% 0.023 0% 0% NA 
Hip involvement 22% 37% 36% <0.001 14% 32% 0.038 
BASDAI* 4.7 (2.2) 6.4 (1.6) 6.1 (1.7) <0.001 4.4 (2.0) 6.0 (1.6) 0.001 
BASFI* 4.4 (2.6) 6.1 (2.0) 5.9 (2.3) <0.001 3.2 (2.2) 5.6 (2.0) 0.000 
BASMI* 3.0 (2.3) 4.1 (2.2) 4.0 (2.4) <0.001 2.3 (1.6) 2.9 (1.8) 0.179 
Age* 45 (11) 44 (11) 44 (11) 0.094 40 (12) 38 (12) 0.607 
Symptom duration 18 (12) 19 (13) 19 (13) 0.163 10 (8) 11 (9) 0.286 
Psoriasis 10% 12% 12% 0.560 9% 23% 0.051 
Uveitis 25% 26% 31% 0.096 12% 32% 0.018 
IBD 9% 9% 10% 0.901 5% 14% 0.116 
Any extra-articular manifestation 39% 42% 44% 0.342 23% 55% 0.003 
BASDAI ⩾4 63% 95% 90% <0.001 60% 91% 0.006 
BASDAI ⩾4 and failing NSAID 55% 90% 85% <0.001 51% 84% 0.008 
BASDAI ⩾4 and failing NSAID + 
elevated CRP at evaluation 
17% 55% 45% <0.001 22% 8% 0.085 
TABLE 8: Description of patients with AS as a function of the presence of anti-TNF treatment at inquiry. 
Definite AS and probable AS are defined according to the New York modified criteria [16] Percentages 
are given, except for continuous data: * mean (SD). P Values are calculated for the contrast without anti-
TNF at inquiry vs with anti-TNF at inquiry for all patients. 
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Table 9 shows that patients who started anti-TNF therapy, stratified for whether or not they fulfilled the 
ASAS recommendations [2], tended to have a higher disease activity, more functional impairment, and a 
worse metrology.  
 
 
No fulfilment of ASAS criteria2 BASDAI <4 
or no NSAID failing 
Fulfilment of ASAS criteria2 BASDAI ⩾4 
and failing NSAID 
Without anti-TNF 
at query  
(n = 131) 
With anti-TNF 
at query  
(n = 34) 
p 
Value 
Without anti-TNF 
at query  
(n = 160) 
With anti-TNF 
at query  
(n = 187) 
p 
Value 
BASDAI 
- Mean 
- SEM 
 
3 
0.13 
 
3.7 
0.34 
 
0.041 
 
 
6.2 
0.11 
 
6.5 
0.09 
 
0.028 
BASFI 
 -  Mean 
 - SEM 
 
3.1 
0.18 
 
3.6 
0.41 
 
0.3 
 
5.6 
0.18 
 
6.2 
0.14 
 
0.005 
BASMI 
   - Mean 
            - SEM 
 
3 
0.25 
 
3.3 
0.38 
 
0.5 
 
3.3 
0.22 
 
4.3 
0.26 
 
0.002 
TABLE 9: BASDAI, BASMI, and BASFI as a function of the fulfilment of the ASAS criteria and the decision 
to start anti-TNF treatment. 
 
Different logistic regression models (Table 10) to predict the start of anti-TNF therapy were fitted after 
backward elimination of the significant variables of Table 8. Model 1 was fitted in a subgroup of 121 
patients with definite AS who started anti-TNF treatment within 1 month after the in-depth profiling. 
This model revealed that BASDAI, CRP, and HLA-B27 significantly contributed to the model, with the 
highest contribution for BASDAI and the lowest contribution for CRP. Model 2 was fitted in the subgroup 
of patients with probable AS and highlighted the potential added value of the presence of extra-articular 
manifestations in this subgroup of patients. Finally, model 3 was fitted in the total population and 
highlighted the added value of hip involvement, BASFI, male sex, and a definite diagnosis of AS.  
 
Model 1 Inclusion: patients with definite AS and a lag time to start anti-TNF therapy <1 month 
 Beta p Value OR (95% CI of OR) 
Elevated CRP 1.089 0.005 2.972 (1.385 to 6.377) 
Carriage of HLA-B27 1.473 0.022 4.361 (1.242 to 15.316) 
BASDAI >4 2.051 0.001 7.774 (2.266 to 26.668) 
Intercept −4.800 0.000 .008 
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Model 2 Inclusion: patients with probable AS 
 Beta  p Value  OR (95% CI of OR)  
Presence of any extra-articular manifestation 0.778 0.027 2.177 (1.093 to 4.338) 
BASDAI >4 1.806 0.019 6.084 (1.338 to 27.656) 
Intercept −3.388 0.000 .034 
Model 3 Inclusion: all probable and definite AS patients 
 Beta p Value OR (95% CI of OR) 
NYm_Def 1.056 0.001 2.876 (1.533 to 5.394) 
Elevated CRP 0.736 0.000 2.087 (1.383 to 3.150) 
Hip involvement 0.635 0.005 1.887 (1.214 to 2.932) 
HLAB27 0.619 0.019 1.858 (1.106 to 3.121) 
Male sex 0.504 0.016 1.655 (1.098 to 2.493) 
BASDAI* 0.228 0.001 1.256 (1.102 to 1.431) 
BASFI* 0.114 0.041 1.121 (1.005 to 1.251) 
Intercept −3.862 0.000 .021 
TABLE 10: Result of a logistic regression model to predict the start of anti-TNF therapy in AS patients. OR, 
odds ratio; 95% CI, 95% confidence interval; CRP, C reactive protein; BASDAI, Bath ankylosing spondylitis 
disease activity index; BASFI, Bath ankylosing spondylitis functional index. *BASDAI and BASFI were 
considered as continuous variables in model 3. 
3.1.5. Discussion 
This study describes a representative, nationwide sample of Belgian AS patients, followed at different 
academic and non-academic centers. Patients were included based on clinical expert diagnosis for AS: 
83% of them fulfilled the New York modified criteria for definite AS and 17% of patients were considered 
as probable AS [16]. This clearly shows that, in daily clinical practice, rheumatologists care for a 
substantial number of AS patients not fulfilling the definite criteria, and this group should receive the 
attention they merit [16]. Not surprisingly, patients with probable AS showed a lower radiological 
grading of sacroiliac joints on conventional radiographs (Table 7). Also, they had a shorter disease 
duration and it thus might be hypothesized that at least a subgroup of those patients would fulfil the 
criteria for definite diagnosis if followed up for a longer time (Table 7) [18] A longer disease duration 
may account for the more severe disease (higher BASMI [15], more syndesmophytes, bamboo spine, 
and hip involvement) in patients with definite AS [19–21]. 
The profile of definite AS patients was characterized by longstanding, severe, and active disease with a 
high frequency of comorbidities and important metrological restriction and functional impairment. Also, 
most patients followed up in rheumatology practice have active disease, which was reflected by a mean 
BASDAI of 5.3 (SD 2.1) and a mean BASFI of 5.1 (SD 2.5) (Table 7).  
The high frequency of comorbidities, functional impairment, and active disease despite optimal use of 
NSAID therapy explains why anti-TNF therapy was initiated in a large proportion of AS patients. After 
one year, anti-TNF therapy was initiated in 44% of the patients with definite AS and in 16% of patients 
with probable AS. The need for anti-TNF therapy was previously estimated as 30% [10] to 49% (38%–
78%) [17]. While these studies asked the treating rheumatologist whether they thought the patient 
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would need to be treated by a TNF blocker, the present study evaluated the effective start of anti-TNF 
therapy under the regulation of reimbursement criteria.  
In accordance with ASAS guidelines and Belgian reimbursement criteria, an elevated BASDAI is the main 
characteristic of patients with probable and definite AS, who start anti-TNF therapy. More than 90% of 
patients who started anti-TNF therapy had a BASDAI ⩾4 [17, 22] However, other recommendations 
given by the Belgian reimbursement criteria appeared to add little value to the BASDAI. Although a 
significant contributor in two of the logistic regression models (Table94, model 1, model 3), the value of 
an increased CRP seems to be moderate since less than half of the patients who started anti-TNF 
therapy had an elevated CRP at the time of the clinical evaluation. The finding that a number of patients 
who started on anti-TNF therapy had a normal CRP may be explained by the fact that the 
reimbursement criteria do not require an elevated CRP when the decision is made to start anti-TNF 
therapy (that is, the criteria can be interpreted as requiring an elevated CRP at any time in disease 
course).  
At least two NSAIDs were used in more than 90% of patients with definite AS involved in this cohort. 
This suggests that trying different NSAIDs is commonly used in the Belgian daily clinical rheumatologists’ 
practice and thus should be recommended before starting anti-TNF therapy.  
A high BASDAI is not the sole criterion on which the physician decides to start anti-TNF therapy. In both 
probable and definite AS patients, functional impairment and hip arthritis (Table 10) also seemed to be 
contributing in the decision to start anti-TNF therapy. Although the presented logistic models require 
further validation, it is an interesting finding that HLA-B27 positivity came up in two models (Table 10, 
model 1 and 3). It can be hypothesized that physicians do not decide on HLA-B27 itself but rather on 
associated variables, such as earlier onset, comorbidities, or severity of AS [23–26]. 
One additional important finding in this study was that anti-TNF therapy was started in a small 
proportion of patients who did not have a definite diagnosis of AS. Our data suggest that the decision to 
start anti-TNF therapy in this subgroup of patients might be justified by the extra-articular 
manifestations in half of these patients with probable AS (Table 8). This has also been suggested in the 
logistic regression model (model 2 in Table 10) and may suggest that comorbidities contributing to the 
burden of disease can be independent reasons to start anti-TNF therapy [27]. 
A few limitations of the study should also be noted. Firstly, the clinical evaluations were performed at a 
distance from the initiation of the therapy. This time lag was important to avoid the suggestion that 
patients were encouraged to overestimate their BASDAI in order to fulfil the reimbursement criteria. 
Although this time lag was limited (with a median of 2 months) changes in disease activity and 
treatment during this time lag might explain why some patients not fulfilling the reimbursement criteria 
started anti-TNF therapy and, inversely, why some patients with a high BASDAI at the clinical evaluation 
did not receive anti-TNF therapy. Secondly, a selection towards a more active and severe disease course 
may have occurred as patients who visited the rheumatologist more frequently may have had a higher 
probability of being included in this study. Finally, it is important to stress that some AS patients may be 
treated by generalists or orthopedic surgeons who have no access to anti-TNF therapy. These patients 
were not sampled in this study.  
In conclusion, we described a large cross sectional cohort of Belgian AS patients. These data provide 
important information on clinical and radiological features of the disease. Some patients started anti-
TNF therapy despite not fulfilling the reimbursement criteria and, inversely, other patients did not start 
anti-TNF therapy despite fulfilling the recommendations. Recommendations play a major part when 
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starting TNF inhibitors. However, in daily clinical practice other factors, dealing with the expert’s opinion 
and patients’ needs and expectations, also contribute to the decision to start TNF blocking therapy.  
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3.2. DAS28 best reflects the physician's clinical judgment of 
response to infliximab therapy in rheumatoid arthritis 
patients: validation of the DAS28 score in patients under 
infliximab treatment. 
3.2.1. Abstract 
This study is based on an expanded access program in which 511 patients suffering from active 
refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg + 
methotrexate (MTX)) at weeks 0, 2, 6 and every 8 weeks thereafter. At week 22, 474 patients were still 
in follow-up, of whom 102 (21.5%), who were not optimally responding to treatment, received a dose 
increase from week 30 onward. We aimed to build a model to discriminate the decision to give a dose 
increase. This decision was based on the treating rheumatologist's clinical judgment and therefore can 
be considered as a clinical measure of insufficient response. Different single and composite measures at 
weeks 0, 6, 14 and 22, and their differences over time were taken into account for the model building. 
Ranking of the continuous variables based on areas under the curve of receiver-operating characteristic 
(ROC) curve analysis, displayed the momentary DAS28 (Disease Activity Score including a 28-joint count) 
as the most important discriminating variable. Subsequently, we proved that the response scores and 
the changes over time were less important than the momentary evaluations to discriminate the 
physician's decision. The final model we thus obtained was a model with only slightly better 
discriminative characteristics than the DAS28. Finally, we fitted a discriminant function using the single 
variables of the DAS28. This displayed similar scores and coefficients as the DAS28. In conclusion, we 
evaluated different variables and models to discriminate the treating rheumatologist's decision to 
increase the dose of infliximab (+MTX), which indicates an insufficient response to infliximab at 3 mg/kg 
in patients with RA. We proved that the momentary DAS28 score correlates best with this decision and 
demonstrated the robustness of the score and the coefficients of the DAS28 in a cohort of RA patients 
under infliximab therapy. 
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3.2.2. Introduction 
Rheumatoid arthritis (RA) is a complex disease with a broad spectrum of manifestations that requires an 
early intensive therapy in order to avoid joint destruction and physical disability. In order to measure the 
effect of therapy in daily practice and in clinical trials, many variables are recorded and different 
composite indices have been proposed to measure the remaining disease activity or the response to 
treatment. Those variables may cover items such as patient self-reported questionnaires, physician's 
scores including different joint scores, and serum markers of systemic inflammation.  
Infliximab, in combination with methotrexate (MTX), is a highly effective therapy for a majority of RA 
patients. After an induction scheme at weeks 0, 2 and 6, the indicated dose of this therapy is 3 mg/kg 
every 8 weeks, although the ATTRACT trial suggested that a higher dose of 10 mg/kg every 8 weeks or a 
shorter perfusion interval may add benefit [1-3].  
The present study is based on an expanded-access program in which patients suffering from active 
refractory RA were treated with intravenous infusions of infliximab (3 mg/kg + MTX) at weeks 0, 2, 6 and 
every 8 weeks thereafter. At week 22, patients not optimally responding to treatment could receive a 
dose increase of 100 mg (1 vial) per infusion from week 30 onwards [4]. The effect of dose escalation for 
the patients of this cohort has been discussed previously [4]. The decision to increase the dose was 
based on the treating rheumatologist's clinical judgment and can be considered as a measure of 
insufficient response to infliximab. It might be questioned which variables can be measured to best 
evaluate the effect of therapy and remaining disease activity in daily practice (and in clinical trials). The 
aim of the present analyses was to evaluate whether the decision to increase the dose could be 
reflected by using single variables or composite indices, alone or together in a model. We also wanted to 
evaluate whether this decision was mainly based on differences over time or on momentary disease 
activity. 
3.2.3. Methods 
3.2.3.1. Study population 
A total of 511 patients, suffering from active refractory RA [5], were treated with intravenous infusions 
of infliximab (3 mg/kg) at weeks 0, 2, 6 and every 8 weeks thereafter in combination with MTX (a 
minimal dose of 15 mg/kg was recommended). Between week 0 and week 22, 37 patients dropped out 
for the following reasons: 16 patients stopped due to side effects (four infusion reactions, five 
infections, one malignancy, one pancytopenia, five disease-related complications), 12 patients stopped 
for withdrawal of consent and 9 patients stopped for protocol violation. Of the remaining 474 patients, 
102 (22%) patients, who were not optimally responding to treatment according to the treating 
rheumatologist's opinion, received a dose increase of 100 mg (1 vial) per infusion from week 30 on. 
Throughout the first 22 weeks, dosage of MTX, steroids and non-steroidal anti-inflammatory drugs 
remained unchanged. 
3.2.3.2. Evaluated variables 
When designing the model, we took the following single variables into account at weeks 0, 6, 14 and 22: 
28 and 66/68 swollen/tender joint counts, erythrocyte sedimentation rate (ESR; mm/h), C-reactive 
protein (CRP; mg/l), Health Assessment Questionnaire (HAQ; 0–3), physician's global assessment of 
disease activity (visual analogue scale (VAS); 0–100 mm), patient's global assessment of disease activity 
(VAS 0–100 mm), patient's assessment of pain (VAS 0–100 mm), patient's assessment of fatigue (VAS 0–
100 mm) and all subscales of the SF-36 questionnaire (0–100 points) [6]. DAS28 (Disease Activity Score 
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including a 28-joint count) [7] and other composite scores such as simplified disease activity index 
(SDAI), clinical disease activity index (CDAI) [8, 9] and the alternative DAS28 scores [10, 11] (Table 11) 
were calculated after data collection so that the treating rheumatologist was unaware of the exact 
values of those composite scores. Also, differences over time and the DAS28 response (no, moderate or 
good) and the ACR (American College of Rheumatology) response (no/20/50) were computed [12, 13]. 
Score Formula AUC (95% CI) Sens at 95%  spec, 
% (95% CI) 
DAS28 
0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 0.70*ln(ESR) + 
0.014*pt global VAS 
0.840 (0.791–
0.889) 42.5 (36.9–48.1) 
DAS28-3 
[0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 
0.70*ln(ESR)]*1.08 + 0.16 
0.815 (0.763–
0.868) 37.8 (32.3–43.3) 
DAS28-
CRP 
0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 
0.36*ln(CRP+1) + 0.014* pt global VAS + 0.96 
0.829 (0.782–
0.876) 35.8 (30.4–41.2) 
DAS28-
CRP-3 
[0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 
0.36*ln(CRP+1)] * 1.10 + 1.15 
0.806 (0.755–
0.858) 28.9 (23.8–33.9) 
SDAI 28TJC + 28SJC + CRP/10 + pt global VAS/10 + phys 
global VAS/10 
0.824 (0.776–
0.873) 
40.7 (35.1–46.2) 
CDAI 28TJC + 28SJC + pt global VAS/10 + phys global 
VAS/10 
0.821 (0.772–
0.870) 
37.8 (32.3–43.2) 
DAS28-3 and DAS28-CRP-3 are the DAS28 and DAS28-CRP scores calculated without the patient's global 
disease activity VAS.  
TABLE 11: Formulas to calculate the different DAS and SDAI score. 
3.2.3.3. Statistics  
We opted to use only statistical methods that are available in a classical statistical package (SPSS 12.0; 
SPSS, Inc., Chicago, IL, USA) or could be computed manually. When needed, the continuous variables 
were normalized (by taking the square root of the joint counts and the natural logarithm of CRP and 
ESR). Robustness of the discriminant analyses and logistic regressions was confirmed by the use of a 
random train and test set. Missing values were handled by pairwise complete case analysis. This means 
that a case with no missing values for a group of variables is included in the analysis of that group of 
variables. The case may have missing values for variables used in other analyses. Confidence intervals 
(95% CI) for sensitivity or specificity were calculated based on the method proposed by Harper [14]. The 
areas under the curves (AUCs) of receiver operating characteristic (ROC) curves were calculated. A 
higher AUC indicates that a single variable has better discriminative characteristics. A statistical test to 
compare AUCs of two variables tested on the same population has been described by Hanley [15]. 
Continuous and categorical variables were compared by adapting the cut-off of the continuous variables 
to the same specificity level as the categorical variable so that sensitivities could be evaluated and 
compared [16]. The selection and comparison of variables by curve analysis was performed since this 
method gives a valid ranking of variables and does not (in contrast to ranking methods based on p 
values) depend on the number of subjects available for that specific variable [17]. In order to find the 
true maximal model and to avoid sticking at a local maximal model, we used different strategies for the 
construction of the final model: binary logistic regressions and discriminant analyses were performed 
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with the default options of SPSS 12.0 and stepwise construction of models was performed by conditional 
forward and backward elimination for logistic regression and by Wilk's lambda for discriminant analysis 
using the strategy described by Hosmer and Lemeshow [18]. 
3.2.3.4. Ethics 
All patients signed informed consent. This study was approved by the local ethics committees. 
 
3.2.4. Results 
3.2.4.1. Ranking of continuous variables  
In order to select the most important variables that correlate with the decision to give a dose increase at 
week 22, we calculated the AUC of ROC curve analysis for all continuous variables and ranked them 
based on this AUC [17]. Since crossing over of ROC curves may affect the diagnostic properties of a 
variable without changing the AUC, we also ranked the variables based on sensitivity levels by adapting 
the cut-off to a given pre-set specificity level of 95% [16]. 
Both ranking methods displayed that the DAS28 score at week 22 had the highest ability to discriminate 
the physician's decision to give a dose increase. Table 12 displays the 10 most important variables 
ranked by AUC of ROC curve analysis and by the sensitivity at the 95% specificity level. Using the method 
described by Hanley [15], we found that there was a significant difference in AUC between the two first 
ranked parameters: DAS28 at week 22 and the 28 tender joint count at week 22 (AUC = 0.840 versus 
0.797, p = 0.02). Additionally, most variables were ranked in such a way that each variable was 
represented first by its measure at week 22 before it was represented by a measure at another week. 
 
 
 
 AUC 95% CI of AUC 
DAS28 w22 0.840 0.791–0.889 
28 TJC w22 0.797 0.744–0.850 
Physician global VAS w22 0.786 0.736–0.836 
Patient pain VAS w22 0.764 0.71–0.814 
DAS28 w14 0.750 0.685–0.815 
Patient disease activity VAS w22 0.750 0.689–0.802 
66TJC w22 0.740 0.689–0.791 
28TJC w14 0.721 0.662–0.780 
66SJC w22 0.717 0.660–0.774 
ESR w22 0.716 0.654–0.779 
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Sensitivity (%) at 95% specificity level 95% CI of sensitivity 
DAS28 w22 42.5 36.9–48.1 
Physician global VAS w22 32.7 28.4–37.0 
28SJC w22 29.8 24.7–34.9 
Patient pain VAS w22 26.8 22.7–30.9 
66SJC w22 24.5 20.6–28.4 
ESR w22 24.1 19.7–28.5 
66SJC w14 23.0 18.6–27.4 
CRP w22 21.3 17.3–25.3 
Patient disease activity VAS w22 20.4 16.6-4.2 
DAS28 w14 20.3 15.3–25.3 
TABLE 12:  Validation of the DAS28 score and coefficients (see text).  
3.2.4.2. Evaluation of the response scores 
To evaluate categorical scores, we adapted the cut-off of the variable with the highest ranking (DAS28 at 
week 22) to the specificity of the categorical score and compared the sensitivities [16]. For the decision 
to give a dose increase, ACR response not reaching the ACR20 criterion ('no ACR response') had a 
sensitivity of 69.6% (95% CI: 65.2–74.0) and a specificity of 64.2% (95% CI: 59.6–68.8). When we adapted 
the cut-off of the DAS28 at week 22 to a specificity of 64.2% (DAS28 = 4.01), we obtained a sensitivity of 
80.0% (95% CI: 75.2–84.7). 'No DAS28 response' had a sensitivity of 46.7% (95% CI: 40.8–52.6) and a 
specificity of 83.3% (95% CI: 78.9–87.7). When we adapted the cut-off of the DAS28 to a specificity of 
83.3% (DAS28 = 4.77), we obtained a sensitivity of 67.5% (95% CI: 61.9–73.1). Similar results were 
obtained when looking at the ACR50 and the good DAS28 response criterion (Table 13). 
TABLE 13: Sensitivity and specificity of the response scores compared with DAS28 set at equal 
specificity. 
 
 
Sensitivity and specificity of the 
different response scores 
Sensitivity of DAS28 at the same 
specificity level 
 Specificity (%) Sensitivity (%) Sensitivity (%) According DAS28 score 
No moderate DAS response 83.3 46.7 67.5 4.8 
No good DAS response 42.4 96.3 97.3 3.1 
No ACR20 response 64.2 69.6 80.0 4.0 
No ACR50 response 33.6 85.9 97.5 2.9 
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Additionally, we fitted a logistic regression model with the decision to give a dose increase as a 
dependent variable and DAS28 at week 22, DAS28 response and ACR response as categorical covariates. 
These analyses retained DAS28 at week 22 as the only significant covariate in the model (data not 
shown). 
3.2.4.3. Effects of change of scores over time on the physician's decision 
To evaluate the effect of differences over time, we plotted the means of the most important normalized 
continuous variables over time (Figure 10).  
 
FIG.10. Plot of the mean scores over time.  
The plot of the variable with the highest ranking (DAS28) shows that patients who get a dose increase 
have a (significantly) higher disease activity at baseline and, after an initial decrease of disease activity, 
regain disease activity from week 6 on. To evaluate this, we calculated differences in DAS28 scores 
between baseline and week 22 (delta DAS28 0–22), and between week 6 and week 22 (delta DAS28 6–
22). Indeed, patients who get a dose increase regain some disease activity between week 6 and week 22 
(mean delta DAS28 6–22: -0.4 versus +0.4, p < 0.001), which is reflected in a smaller decrease of disease 
activity between baseline, and week 22 (mean delta DAS28 0-22: -2 versus -1, p < 0.001). However, the 
AUC of the ROC curve of delta DAS28 0–22 was 0.725 (95% CI: 0.659–0.790) and the AUC for delta 
DAS28 6–22 was 0.672 (95% CI: 0.590–0.754), which is much lower than the AUC of the momentary 
DAS28 (0.840) at week 22. Additionally, when we fitted a logistic regression model with the decision to 
give a dose increase as a dependent variable and DAS28 at week 22, delta DAS28 0–22 and delta DAS28 
6–22 as covariates, only DAS28 at week 22 was a significant variable in the model. 
Similar analyses were performed for the other variables. The AUC of the differences between weeks 0–
22, weeks 6–22 and weeks 14–22 of the other variables were all less than 0.700 (data not shown). These 
analyses indicate that, although the differences in disease activity over time are statistically significant, 
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those differences over time are not important enough to incorporate in a model to discriminate the 
physician's decision. 
3.2.4.4. Building a model to discriminate the physician's decision to give a dose increase 
The first three analyses (ranking of continuous variables, evaluation of the response scores and effects 
of change of scores over time on the physician's decision) allowed us to narrow the selection of 
variables for the model by eliminating variables that are already incorporated into the DAS28 (or are 
highly related to them such as CRP and 68 tender joint and 66 swollen joint count) and taking into 
account only those variables at week 22. This resulted in the following list: DAS28, HAQ, physician global 
VAS, patient pain VAS, patient fatigue VAS and the scores of the SF36 questionnaire at week 22. We 
screened those variables using forward and backward elimination in a logistic regression model and by 
the stepwise Wilk's lambda method. The probability scores of the logistic regression and discriminant 
scores we thus obtained were compared using ROC curve analysis. The model with the highest AUC was 
a model from discriminant analysis with the following variables (and standardized canonical discriminant 
function coefficients): DAS28 week 22 (0.863), physician global VAS (0.796), patient pain VAS (0.735), 
and physical functioning (-0.227). The discriminant score of this model had an AUC of 0.870 (95% CI: 
0.828–0.912) with a sensitivity at the 95% specificity level of 45.5% (95% CI: 38.7–50.3). 
3.2.4.5. Evaluation of the discriminant score of the variables of DAS28 
To validate the score and coefficients of the DAS28, we calculated a discriminant function using the 
(normalized) variables of the DAS28 score: 28 tender and swollen joint count, ESR and patient global 
VAS. After rescaling, we obtained the following discriminant coefficients: 0.52 for 28 tender joint count 
(28TJC), 0.28 for 28 swollen joint count (28SJC), 0.56 for ESR and 0.025 for patient disease activity. This 
discriminant score had an AUC of 0.844 (0.797–0.891) and a sensitivity at the 95% specificity level of 
43.8% (95% CI: 38.1–49.2), which is equal to the DAS28 at week 22. The Pearson's correlation coefficient 
between this discriminant score and the DAS28 was 0.986 (Figure 11). We also performed logistic 
regression with similar results (data not shown). 
3.2.4.6. Comparison with the other DAS scores and SDAI/CDAI 
Since different alternative methods are available to calculate the DAS scores (Table 11), we additionally 
evaluated the properties of those alternative scores. We also evaluated the SDAI and CDAI [8, 9], after 
normalization, by taking the squared root. The Pearson's correlation coefficient of those alternative 
scores with the DAS28 at week 22 was 0.982 for the DAS28-3, 0.952 for the DAS28-CRP, 0.928 for the 
DAS28-CRP-3, 0.914 for the SDAI and 0.893 for the CDAI. The AUC and sensitivity at the 95% specificity 
level are shown in Table 11 and indicate that all those alternative scores perform similarly or slightly 
worse than the original DAS28.  
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FIG.11. Validation of the DAS28 score and coefficients (see text). 
3.2.4.7. Detailed ROC curve analysis of the DAS28 
We plotted the ROC curve of the DAS28 in Figure 12 and listed sensitivities and specificities in Table 14. 
Also, predictive values and the accuracies of classification in function of the different DAS28 cut-offs are 
shown in Table 14. Beneath a cut-off of 3.2, we found a high predictive value for continuing the current 
dose as a measure of good response. The maximal accuracy of 84% could be found at a cut-off of 5.5. 
 
FIG. 12: ROC curve analysis of the DAS28 at week 22 (plotting the 1-specificity versus the sensitivity). Also 
the accuracy, PPV and NPV are plotted.  
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DAS cut-off Sensitivity Specificity PPV NPV Accuracy 
2.0 0.99 0.13 0.23 0.98 0.31 
2.5 0.99 0.22 0.25 0.99 0.38 
2.6 0.99 0.26 0.26 0.99 0.41 
3.0 0.98 0.38 0.29 0.98 0.50 
3.2 0.96 0.46 0.32 0.98 0.57 
4.0 0.79 0.66 0.38 0.92 0.68 
4.5 0.76 0.77 0.47 0.92 0.77 
5.0 0.58 0.87 0.55 0.89 0.81 
5.1 0.53 0.88 0.55 0.88 0.81 
5.5 0.43 0.95 0.69 0.86 0.84 
6.0 0.34 0.97 0.73 0.85 0.83 
6.5 0.19 0.98 0.72 0.82 0.81 
DAS, disease activity score; PPV, positive predictive value (predictive value to give a dose increase as a 
measure of insufficient response); NPV, negative predictive value (predictive value to continue on the 
current dose as a measure of good response); PPV, NPV and accuracy were calculated using the 
following formulae:  
 
 
c) Accuracy = sensitivity* a_priori_chance + specificity* (1-a_priori_chance)  
The a priori chance is given by the percentage of patients that need a dose increase as a measure of 
insufficient response.  
TABLE 14: Performance at different cut-offs of DAS28 at week 22 for dose increase. 
3.2.5. Discussion 
The aim of the present analyses was to evaluate which single or composite variables, combined in a 
model, could discriminate the treating rheumatologist's decision to give a dose increase of infliximab to 
RA patients not optimally responding to an indicated dose of 3 mg infliximab every 8 weeks. Since 
different variables on different time points were available, we started to rank the continuous variables 
based on the AUC of ROC curves and sensitivities at the 95% specificity level. This strategy has previously 
been proposed for microarray data [17]. The calculation of sensitivities at the 95% specificity level is 
important in order not to overlook some variables with a relative small AUC but with a high specificity 
[16]. So, both methods ranked the DAS28 at week 22 as the variable which best discriminates the 
decision to give a dose increase. In a second and third analysis, we looked at whether response scores 
and differences in disease activity over time could give additional information to discriminate the 
rheumatologist's decision. Those analyses indicated that variables, including differences over time, seem 
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to be less important than the momentary remaining disease activity at week 22, to discriminate the 
rheumatologist's decision. 
After the prior selection of variables, based on the findings of the previous steps, we built the final 
model to discriminate the rheumatologist's decision, which was only slightly better than the DAS28. We 
think that the small gain in discriminative properties in comparison with the DAS28 is not enough to 
accept the increased complexity of this model. Moreover, in contrast to the DAS28, this model included 
the physician's global assessment of disease activity (VAS), which is investigator-dependent and has the 
draw-back that it cannot be calculated by a study nurse. All four analyses together indicated that the 
DAS28 is an important variable for evaluating insufficient response to infliximab therapy (especially in 
daily practice) and that this variable can only slightly be improved by adding supplemental variables. 
DAS was developed in the early 1990s [19, 20] and later on, it was transformed into the DAS28 [7] in an 
era when therapy with biologicals was not yet available. In those initial studies, patients were scored by 
the same two independent nurses and the decision to change disease-modifying anti-rheumatic drug 
(DMARD) therapy during a follow-up period of up to 3 years was considered as a measure of insufficient 
response [20]. The present study is a multi-centre study where patients were scored by the treating 
physician and the decision to give a dose increase of infliximab could happen only at one time point. This 
difference in study design and therapy may explain why in the present study the AUC of DAS28 is 
smaller than in other studies (AUC = 0.840 versus 0.933) [21]. Therefore, it is remarkable that despite 
those differences in study design, we could calculate a discriminant function (in the fifth analysis) that 
correlated so well with the DAS28 by using the 28SJC, 28TJC, ESR and patient disease activity VAS as 
independent variables and the physician's decision as a grouping variable. Not only the discriminant 
scores, but also the coefficients of this discriminant function were quite similar to the coefficients of the 
DAS28, indicating the robustness of the scores and coefficients of the DAS28 score. 
In another, final analysis, we evaluated the alternative DAS scores and the squared root transformed 
SDAI and CDAI. All those alternative scores have a slightly worse AUC than the original DAS28, but seem 
good enough to be useful when some other variables are not available. We think the use of the DAS28 is 
feasible and time-effective using a preprogramed calculator, spreadsheet or web-based calculator [11]. 
The unique characteristics of the DAS score make it a useful measure in a lot of applications. DAS28 as a 
continuous variable is a sensitive tool for measuring response to treatment in randomized controlled 
trials and facilitates the use of more complex statistical methods that can handle repeated measures 
over different time points [22-24]. 
Other studies demonstrated that a low DAS is an important prognostic factor of persistent remission 
and that DAS correlates with radiological progression [25, 26]. DAS may also be a useful parameter in 
daily clinical practice as a treatment goal and to evaluate the actual disease activity (which cannot be 
assessed by the categorical response scores) [27-31]. Our findings that the physician's decision to give a 
dose increase can best be modelled by a combination of measurements of remaining/momentary 
disease activity, represented by the DAS28 does not reduce the value of the response scores such as 
ACR response or DAS response scores. Indeed, those scores are important for measuring differences 
over time as a measure of global treatment effects in clinical trials [12, 13] but, as demonstrated by the 
present study, are not useful for evaluating the momentary disease activity in a single patient, which is 
important in daily practice. The continuous properties of the DAS28 score provide the additional 
opportunity for a cut-off, which can be chosen as a function of the purpose. Interestingly, we found a 
high predictive value for continuing the current dose as a measure of good response below a cut-off of 
3.2. It is noteworthy that a DAS score of 3.2 is an important threshold for a good DAS response 
according to the EULAR criteria [12]. In contrast, for classification purpose, a higher cut-off (5.5) is more 
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appropriate since this level displayed the highest accuracy. One should be aware that the displayed 
predictive values and accuracies may be highly influenced by the prevalence of insufficient response, 
reflected by the need for a dose increase, which was 21.5% in the present study. A lower a priori chance 
of the need for a dose increase may increase the accuracy of DAS (given the fixed cut-off of 5.5) and vice 
versa. Indeed, at a cut-off with a high specificity, the accuracy will increase when the a priori chance 
decreases (applying formula c given in the legend to Table 14). 
Conclusion The results of the present analyses indicate that the momentary DAS28 as a continuous 
composite index correlates best with the decision to give a dose increase of infliximab, which is a 
measure of insufficient response. The discriminative characteristics of the DAS could be slightly 
improved by the use of supplemental variables, although this results in the disadvantage of a more 
complex model and calculations. This study also demonstrates the robustness of the scores and 
coefficients of the DAS28 in a cohort of RA patients under infliximab therapy and therefore validates the 
DAS28 as a measure of disease activity in patients under treatment with biologicals. 
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Chapter 4: Prediction Models of Anti-TNF 
alpha Outcomes in RA and AS 
Four studies that had as aim to investigate for which patients anti-TNF treatment would be most 
valuable as determined by the likelihood of achieving a desired outcome are reported. 
 
 
 
A pilot risk model for the prediction of rapid radiographic 
progression in rheumatoid arthritis. 
Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. 
Rheumatology (Oxford). 2009 Sep; 48(9):1114-21. Epub 2009 Jul 9. 
Prediction of Remission and Low Disease Activity in DMARD-
refractory Patients with RA Treated with Golimumab. 
Vastesaeger N, Garcia Kutzbach A, Amital H, Pavelka K, Lazaro A, Moots RJ, Wollenhaupt J, Zerbini 
CAF, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, 
Durez P. 
Submitted manuscript. 
Predicting the outcome of ankylosing spondylitis therapy. 
Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, 
Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. 
Ann Rheum Dis. 2011 Jun; 70(6):973-81. Epub 2011 Mar 14. 
ASDAS high disease activity versus BASDAI elevation in 
patients with ankylosing spondylitis as selection criterion for 
anti-TNF therapy. 
Vastesaeger N, Vander Cruyssen B, Mulero J, Gratacós Masmitjá J, Zarco P, Almodovar R, Font P, 
Juanola X, Collantes-Estevez E; REGISPONSER Working Group. 
Reumatol Clin. 2014 Jul-Aug; 10(4):204-9. Epub 2014 Mar 2. 
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4.1. A pilot risk model for the prediction of rapid radiographic 
progression in rheumatoid arthritis 
4.1.1. Abstract 
Objectives  
Identifying patients with RA at high risk of rapid radiographic progression (RRP) is critical for making 
appropriate treatment decisions. We developed an exploratory prediction model for the risk of RRP 
using an RA study population undergoing either conservative or aggressive disease management.  
Methods  
Using data from the active-controlled study of patients receiving infliximab for the treatment of 
rheumatoid arthritis of early onset (ASPIRE) early RA study, RRP was defined as a threshold change in 
modified Sharp/van der Heijde score (SHS) of ⩾5 U/year. Spearman's rank analysis was used to identify 
baseline risk factors for RRP. Logistic regression was used to calculate the probability of RRP in 1 year. 
The results were combined into a matrix model that consisted of risk factors and initiated treatment 
arranged in increasing risk of RRP. Data from the anti-TNF trial in rheumatoid arthritis with concomitant 
therapy (ATTRACT) established RA study were applied to the model to test its generalizability in another 
population.  
Results 
The 28 swollen joint count, RF, CRP and ESR are included as trichotomous variables and initiated 
treatment (monotherapy or combination therapy) as a dichotomous variable. Two models, one 
incorporating all risk factors except CRP and another incorporating all risk factors except ESR, were 
developed to adjust for collinearity. These models identify subpopulations of RA patients at higher 
predicted risk for RRP.  
Conclusions 
These preliminary matrix models predict the risk of RRP using initiated treatment and easily accessible 
clinical and laboratory variables. Further testing in other populations and with other therapies is needed 
to obtain a definitive risk model that will guide rheumatologists in making treatment decisions for 
individual RA patients.  
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4.1.2. Introduction 
RA is a chronic systemic inflammatory disease predominantly characterized by joint inflammation and 
frequent progression of joint destruction resulting in decreased functional capacity, work disability and 
reduced quality of life [1-4]. Rapid radiographic progression (RRP) in RA usually occurs in a minority of 
treated patients. In these patients, effective therapy can reduce the odds of progression by as much as 
78% [5], and both early and intensive treatment can alter the course of the disease by slowing the rate 
of radiographic progression [6-8]. The identification of individual RA patients at high risk of RRP is 
therefore critical to making appropriate treatment choices. Various clinical and biological markers have 
been identified as baseline risk factors for the progression of joint damage in patients with RA [8-12]. 
Although the use of any single baseline variable has limited value [13], combining multiple markers has 
been shown to improve predictive power [12-16].  
One of the most widely used risk models in medicine is the Systematic Coronary Risk Evaluation (SCORE) 
Risk Chart [17]. This model predicts the 10-year probability of cardiovascular mortality based on a 
number of widely accepted risk factors (e.g. sex, blood pressure, lipid levels and tobacco use) that have 
been organized into a simple, visual, color-coded matrix relative to an individual's specific risk profile. 
However, a limitation of the SCORE chart is that it does not account for the associated adverse effects of 
the therapies that may influence the risk of adverse outcomes.  
We aimed to create a similar visual matrix model that would predict the 1-year risk of RRP for individual 
RA patients based on associated risk factors and the type of initiated therapy (conservative vs aggressive 
management). We describe the first stage of development of this exploratory model using data from the 
active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early 
onset (ASPIRE) from an early RA study population [18] and test whether the proposed method for 
outcome prediction could also be used in the anti-TNF trial in rheumatoid arthritis with concomitant 
therapy (ATTRACT) from an established RA study population [19]; both these groups were receiving 
either DMARD monotherapy or intensive anti-TNF plus DMARD combination therapy.  
4.1.3. Methods 
4.1.3.1. The ASPIRE and ATTRACT studies 
In ASPIRE, 1049 MTX-naïve, early RA patients (disease duration 3 months–3 years) were double-blinded 
to randomly receive MTX monotherapy or MTX in combination with 3 or 6 mg/kg infliximab through 46 
weeks [18]. In ATTRACT, 428 established RA patients with active disease despite treatment with stable-
dose MTX (⩾12.5 mg/week) were continued on MTX and additionally double-blinded to randomly 
receive placebo or 3 or 10 mg/kg infliximab through 54 weeks [19]. For this analysis, the infliximab plus 
MTX groups were combined in each respective study, since all dose groups within each study were well 
balanced for demographics and baseline disease characteristics and showed similar rates of radiographic 
progression through Week 54. This study is a subanalysis of the ASPIRE and the ATTRACT studies, both 
of which had ethical approval and informed patient consent. The authors had full access to the data of 
these studies. Relevant baseline demographics and disease characteristics are summarized in Table 15.  
 
 
 
 60  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
 
ASPIRE ATTRACT 
n 1049 428 
Age, years 51 (41, 60) 53.5 (45, 60) 
Sex, female 742 (71.1) 332 (77.6) 
Disease duration, years 0.6 (0.4, 1.1) 8.4 (4.3, 14.7) 
HAQ score (scale 0–3) 1.5 (1.0, 1.9) 1.8 (1.3, 2.1) 
TJC 31 (22, 44) 31 (19, 44) 
SJC 19 (14, 26) 20 (13, 29) 
CRP, mg/dl 1.4 (0.4, 4.1) 2.6 (1.1, 5.1) 
ESR, mm/h 40 (23, 61) 42 (32, 65) 
RF, U/ml 175 (30, 357) 178 (48, 425) 
Total modified SHS 5.0 (1.5, 14.0) 51.5 (20.6, 113.0) 
Patients with joint erosion 854 (82.0) 415 (99.1) 
Patients with joint space narrowing 687 (65.9) 402 (95.9) 
Patients with prior joint surgery 3 (0.3) 90 (21.0) 
TABLE 15: Baseline demographics and disease characteristics across treatment groups. Data are 
presented as median (interquartile range) or n (%). 
In both studies, patients were assessed at baseline for the 68 tender joint count (TJC), the 66 swollen 
joint count (SJC), ESR, CRP, RF and radiographs of the hands and feet. The Westergren method was used 
to determine ESR at the local laboratory. CRP was measured by nephelometry. IgM-RF was evaluated at 
the central laboratory. Two readers blinded to treatment and timepoint scored the radiographs 
independently. The average of the two readers’ scores at each timepoint was used to calculate joint 
damage progression as defined by the change in the van der Heijde modification of the Sharp score 
(SHS) [20] from baseline to Week 54. In ASPIRE, the intraclass correlation coefficients were 0.87 at 
baseline and 0.88 at Week 54. The smallest detectable difference in SHS was defined at 9.0 and 8.6 U 
from baseline, respectively, in the ASPIRE and the ATTRACT studies.  
4.1.3.2. Determination of RRP 
To define RRP for the model, the proportions of patients in ASPIRE who rapidly progressed according to 
a range of thresholds of annual change in SHS (>0 to ⩾9) were compared with the mean/median 
progression rate and to the proportion of patients who had any progression. Sensitivity analyses using 
other thresholds of annual change in SHS were done to determine whether using an equally higher or 
lower definition of RRP would significantly affect the multivariate model.  
4.1.3.3. Selection of baseline risk factors 
Baseline risk factors to be included in the model were identified from the ASPIRE data set. The ASPIRE 
study design, which allowed for the inclusion of a range of RA patients (e.g. those with normal CRP, 
negative RF or no erosive disease) [18], provides an apt data set for examining 1-year radiographic 
progression in relation to various clinical and biological variables as well as administered therapy. 
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Without making any assumptions on the distribution of the variables, Spearman's correlation 
coefficients were used to evaluate the relationship between all available baseline variables and 
radiographic progression. Any two risk factors having a correlation coefficient >0.3 were investigated for 
collinearity to minimize the inclusion of duplicative factors. A comparison of the maximum rescaled R2 
was used to evaluate whether including only one of any pair of collinear factors would improve the face 
validity of the model without significantly reducing the predictive power.  
Logistic regression analyses were performed to predict the risk of RRP from the selected baseline risk 
factors after adjustment for treatment group. These baseline risk factors include SJC, RF, and ESR or CRP, 
treated as ordinal variables. No adjustments were made for multiple testing. Predicted probability of 
RRP was calculated using a logistic regression analysis. For selected risk factors that are continuous 
variables, treatment group differences in the change in SHS from baseline to Week 54 were further 
explored using analysis of variance on van der Waerden normal scores to test for interaction among 
baseline characteristics. Statistical analyses were done using the SAS system (SAS Institute, Cary, NC, 
USA). All statistical tests were two-sided and tested at α = 0.05.  
4.1.3.4. Development of the matrix risk model 
The selected baseline risk factors and initiated treatments were combined and arranged so that the risk 
of RRP increases from left to right and from bottom to top in the matrix model. Each continuous risk 
factor was presented in approximate tertiles based on clinical utility and the ability to identify subgroups 
of relevant size. A colour scheme ranging from blue (low risk) to red (high risk) was used to enhance 
visual readability. Patient baseline and radiographic data from ASPIRE were then used to generate the 
probabilities of RRP to populate the exploratory matrix risk model. Absolute and relative risk ratios and 
numbers needed to treat (NNT) were calculated using this generated model to evaluate the relative 
benefit of MTX monotherapy vs MTX plus infliximab in ASPIRE.  
4.1.3.5. Application of the matrix risk model 
To assess whether our matrix risk model—i.e. the method we used to arrange the combination of 
selected risk factors for risk prediction in an early RA data set—would be similarly predictive of the same 
definition of RRP in more advanced RA populations undergoing similar treatment, patient baseline and 
radiographic data from the ATTRACT study were used to generate the probabilities of RRP in a second, 
exploratory matrix risk model.  
Finally, to highlight the impact of the choice of conservative vs aggressive management on actual 
radiographic progression early in the disease course, we show the cumulative probability plots as 
described by van der Heijde et al. [21] of two ASPIRE patient subgroups selected based on their baseline 
risk factor profiles.  
4.1.4. Results 
4.1.4.1. Determination of RRP 
The observed proportion of patients with radiographic progression in ASPIRE was inversely related to 
the threshold values tested, i.e. higher proportions for lower thresholds and vice versa (Table 16). 
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 MTX monotherapy Infliximab plus MTX 
Progression in the modified SHS, U/year   
    Mean ± s.d.  3.7 ± 9.6 0.5 ± 5.6 
    Median (interquartile range) 0.3 (0.0, 4.4) 0.0 (−1.0, 1.3) 
    Range (−22.3, 67.9) (−34.7, 48.0) 
Patients with progression in SHS, U/year, %   
    >0 52.0 39.2 
    >=1 42.3 30.4 
    >=2 32.9 20.1 
    >=3 29.5 13.6 
    >=4 26.5 10.7 
    >=5 22.8 8.3 
    >=6 19.1 6.5 
    >=7 17.8 5.2 
    >=8 15.4 4.8 
    >=9 14.1 3.9 
TABLE 16. Radiographic progression through Week 54 according to various thresholds in the ASPIRE 
early RA population. The bold values were calculated from the sensitivity analysis. Higher SHS U/year 
indicates more severe radiographic progression of joint damage.  
Based on our clinical experience and the fact that the complete destruction of one joint during 1 year is 
equal to an increase of 5 SHS units [22, 23], we arbitrarily selected this increase in SHS of ⩾5 U/year as 
the definition of RRP for conceptual simplicity. Among patients who showed any radiographic 
progression, a threshold of ⩾5 U/year in the SHS identified ∼23% of those on MTX monotherapy and 8% 
of those on infliximab plus MTX. Sensitivity analysis with the threshold changes in SHS of ⩾2 and ⩾8 
U/year demonstrated the same inversely proportional relationship for the logistic regression modelling 
of the selected baseline risk factors and the identified subgroups of patients with radiographic 
progression, i.e. the higher the threshold change, the smaller the identified subgroup. As an example, 
the sensitivity analysis for CRP is shown in Figures 13A and B.  
4.1.4.2. Selection of baseline risk factors 
In ASPIRE, the following continuous baseline risk factors were selected for inclusion in the model as 
trichotomous variables: CRP (<0.6, 0.6–3 or >3 mg/dl), ESR (<21, 21–50 or >50 mm/h), SJC (<10, 10–17 
or >17) and RF (<80, 80–200 or >200 U/ml) (Figures 13C–F).  
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FIG.13. Predicted risk of RRP as a function of (A) CRP (RRP ⩾ 2 SHS U/year); (B) CRP (RRP ⩾ 8 SHS 
U/year); (C) CRP (RRP ⩾ 5 SHS U/year); (D) ESR (RRP ⩾ 5 SHS U/year); (E) 28 SJC (RRP ⩾ 5 SHS U/year); 
(F) RF (RRP ⩾ 5 SHS U/year) at baseline in the ASPIRE population. Dotted vertical lines represent the 
selected ranges. Higher percentage indicates more severe radiographic progression of joint damage.  
CRP and ESR were highly correlated (coefficient = 0.61) and showed limited collinearity. When ESR was 
excluded from the model, the maximum rescaled R2 decreased only slightly, from 0.1616 to 0.1428. 
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From this decrease, we concluded that the model could be simplified by using just one of the two risk 
factors without compromising its predictive power. Although both the 66 (data not shown) and the 28 
joint counts for SJC correlated similarly with radiographic progression, the 28 joint count was selected 
for its greater practicality in the clinical setting [24]. RF titer was included as a trichotomous variable, 
because it contributed significantly to the model as a continuous variable but not as a categorical 
variable (i.e. RF-positive or -negative). Initiated treatment (MTX monotherapy or infliximab plus MTX) 
was included in the model as a dichotomous variable. Treatment through 46 weeks with infliximab plus 
MTX resulted in significantly better radiographic outcome compared with MTX monotherapy for the 
total sample patient population and for all high-range subgroups defined by risk profile (Figure 14).  
 
FIG. 14. Differences between treatment groups in mean van der Waerden (VW) normal scores of the 
change of ⩾ 5 U/year in total modified SHS for subgroups defined by selected baseline risk factors in the 
ASPIRE population. 
 
Notably, radiographic damage or radiographic score at baseline was not a prognostic variable. Eighty-
two percent and 66% of the patients had erosions and joint space narrowing, respectively, at baseline, 
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which did not allow us to take into account the presence of damage at baseline as a prognostic factor in 
our model. Radiographic score at baseline was inversely associated with the radiographic progression in 
patients treated with infliximab plus MTX and was, therefore, not retained as a negative prognostic 
factor in the model.  
4.1.4.3. Development of the matrix risk model 
Using clinical, serological and radiographic data from the ASPIRE early RA population, two alternate 
models—one incorporating all risk factors except ESR (Figure 15A) and another incorporating all risk 
factors except CRP (Figure 15B)—were generated to enable the interchangeable use of these two acute-
phase measures depending on clinical availability.  
 
FIG.15. Matrix risk model for the probability of RRP in 1 year including all selected baseline risk factors 
except (A) ESR or (B) CRP, generated from the ASPIRE early RA data set. The numbers in each cell 
represent the percentage (95% CI) of patients who had RRP out of all patients who have the baseline 
characteristics and receive the initiated treatment as indicated. Colour scheme: blue: 0–9%; green: 10–
19%; yellow: 20–29%; orange: 30–39%; red: 40–100% predicted probability of RRP. Higher percentage 
indicates more severe radiographic progression of joint damage. 
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The numbers in each cell of the matrix represent the percentage (95% CI) of patients who had RRP out 
of all patients who have the baseline characteristics and receive the initiated treatment as indicated by 
the location of the cell within the matrix. For example, a patient with RA who has 18 swollen joints and 7 
mg/dl CRP and 380 U/ml RF serum concentrations would have a 47% (95% CI 36%, 59%) probability of 
RRP if treated with MTX monotherapy or a 14% (95% CI 9%, 20%) probability if treated with infliximab 
plus MTX combination therapy. Due to the even distribution of the ASPIRE patient population over each 
of the selected risk factors (also see patient numbers in Figure 14), approximate tertiles were used to 
identify subgroups of relevant size in these matrix models. For example, the subgroup at the highest risk 
(SJC >17, RF >200 U/ml, CRP >3 mg/dl) comprised 65 patients in the CRP-based model shown in Figure 
15A.  
The relative risk reduction of RRP with infliximab plus MTX vs MTX monotherapy was 43 and 71% for 
those within the low ranges and 70 and 59% for those within the high ranges of all baseline risk factors, 
respectively, in the CRP- and ESR-based models. The absolute risk reduction of RRP with infliximab plus 
MTX as compared with MTX monotherapy was 3 and 5% for those within the low ranges and 33 and 
24% for those within the high ranges of all baseline risk factors, respectively, in the CRP- and ESR-based 
models. The NNT with aggressive management to prevent one patient from rapidly progressing with 
conservative management was 3 for those within the high ranges for CRP, SJC and RF and 33 for those 
within the low ranges.  
The cumulative probability plots of a subpopulation with a high risk of radiographic progression (CRP >3 
mg/dl, RF >200 U/ml, SJC >17; n = 65) and a subpopulation with a low risk of radiographic progression 
(CRP <0.6 mg/dl, RF <80 U/ml, SJC <10; n = 68) from ASPIRE are presented in Figure 16A and B.  
 
FIG.16. Cumulative probability plots of actual radiographic progression in modified SHS (U/year) in (A) an 
ASPIRE subpopulation with a high risk of radiographic progression (CRP > 3 mg/dl, RF > 200 U/ml, SJC > 
17; n = 65) and in (B) an ASPIRE subpopulation with a low risk of radiographic progression (CRP < 0.6 
mg/dl, RF < 80 U/ml, SJC 10–17; n = 68). Higher SHS U/year indicates more severe radiographic 
progression of joint damage. 
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4.1.4.4. Application of the matrix risk model 
As expected, all patients who received conservative management in the ATTRACT study tended to be at 
high risk of RRP, irrespective of baseline risk factor values (Figures 17A and B). To a greater extent than 
observed in the ASPIRE data set, combination therapy with infliximab considerably reduced the 
proportion of ATTRACT patients with RRP, since these patients were not initiating MTX but rather 
continuing their pre-study MTX despite having active disease. By contrast, patients receiving aggressive 
therapy within the low or intermediate ranges of all baseline risk factors tended to be at low risk of RRP; 
and only those within the highest ranges of baseline risk factors tended to be at high risk, albeit to a 
lesser degree than patients receiving conservative management.  
 
FIG17. Matrix risk models for the probability of RRP in 1 year including all selected baseline risk factors 
except (A) ESR or (B) CRP, generated from the ATTRACT established RA data set. The numbers in each cell 
represent the percentage (95% CI) of patients who had RRP out of all patients having the baseline 
characteristics and receiving the initiated treatment as indicated. Colour scheme: blue: 0–9%; green: 10–
19%; yellow: 20–29%; orange: 30–39%; red: 40–100% predicted probability of RRP. Higher percentage 
indicates more severe radiographic progression of joint damage. Mono: monotherapy; IFX: infliximab. 
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4.1.5. Discussion 
We developed two preliminary, exploratory matrix risk models for the prediction of radiographic 
outcome in RA based on multiple risk factors associated with joint damage and related to treatment 
type. The uniqueness of our preliminary models lies not in the included baseline risk factors whose 
prognostic capabilities are well recognized [13, 25-30], but in the way the combination of these markers 
are arranged into a visual matrix that is able to predict the 1-year risk of RRP based on where a patient's 
baseline risk factors fall within the matrix. This preliminary matrix risk model, once refined to a finalized 
model through further development—using a greater variety of RA populations, such as those seen in 
daily practice, and treatment options reflective of the daily clinical setting (e.g. treatment adjustment 
upon non-response), and perhaps in the future the inclusion of genetic markers—may be used in clinical 
practice to predict the risk of RRP in the individual RA patient. Further, the inclusion of conservative vs 
aggressive management in our models can guide rheumatologists in making appropriate treatment 
choices for patients, particularly for early RA patients naïve to DMARDs. The data sets available to 
perform this exploratory analysis limited our comparison of the drug regimen (MTX vs infliximab plus 
MTX). The management choices that can be made in light of the predicted prognosis need not be limited 
to the choice of drug regimen but can be an adjustment of the frequency and the method for measuring 
disease activity, the rapidity of including a biological agent in the regimen after an initial course with 
DMARDs, and the choice of imaging method for detecting joint damage. Rather than defining risk in 
terms of means, medians, ranges and S.D., we predicted risk in terms of ‘probability’, as the more 
practical method to refer to risk (prognosis) in a patient–doctor conversation.  
For our matrix model, we chose an annual progression rate of ⩾5 SHS U/year as our definition of RRP. 
Whereas harder endpoints, such as surgery and death, may be interesting to pursue in the future, both 
are usually very distant outcomes and becoming less prevalent in recent years [31-33]. Prevention of 
death is not thought to be a primary goal for treatment in RA. With better use of the therapeutic 
armamentarium that rheumatologists currently have access to, it can also be argued that joint surgery 
still has a place in the therapy for RA [33]. Although HAQ is an important outcome for clinicians and 
especially for patients, whether it can be considered an objective hard outcome is debatable. HAQ is 
primarily determined by disease activity [34], and much of the functional impairment is therefore 
reversible, especially early in the disease course [35]. However, it is well established that radiographic 
damage has an important effect on long-term functionality [1, 4, 34]. Therefore, choosing joint damage 
over a 1-year time-frame as our predicted outcome is a good surrogate of the consequences of disease 
activity as the driver of destruction and long-term disability resulting from this damage.  
Of course, we do not consider progression <5 SHS U/year insignificant, given the increase in irreversible 
disability with the accrual of joint damage [1, 35]. Applying a lower threshold of ⩾2 SHS U/year in the 
sensitivity analysis resulted in models showing the same inversely proportional relationship between 
threshold value and subgroup size, but with higher probabilities of RRP overall. Conversely, although the 
smallest detectable difference in SHS U/year was 9 U in ASPIRE, we did not choose a higher threshold 
value because a threshold of 9 SHS U/year was deemed too high by the advisory board and, as seen in 
Table 16, using a definition of ⩾9 SHS U/year identified much smaller subsets of patients meeting this 
rigorous definition of extensive RRP. Although ⩾5 SHS U/year was also deemed too high a threshold by 
the advisory board, our chosen definition identified subsets of relevant size.  
The 1-year endpoint was chosen because it is the most commonly reported radiographic endpoint and 
yearly progression rate is therefore likely to be the easiest for clinicians to interpret. Radiographic 
progression from baseline to Week 52 was the co-primary endpoint in the ASPIRE study [18] and it was 
the primary radiographic outcome parameter in the ATTRACT study [19]. Epidemiological studies have 
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shown that progression of radiographic damage on the group level is more or less linear [36]. 
Radiographic data at Week 30 were available for both ASPIRE and ATTRACT studies and confirmed the 
linearity of progression within the first year at the group level (data not shown). In light of this, as we are 
reporting on a yearly progression rate rather than the overall SHS, progression times <1 year (e.g. 3 and 
6 months) or >1 year can be extrapolated from the yearly progression rate. Thus, because our aim was 
to focus on extensive radiographic progression rather than any progression, our definition was chosen 
based on practicality, clinical experience, and conceptual simplicity to reflect only a subgroup of patients 
with extensive progression [22, 23].  
Interestingly, two types of risk factors were identified from the early RA population in ASPIRE as well as 
the established RA population in ATTRACT: ‘disease activity-related factors’ such as CRP, ESR and SJC, 
and ‘serological factors’ such as RF. Indeed, serum markers reflecting acute inflammation have been 
described to be the most important predictors of radiographic progression [37] and in our models, the 
probabilities of rapid progression increase mainly with increasing CRP and ESR (i.e. higher slopes in 
Figure 15). Similarly, SJCs but not TJCs were associated with RRP [30]. Finally, our findings corroborate 
existing reports [13, 26, 28] that adduce the ‘serological profile’, i.e. the combination of these 
serological markers, of a patient is an important contributor to radiographic progression during early RA 
(e.g. increase in radiographic progression with higher RF when all other risk factors are stable).  
Using the results from ASPIRE, we generated two alternate risk models for early RA, one excluding CRP 
and another excluding ESR. To perform an initial assessment of whether the risk factors selected for the 
models were generalizable to other RA population samples, we applied data from the established RA 
patients in ATTRACT to the ASPIRE-based models and generated two very similar matrix risk models. A 
few important differences between the two data sets are of note. First, RF contributed less to the 
ATTRACT-based models than to the ASPIRE-based models, possibly due to the differences between the 
study populations (e.g. disease duration and treatment history). Another explanation may be that 
‘serological factors’ are less important in established disease than in early disease and that the 
progression of joint damage is primarily influenced by current disease activity in patients with 
established disease. Secondly, differences in the effect of aggressive combination therapy between the 
ASPIRE- and ATTRACT-based models should be considered in light of the distinct patient sample 
populations (ATTRACT patients had longer disease duration, higher X-ray scores and disability, etc.), and 
their treatment history (i.e. MTX-failure vs -naïve), as delayed treatment itself is likely to have played a 
role in disease progression [6]. Thirdly, RRP in all risk groups may not be surprising in ATTRACT, since all 
patients were refractory to MTX and those assigned to MTX monotherapy essentially received placebo. 
Regardless, the risk profiles of patients on aggressive therapy in both ASPIRE and ATTRACT were 
similarly influenced by all selected baseline risk factors.  
The utility and widespread success of the SCORE chart [17] motivated us in part to develop a similar risk 
model for RA. Whereas our matrix risk models predict the risk of joint destruction using correlated risk 
factors rather than cardiovascular mortality using independent risk factors, they also incorporate 
treatment as a contributor to the risk of RRP. In the context of the data sets used to build our models, 
MTX monotherapy can be considered conservative management, whereas infliximab plus MTX can be 
considered aggressive management. Although our matrix risk models should not be used to determine 
the appropriateness of initiating biological therapy before a conservative regimen, such as MTX 
monotherapy, in any individual patient, differential radiographic outcomes resulting from these two 
treatments were clearly observed and might warrant initiation of an aggressive regimen that includes 
several DMARDs in combination with corticosteroids. Our models identified subgroups of patients with 
low predicted risk of RRP in whom conservative management provides effective treatment (Figure 16B) 
as well as subpopulations of RA patients in whom it had a high risk of failure to prevent RRP (Figure 
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16A). Moreover, patients with values for the selected baseline risk factors exceeding the upper limits of 
the matrix models (e.g. CRP >3 mg/dl in combination with high values for the other factors) had an even 
higher likelihood of RRP with an NNT that approached 1. It is specifically in these very high-risk 
subpopulations that aggressive therapy demonstrated improved treatment benefit, and in whom early 
combination therapy may be warranted in light of the worse prognosis.  
For a risk model to be broadly applicable, it should be easy to use, reflective of current clinical practice, 
and representative of the range of patients seen in the real-life clinical setting from those with DMARD-
naïve, early RA to DMARD-refractory, established RA. An overview of the selected variables in a number 
of recent publications of large early RA cohorts (Table 17) suggests that the number of swollen joints is 
lower in clinical practice than in ASPIRE. However, the medians and quartiles of CRP and ESR in ASPIRE 
(Table 15), i.e. the most important predictors of RRP, do appear representative of what are seen in daily 
practice (Table 17).  
Our study has several important limitations. First, the ASPIRE study was not specifically designed to 
create a matrix risk model. Unlike the goal-driven strategies used in current clinical practice, treatment 
assignment was fixed for 1 year for patients in the ASPIRE study to allow for true placebo control. The 
entry criteria selected a specific group of early RA patients in ASPIRE; it is certain that in daily 
rheumatology practice the proportion of patients at high risk is smaller than it was in the ASPIRE study.  
Further, the selected risk factors for RRP were limited to the variables collected and analysed for the 
ASPIRE study, which may limit their applicability to other data sets. Introducing novel ‘disease activity-
related risk factors’ for radiographic progression, such as MMP-3 and IL-8 [38], or ‘serological factors’, 
such as HLA-DR shared epitope [39], may have improved the predictive value of our models. However, 
the limited accessibility of tests for some of these parameters restricts their utility in routine practice.  
Additionally, although anti-cyclic citrullinated peptide antibodies (ACPAs) are now considered one of the 
most important risk factors for joint progression in RA [40, 41] and their use is becoming increasingly 
routine in clinical practice, we were unable to include this predictive marker in our models because only 
a small number of ASPIRE patients had ACPA assessments available. Research on the relationship 
between levels of RF and ACPA, separately and combined, has shown that the prognostic value of high-
titre RF and ACPAs for erosive disease are comparable. Testing patients with high-titre RF additionally 
for ACPAs, however, appears to be of limited prognostic benefit. Despite the excellent performance of 
high-titre RF overall, ACPAs proved slightly better for prognostic value [42]. In practice, ACPA testing is 
considerably more expensive and less available in clinical practice than RF. However, as with CRP and 
ESR, ACPAs and RF can likely be interchanged in our model and clinicians can use the marker they are 
most familiar with.  
Lastly, due to a lack of available RA patient data sets with placebo-controlled treatment regimens similar 
to ASPIRE, we could not test our preliminary matrix models in another early RA cohort and, instead, 
tested the models using the ATTRACT established RA sample population. Therefore, the differences 
between the ASPIRE- and ATTRACT-based matrix risk models should be interpreted with caution, 
especially in light of the much smaller sample size in ATTRACT.  
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Study Duration (Sub) cohort, n 
CRP, mg/dl, 
mean (range) 
ESR, mm/h, 
mean (range) 
SJC, mean 
(range) 
RF+, 
% Treatment 
Kiely et al. [43] 2002–07 808 1.2 (0.5, 2.7) 25 (13, 43) 4 (2, 10) 58 51% MTX, 41% SSZ, 8% other DMARD, 9% combination 
Welsing et al. 
[44] 1985–90 167 NA 40.5 (22, 60) 12 (8, 17) 79 2% MTX, 60% SSZ, other 
 1990–95 132 NA 34 (13.5, 49) 11 (6, 17) 74 9% MTX, 82% SSZ, other 
 
1995–
2000 114 NA 
24.5 (9.5, 
38.5) 10 (5, 13) 76 10% MTX, 76% SSZ, other 
 2000–05 112 NA 19 (10, 34) 9 (6, 14) 67 NA 
Gossec et al. 
[45] 1993–94 191 3.4 ± 4.3 40.2 ± 28.5 9.0 ± 5.9 81 
30% MTX, 31% SSZ, 7% other 
DMARD, 25% combination 
Nikolaisen et 
al. [46] 2000–06 820 2.6 (0, 25.2) 30.2 (2, 112) 8.8 (0, 32) 57 
78% MTX, 19% SSZ, 2% other 
DMARD, 2% combination 
Combe et al. 
[47] 2002–05 814 2.2 ± 3.4 29.4 ± 24.5 7.2 ± 5.4 44.2 NA 
Carbonell et 
al. [48] 2004–05 111 male 1.0 (0.3, 2.7) 28 (16, 51) NA 48 NA 
 2004–05 
251 
female 0.7 (0.3, 2.1) 32 (17, 55) NA 56 NA 
Carli et al. [49] 1997–2001 2584 3.1 ± 3.4 35.4 ± 25.4 9.3 ± 5.3 69 DMARD 
TABLE 17. Disease status and treatment in recently published early-RA cohort . Data are presented as 
median (interquartile range) or mean ± s.d. unless noted otherwise. aN = 71 fulfilled ACR criteria for RA. 
In summary, using the radiographic data from the ASPIRE study, we developed two novel models for the 
risk of RRP in patients with early RA. Our preliminary risk models use some of the established disease 
characteristics (SJC, ESR, CRP and RF) that are readily available in routine clinical setting to generate 
easy-to-use, visual matrices that, once refined through future development, can be used to predict the 
risk of joint damage progression in RA patients, particularly those with DMARD-naïve early disease. 
Additional exploratory development and testing of the matrix risk models in other populations and with 
other therapies is needed to finalize a single risk model that can be used to guide rheumatologists in 
making treatment decisions for individual patients with RA.  
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4.2. Validation of the poor prognosis model in RA 
It is obvious that outcomes predicted with a model that is created from one clinical trial with selected 
patients may not accurately predict outcome in patients that were not selected in accordance with the 
same in- and exclusion criteria. Validation of the model in other RA population is therefore needed to 
increase the generalizability of the results. In order to investigate the value of this methodology for 
prediction of rapid radiographic progression, a number of groups that that have access to databases of 
randomized clinical trials were approached and were asked to apply the modeling in their dataset. The 
results of these efforts are briefly described.  
In the BeSt Study conducted in the Netherlands [1], data from 465 patients with recent-onset RA 
randomized to receive initial monotherapy or combination therapy were used to develop a matrix 
model for the prediction of RRP defined identically as above mentioned. The presence of 
autoantibodies, baseline CRP level, erosion score and treatment group were significant independent 
predictors of RRP in the matrix. The proportion of patients with RPP ranged from 5% to 78% in patients 
on initial monotherapy and from 1% to 42% and 1% to 34% in patients with initial combination therapy 
with prednisone or infliximab respectively (Figure 18).  
 
FIG.18: Matrix predicting rapid radiographic progression in the BeSt study. From Visser et al. Ann Rheum 
Dis. 2010 Jul; 69(7):1333-7. 
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Combination therapy was thus associated with a markedly reduced risk of RRP especially in patients with 
(a combination of) high CRP, baseline erosions and presence of RF and/or ACPA. The NNT with initial 
combination therapy to prevent one patient from RRP with monotherapy was in the range 2–3, 3–7 and 
7–25 for patients with a high (i.e. >=50%), intermediate (i.e. 20%-50%) and low predicted risk (<20%), 
respectively. Positive and negative predictive values of the matrix were 62% and 91%, respectively. They 
concluded that the model, having a better negative predictive (NPV) value than a positive predictive 
value (PPV), is a better tool to help decide who should not rather than who should undergo a more 
intensive treatment strategy. 
In the SWEFOT study from Sweden [2], radiological data of 277 DMARD naïve patients who were initially 
started on methotrexate (MTX, target dose 20 mg/week) were used for a similar analysis. In this study, 
patients who achieved a low disease activity after 3-4 months continued on MTX, while the other 
patients were randomized to add either SSZ and hydroxychloroquine (HCQ) or infliximab. Sixty five 
patients had RRP. Different combinations of predictors of RRP were combined in 3-parameter matrices 
and the results compared for overall differentiation between low-risk versus high-risk as well as for 
clinical feasibility and ease of use. The model which included CRP, baseline erosions and current 
cigarette smoking differentiated best between RA patients with and without risk of RRP. Rheumatoid 
factor (RF)/anti-cyclic citrullinated peptide (anti-CCP) positivity did not significantly predict radiographic 
progression using the definition of RRP with ≥5 units increase on the SHS score as cut-off. In a secondary 
exploratory analysis using cut-off >1 for radiographic progression, both RF and anti-CCP positivity were 
significant predictors in unadjusted, but not adjusted analyses. A step-up gradient was observed, where 
63% of the patients carrying all the predictors had developed RRP after 1 year in comparison to only 12 
% of patients without these predictors. The risk ratio for highest versus lowest risk was 5.88 (95% CI 
2.36-14.62).   
Researchers from France [3] used a registry to quantify RRP in daily practice and evaluated whether 
matrix models incorporating characteristics that are associated with radiographic progression could be 
used for risk stratification. In the ESPOIR cohort RRP was measured in 11.1% of 370 early RA patients 
who had received a DMARD during the first year of follow up and combining autoantibodies, CRP, 
swollen joint counts and baseline erosions allowed predicting a risk of RRP that ranged from 2% to 64% 
(Figure 19). 
 
FIG.19: Matrix predicting RRP in early RA patients in clinical practice in France. From Arthritis Res Ther. 
2012; 14(6): R249. 
 76  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
References 
1. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. A matrix risk model for the prediction of rapid radiographic progression in 
patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum 
Dis. 2010 Jul;69(7):1333-7. 
2. Saevarsdottir S, Rezaei H, Geborek P et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid 
arthritis: Results from the SWEFOT trial. Ann Rheum Dis  2014 - Early Online - April 4, 2014 
3. Fautrel B, Granger B, Combe B, et al. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the 
community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther. 2012; 14(6): R249.  
 77  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
 78  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
4.3. Prediction of Remission and Low Disease Activity in 
DMARD-refractory Patients with Rheumatoid Arthritis 
Treated with Golimumab 
 
4.3.1. Abstract  
Objective  
To create a tool to predict probability of remission and low disease activity (LDA) in patients with 
rheumatoid arthritis (RA) being considered for anti-TNF treatment in clinical practice.  
Methods  
We analyzed data from GO-MORE, an open-label, multinational, prospective study in biologic-naïve 
patients with active RA (28-joint disease activity score based on erythrocyte sedimentation rate [DAS28-
ESR] ≥3.2) despite DMARD therapy. Patients received 50-mg subcutaneous golimumab (GLM) once 
monthly for 6 months. In secondary analyses, regression models were used to determine the best set of 
baseline factors to predict remission (DAS28-ESR <2.6) at month 6 and LDA (DAS28-ESR ≤3.2) at month 
1. 
Results  
In 3280 efficacy-evaluable patients, of 12 factors included in initial regression models predicting 
remission or LDA, 6 were retained in final multivariable models. Greater likelihood of LDA and remission 
was associated with being male; younger age; lower Health Assessment Questionnaire (HAQ), 
erythrocyte sedimentation rate (or C-reactive protein), and tender joint count (or swollen joint count) 
scores; and absence of comorbidities. In models predicting 1-, 3-, and 6-month LDA or remission, area 
under the receiver operating curve was 0.648 to 0.809 (R²=0.0397 to 0.1078). The models also predicted 
6-month HAQ and EuroQoL-5-Dimension scores. A series of matrices were developed to easily show 
predicted rates of remission and LDA. 
Conclusions  
A matrix tool was developed to show predicted GLM treatment outcomes in patients with RA, based on 
a combination of 6 baseline characteristics. The tool could help provide practical guidance in selection of 
candidates for anti-TNF therapy. 
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4.3.2. Introduction 
To make best use of resources for biologic treatment in patients with rheumatoid arthritis (RA), it would 
be useful to identify a set of predictors that enable selection of patients who will benefit most from such 
treatment and avoid treatment of patients who are unlikely to respond. Several studies have evaluated 
predictors of outcomes during anti-tumor necrosis factor (TNF) treatment (for a review, see Callaghan, 
2014 [1]; Katchamart, 2010 [2]). One limitation of some of these studies [3] is that the predictive 
capacity of single predictors is low (vs combinations of predictors), and they are less useful when making 
practice decisions for individual patients.  
Although there is variability in which factors have predictive ability, some of the baseline characteristics 
that have been found to predict anti-TNF outcomes include baseline age (e.g., Hetland, 2010;[4] 
Radovits, 2009[5]), smoking (eg, Barnabe, 2014 [6]; Hyrich, 2006 [7]; Mattey, 2009 [8]), gender (eg, 
Barnabe, 2014 [6]; Mancarella, 2007[9]), disease activity (eg, Kristensen, 2008 [10]; Listing, 2006 [11]) 
and functional ability (eg, Hetland, 2010[4]). Predictors that are significant across studies may depend 
on factors such as the patient population, type of treatment, the outcome being evaluated, and whether 
the outcome is a state measure or an improvement measure. 
Current European League Against Rheumatism (EULAR) recommendations emphasize low disease 
activity (LDA) or remission as the treatment goal in RA and advocate the use of poor prognostic factors 
to guide treatment decisions [12]. If a patient does not attain remission or LDA with disease-modifying 
anti-rheumatic drugs (DMARDs) and if poor prognostic factors are present (eg, high disease activity, 
rheumatoid factor [RF] positivity, and anti-cyclic citrullinated peptide [CCP] antibodies, erosive disease), 
EULAR recommendations suggest the addition of a biologic treatment. However, poor prognostic factors 
such as high baseline disease activity have also been shown to be associated with poorer anti-TNF 
treatment outcomes; that is, patients who begin anti-TNF treatment with high disease activity have 
been reported to be less likely to achieve remission or LDA than patients who begin treatment with 
more moderate disease activity (eg, Combe, 2014 [13]; Listing, 2006 [11]). This adds complexity to 
clinical decisions balancing risks and benefits to determine which patients will benefit most from anti-
TNF treatment. 
The goal of these analyses was to develop a tool that can be used to assist in decision making to 
optimize treatment goal attainment in patients with RA who have failed DMARD treatment. The tool 
identifies groups of patients who would most likely benefit from golimumab (GLM) therapy and presents 
findings in a form that is simple and can be used in daily clinical practice. 
4.3.3. Methods 
4.3.3.1. Design and Patients  
Analysis of associations between baseline characteristics and outcomes of treatment was a key 
secondary objective of the GO-MORE trial. GO-MORE was an open-label, prospective study of add-on 
treatment with GLM in patients with active RA despite DMARD treatment in 40 countries (protocol 
P06129; NCT00975130). Details of the study procedures have been previously reported (Combe et al, 
2014) and are only briefly described here. The study received approval from appropriate research ethics 
committees and was conducted in accordance with the Declaration of Helsinki and standards of good 
clinical research practice. All patients consented to participate. Data were collected from October 29, 
2009, to July 21, 2011. 
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Patients in GO-MORE were biologic-naïve with active RA (28-joint disease activity score based on the 
erythrocyte sedimentation rate [DAS28-ESR] ≥3.2) despite DMARD therapy and had no contraindications  
for TNF inhibitor treatment. 
4.3.3.2. Study Procedures 
In the first 6 months of GO-MORE, all patients received monthly subcutaneous GLM 50 mg administered 
by autoinjector and had efficacy and safety assessments at month 1, 3, and 6. At month 6, patients who 
had good or moderate EULAR response but were not in remission were able to continue to part 2 of the 
study, an extension phase which is described in length elsewhere [13]. 
4.3.3.3. Statistical Analyses  
A sequence of steps was used to develop an optimal model to predict remission. The main outcomes to 
be predicted were DAS28-ESR LDA at end of month 1 (after 1 injection) and remission at the end of 
month 6. The model’s ability to predict DAS-28-ESR remission, DAS28-ESR LDA, Simple Disease Activity 
Index (SDAI) remission (SDAI ≤3.3) and LDA (SDAI ≤11=LDA), and DAS28 based on C-reactive protein 
(CRP) (cutoff criteria: <2.6 and ≤3.2) at different time-points during treatment was also explored.  
Baseline predictors included in the initial univariate analyses were gender, age, disease duration, 
smoking status, comorbidities, number of previously failed DMARDs, 28-joint tender joint count (TJC28), 
28-joint swollen joint count (SJC28), patient global assessment of disease activity (PGA; measured on a 
100-mm visual analog scale [VAS]), health assessment questionnaire (HAQ) score, methotrexate dose, 
and log ESR. Characteristics that predicted DAS28-ESR remission at month 6 and LDA at month 1 at the 
p<0.10 level were retained and used in multivariable models. Stepwise selection was used as a 
sensitivity analysis to confirm the factors selected for the model.  
To determine whether TJC and SJC or ESR and CRP could be used interchangeably with no loss in 
predictive power, multivariable models switching out these components were compared. Area under 
the receiver operating characteristic curve (AUC-ROC) analysis and R² were used to evaluate the models. 
To create the matrix tool, continuous variables were transformed to categorical variables, using tertiles 
or quartiles. Models with 3- and 4-level categories were evaluated using AUC-ROC analysis. The 
predicted LDA/remission rates were displayed in an easily readable color-coded matrix.  
Additional analyses were performed to explore the model’s usefulness and limitations. First, the 
associations between the predictors and outcomes of physical function (HAQ) and quality of life 
(EuroQol-5-dimension [EQ-5]) were explored. Next, the association between the predictors and DAS28 
improvement (as opposed to DAS28 disease state) over 6 months was investigated. Finally, the 
association between the predictors and EULAR response was evaluated, because EULAR response 
included measures of both disease state and amount of improvement from baseline. For these 
additional analyses, patients were divided into subgroups of DAS28 predicted remission at 6 months 
(patients predicted to have <10% chance of DAS28 remission, 10%–<20%, 20%–<30%, 30%–<40%, 40%–
<50%, and ≥50%) For patients in each prediction subgroup, median and interquartile ranges for DAS28, 
HAQ, and EQ-5D at baseline and 6 months and the change in value from baseline to 6 months were 
calculated.  
4.3.4. Results  
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4.3.4.1. Disposition and baseline characteristics. 
Of 3366 patients enrolled in GO-MORE, 3280 were included in the efficacy evaluable population. The 
patient disposition and baseline characteristics are fully reported in Combe et al, 2014. A summary of 
baseline characteristics is shown in Table 18.  
Patient Characteristics N=3280 
Demographic Characteristics  
Female, n (%) 2716 (82.8%) 
Age, y 
Mean (SD) 
Median (min, max) 
52.3 (12.8) 
53.0 (18, 88) 
Disease Characteristics  
Disease duration (y)  
Mean (SD) 
Median (min, max) 
n=3279 
7.6 (7.9) 
4.9 (0.01, 56.6) 
TJC28, Mean (SD)  13.0 (6.81) 
SJC28, Mean (SD) 9.6 (5.56) 
DAS28-ESR 
Moderate Disease Activity (3.2–5.1), n (%) 
High Disease Activity (>5.1), n (%) 
Mean (SD) 
DAS28-CRP 
Mean (SD) 
n=3270 
698 (21.3) 
2572 (78.7) 
5.97 (1.095) 
n=3236 
5.41 (0.998) 
CRP (mg/L) 
Mean (SD) 
ESR (mm/hr) 
Mean (SD) 
Anti-CCP 
Positive (≥20 U/mL), n (%) 
Rheumatoid Factor 
Positive (≥15 IU/mL), n (%) 
HAQ-DI, Mean (SD)   
n=3236 
14.48 (20.376) 
n=3280 
34.9 (24.64) 
n=3225 
2318 (71.9) 
n=3234 
2344 (72.5) 
1.44 (0.67) 
Table adapted from Combe et al, 2014. Ann Rheum Dis 2014 Aug;73:1477–86 [13]. 
TABLE 18: Demographics & Baseline Characteristics of Patients in the Efficacy Population of GO-MORE. 
A majority of patients were female (82.8%, 2716/3280) and the mean age was 52.3 years (SD=12.8). A 
majority of patients 78.7% (2572/3280) had high disease activity (DAS28-ESR >5.1) at baseline; the 
remaining patients had moderate disease activity (DAS28-ESR of 3.2–5.1) at baseline. At least 1 
comorbidity was reported by 76.2% of patients (2499/3280). See Table 19 for a list of the comorbidities 
that were reported in ≥2% of patients. 
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System Organ Class Preferred Term n (%) 
Blood and lymphatic system disorders Anemia 113 (3.45) 
Endocrine disorders Hypothyroidism 270 (8.23) 
Gastrointestinal disorders Gastritis 156 (4.76) 
Gastrooesophageal reflux disease 86 (2.62) 
Dyspepsia 72 (2.20) 
Immune system disorders Drug hypersensitivity 112 (3.41) 
Infections and infestations Latent tuberculosis 244 (7.44) 
Metabolism and nutrition disorders Hypercholesterolemia 266 (8.11) 
Diabetes mellitus 167 (5.09) 
Hyperlipidemia 108 (3.29) 
Dyslipidemia 103 (3.14) 
Obesity 87 (2.65) 
Musculoskeletal & connective tissue disorders Osteoporosis 336 (10.24) 
Osteoarthritis 276 (8.41) 
Osteopenia 135 (4.12) 
Spinal osteoarthritis 96 (2.93) 
Back pain 74 (2.26) 
Sjogren's syndrome 69 (2.10) 
Psychiatric disorders Depression 197 (6.01) 
Insomnia 78 (2.38) 
Respiratory, thoracic & mediastinal disorders Asthma 133 (4.05) 
Social circumstances Postmenopause 89 (2.71) 
Menopause 84 (2.56) 
Vascular disorders Hypertension 962 (29.33) 
Varicose vein 77 (2.35) 
Note: Patients were excluded from the trial for the following conditions: 
1. Evidence of active TB or latent TB that is untreated 
2. History of lymphoproliferative disease or any unknown malignancy or history of malignancy within 
the previous 5 years, with the exception of non-melanoma skin cancer that has been treated with no 
evidence of recurrence. 
3. History of moderate to severe heart failure even if medically controlled. 
4. An inflammatory rheumatic disease other than RA that might confound the evaluations of safety 
and toxicity such as, but not limited to, ankylosing spondylitis and psoriatic arthritis.  
5. Any systemic inflammatory condition with signs and symptoms that might confound the evaluations 
of safety and toxicity from GLM therapy, including, but not limited to: active Lyme disease, systemic 
lupus erythematosus, infectious or reactive arthritis, Reiter’s syndrome, non-rheumatoid vasculitis, 
or parvovirus infection. 
6. Allergy/sensitivity to investigational product(s) or its/their excipients, including latex. 
7. Pregnant or intending to become pregnant. 
8. Any clinically significant condition or situation, other than the condition being studied that, in the 
opinion of the investigator, would interfere with the trial evaluations or optimal trial participation.  
 
TABLE 19: Comorbidities Reported in at Least 2% of Patients (N=3280). 
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4.3.4.2. Regression model for prediction of remission and LDA. 
At the end of month 6, 23.9% of patients had achieved DAS28-ESR remission and 37.4% achieved LDA; at 
the end of month 1, 16.6% of patients had achieved LDA (Combe et al, 2014). Initial univariate analyses 
narrowed the set of factors that were candidates for the multivariable models predicting remission and 
LDA. Factors retained (those that had significant relationships [P <.10] with DAS28 remission at month 6 
and LDA at month 1) were analyzed in a multivariable model predicting DAS28-ESR remission at month 6 
(Table 20). Factors retained after this step were gender, HAQ, presence of comorbidities, age, TJC, and 
ESR. Smoking was associated with remission at 6 months but not with LDA at 1 month, and therefore 
was not retained. 
 
Baseline Variable Wald Chi-square P value 
 Remission at Month 6 
Gender 13.1130 .0003 
Smoking history 7.0247 .0298 
MTX category 1.2557 .7397 
HAQ category 14.5097 .0007 
Comorbidities 9.4939 .0021 
Age 18.4272 <.0001 
TJC28 48.2602 <.0001 
SJC28 0.6006 .4384 
Disease duration, y 0.2943 .5875 
Patient VAS 2.5396 .1110 
ESR (log) 109.9716 <.0001 
 Low Disease Activity at Month 1 
Gender 9.3505 .0022 
Age 8.1473 .0043 
MTX category 2.1650 .5389 
HAQ category 6.2534 .0439 
Comorbidities 10.0289 .0015 
TJC28 103.1994 <.0001 
SJC28 5.5348 .0186 
Patient VAS 9.8722 .0017 
ESR (log) 150.1696 <.0001 
TABLE 20: Initial Multivariate Model Predicting DAS28-ESR Remission at Month 6 and Low Disease 
Activity at Month 1 
Overall, the predictive value of the model (Table 21) was slightly weakened by replacing TJC with SJC or 
by replacing CRP with ESR in the models predicting DAS28. The patterns were similar for models 
predicting SDAI and DAS28-CRP outcomes at months 1, 3, and 6. Prediction of outcomes at month 1 was 
slightly better than for outcomes at month 6.  
 
 
 84  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
Outcome 
predicted 
Baseline Predictor 
Seta 
Month 1 Month 3 Month 6 
AUC R2 AUC R2 AUC R2 
DAS28-ESR 
remission 
With TJC, ESR 0.809 0.0954 0.738 0.1002 0.717 0.1078 
With SJC, CRP 0.729 0.0521 0.694 0.0696 0.687 0.0815 
With TJC, CRP 0.758 0.0660 0.707 0.0788 0.702 0.0949 
DAS28-ESR 
LDA 
With TJC, ESR 0.795 0.1565 0.734 0.1372 0.710 0.1261 
With SJC, CRP 0.724 0.0937 0.682 0.0874 0.665 0.0807 
With TJC, CRP 0.757 0.1202 0.702 0.1057 0.690 0.1052 
SDAI remission With TJC, ESR 0.708 0.0168 0.664 0.0282 0.655 0.0394 
With SJC, CRP 0.703 0.0153 0.648 0.0226 0.648 0.0353 
With TJC, CRP 0.706 0.0158 0.663 0.0288 0.658 0.0409 
SDAI  
LDA 
With TJC, ESR 0.707 0.0145 0.661 0.0266 0.660 0.0397 
With SJC, CRP 0.705 0.0144 0.649 0.0224 0.651 0.0352 
With TJC, CRP 0.701 0.0142 0.662 0.0281 0.664 0.0418 
DAS28-CRP 
<2.6 
With TJC, ESR 0.738 0.0777 0.687 0.0785 0.674 0.0820 
With SJC, CRP 0.698 0.0536 0.658 0.0570 0.661 0.0711 
With TJC, CRP 0.737 0.0780 0.687 0.0795 0.683 0.0924 
DAS28-CRP 
≤3.2 
With TJC, ESR 0.751 0.1448 0.700 0.1152 0.683 0.0995 
With SJC, CRP 0.712 0.1063 0.681 0.0954 0.661 0.0791 
With TJC, CRP 0.753 0.1473 0.705 0.1209 0.689 0.1071 
aAll factor sets include continuous HAQ and categorical gender and comorbidity. Inclusion of ESR, CRP, 
TJC, and SJC varied as indicated. TJC, SJC, ESR, and CRP were all continuous variables. CRP was used in 
logarithm scale. 
TABLE 21: AUC and R2 for Prediction of Several Different Outcomes With 3 Different Sets of Baseline 
Factors. 
To translate the data into the prediction matrix tool, continuous predictor variables (age, ESR, and TJC) 
had to be transformed to categorical variables with either 3 or 4 levels. AUC and R2 values for models 
with the continuous versus categorical variables indicated that little predictive power was lost moving 
from continuous to categorical variables (data not shown). Categorical variables with 3 levels were 
selected for all but age because this resulted in a simpler matrix tool.  
4.3.4.3. Prediction matrix tool  
Predicted remission and LDA rates from the final multivariable models were used to create a series of 
matrix tools, as shown in Figure 20 and Figure 21. Figures for males and females were generated 
separately (the impact of each predictor was similar in each gender group, but males had better 
outcomes overall). Separate models were generated to predict DAS28 remission and LDA, and for SDAI 
remission and LDA. In addition, separate models were created for use with ESR versus CRP as the 
inflammatory marker.  
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A. 6-Month DAS28-ESR remission in females 
 
B. 6-Month DAS28-ESR remission in males   
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C. 6-Month DAS28-ESR LDA in females 
 
D. 6-Month SDAI LDA with CRP instead of ESR as a predictor in females 
 
FIG. 20: Matrix model estimates of outcomes at month 6 of golimumab treatment by each combination 
of predictor variables. Predicted rates shown for DAS28-ESR remission in female (A) and male (B) 
patients, DAS28-ESR LDA in female patients (C), and SDAI low disease activity in female patients using 
CRP instead of ESR as a predictor (D).  
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A. 6-Month DAS28-ESR LDA in males 
 
B. DAS28-ESR LDA in male patients with CRP instead of ESR as a predictor  
 
FIG. 21: Matrix model for prediction of DAS28-ESR LDA in male patients (A) and DAS28-ESR LDA in male 
patients using CRP instead of ESR as a predictor (B).  
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 OR (95% CI) 
 DAS28-ESR Remission 
Variable Month 1 Month 3 Month 6 
ESR    
<15 vs ≥45 9.18 (5.62–15.01) 4.71 (3.45–6.42) 3.43 (2.66–4.41) 
≥15 to <45 vs ≥45 2.62 (1.60–4.29) 2.20 (1.64–2.94) 1.68 (1.33–2.11) 
Gender    
Male vs female 1.58 (1.16–2.15 1.73 (1.37–2.19) 1.64 (1.33–2.02) 
HAQ    
0 to 1.125 vs ≥1.75 1.70 (1.18–2.45) 1.40 (1.09–1.80) 1.79 (1.44–2.22) 
≥1.125 to <1.75 vs ≥1.75 1.48 (0.99–2.19) 1.19 (0.91–1.56) 1.20 (0.95–1.51) 
Age, y    
<35 vs ≥65 1.71 (1.02–2.87) 2.00 (1.33–2.99) 1.92 (1.35–2.73) 
≥35 to <50 vs ≥65 1.15 (0.74–1.78) 1.59 (1.14–2.21) 1.54 (1.16–2.04) 
≥50 to <65 vs ≥65 0.88 (0.57–1.34) 1.23 (0.90–1.70) 1.14 (0.88–1.49) 
Comorbidities     
No vs yes 1.51 (1.11–2.04) 1.44 (1.15–1.81) 1.34 (1.10–1.65) 
TJC    
<10 vs ≥20 5.12 (2.92–9.00) 2.81 (2.02–3.92) 2.87 (2.14–3.84) 
≥10 to <20 vs ≥20 2.09 (1.18–3.70) 1.43 (1.03–1.99) 1.85 (1.39–2.45) 
 DAS28-ESR Low Disease Activity 
 Month 1 Month 3 Month 6 
ESR    
<15 vs ≥45 5.92 (4.32–8.11) 4.35 (3.40–5.55) 3.34 (2.67–4.18) 
≥15 to <45 vs ≥45 2.13 (1.58–2.87) 1.78 (1.44–2.21) 1.67 (1.38–2.02) 
Gender    
Male vs female 1.65 (1.30–2.10) 1.46 (1.18–1.80) 1.44 (1.18–1.76) 
HAQB    
0 to 1.125 vs ≥1.75 1.79 (1.38–2.32) 1.59 (1.30–1.96) 1.68 (1.39–2.03) 
≥1.125 to <1.75 vs ≥1.75 1.34 (1.01–1.79) 1.25 (1.00–1.56) 1.16 (0.95–1.41) 
Age, y    
<35 vs ≥65 1.58 (1.07–2.33) 1.47 (1.05–2.06) 1.65 (1.20–2.26) 
≥35 to <50 vs ≥65 1.07 (0.78–1.46) 1.24 (0.96–1.61) 1.27 (1.00–1.62) 
≥50 to <65 vs ≥65 0.82 (0.61–1.11) 1.02 (0.80–1.30) 1.07 (0.86–1.34) 
Comorbidities     
No vs yes 1.49 (1.18–1.89) 1.36 (1.11–1.65) 1.15 (0.95–1.39) 
TJC    
<10 vs ≥20 6.13 (4.13–9.08) 3.65 (2.77–4.81) 3.35 (2.62–4.28) 
≥10 to <20 vs ≥20 2.04 (1.37–3.03) 1.85 (1.42–2.42) 1.85 (1.46–2.33) 
TABLE 22: Odds Ratios for Associations of Individual Predictor Variables with DAS28-ESR Remission and 
LDA at Months 1, 3, and 6 
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Each matrix shows the predicted remission or LDA rate for every combination of the 6 baseline factors, 
representing a total of 432 different RA subpopulations. Across all the models, the highest remission 
rates are in the cells at the upper right and the lowest rates in the cells at the lower left. The color codes 
have been added for easier visual perception use of the matrix, with each color representing an 
estimated range of 10% likelihood of remission or LDA; warmer colors (e.g., red, yellow) indicate worse 
predicted outcomes and cooler colors (e.g., blue, purple) indicate better predicted outcomes. Odds 
ratios associated with each factor are shown in Table 22.  
Overall, higher remission rates are predicted for patients with male gender, absence of comorbidities, 
younger age, and who have lower baseline HAQ. Low baseline TJC and ESR were the strongest predictors 
in the model.  
4.3.4.4. Additional analyses to explore the matrix model’s usefulness and limitations. 
The factors in the model built to predict DAS28 remission or LDA also were associated with attainment 
of meaningful EQ-5D and HAQ cutoffs (Table 23). Of all the factors included in the model, baseline HAQ 
was most strongly related to attainment of cutoff levels for EQ-5D (≥.7 and ≥.8) and HAQ (<.5) at month 
6 (ORs from 2.38 to 6.55 for the lowest vs highest HAQ score categories).  
 
 Month 6 Response 
OR (95% CI) 
 EQ-5D HAQ 
Baseline predictor variable ≥0.7 ≥0.8 ≤0.5 
ESR    
<15 vs ≥45 1.06 (0.85–1.33) 0.83 (0.65–1.08) 0.80 (0.63–1.02) 
≥15 to <45 vs ≥45 0.98 (0.81–1.18) 0.99 (0.80–1.22) 0.80 (0.66–0.98) 
Gender    
Male vs female 0.80 (0.65–0.99) 0.96 (0.77–1.21) 1.47 (1.19–1.81) 
HAQ     
0 to 1.125 vs ≥1.75 5.86 (4.81–7.13) 2.38 (1.91–2.96) 6.55 (5.31–8.09) 
≥1.125 to <1.75 vs ≥1.75 1.62 (1.32–2.00) 1.26 (0.99–1.60) 1.60 (1.28–2.01) 
Age, y    
<35 vs ≥65 1.36 (0.99–1.87) 1.36 (0.97–1.92) 2.91 (2.06–4.12) 
≥35 to <50 vs ≥65 0.90 (0.71–1.15) 0.94 (0.71–1.24) 2.18 (1.65–2.87) 
≥50 to <65 vs ≥65 0.93 (0.75–1.17) 0.94 (0.75–1.22) 1.75 (1.35–2.27) 
Comorbidities     
No vs yes 1.29 (1.06–1.56) 1.63 (1.33–1.99) 1.70 (1.39–2.07) 
TJC    
<10 vs ≥20 1.51 (1.19–1.92) 1.44 (1.09–1.89) 1.23 (0.96–1.59) 
≥10 to <20 vs ≥20 1.36 (1.09–1.71) 1.21 (0.93–1.57) 1.10 (0.86–1.39) 
TABLE 23: Relationships Between Baseline Predictor Variables and 6-Month Outcomes of HAQ 
and EQ-5D scores 
In Figure 22, patients are divided by their predicted rate of remission from the matrix tool, which is 
determined by their baseline characteristics. For each category of predicted remission (eg, patients with 
10% predicted rate of remission, shown in red in both the matrix model and Figure 22), the median and 
IQR for baseline and month 6 DAS28-ESR are shown.  
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FIG. 22: Relationship between remission rate category predicted by the matrix model and observed 
DAS28 (A), EQ-5D (B), and HAQ (C) scores in the GO-MORE study. The figure shows, for example, that for 
the patients who were predicted by the matrix tool to have a remission rate of less than 10% (red line), 
the actual mean DAS28 score at baseline was 7.36, with improvement of 2.61 at month 6. For patients 
predicted by the matrix tool to have ≥50% remission rate (blue line), their mean baseline DAS28 ESR 
score was 4.43, with improvement of 1.81 at month 6. Note that improvement is positive change for EQ-
5D; improvement is negative change DAS28 and HAQ. Δ refers to median change. 
The data reveal that patients who were predicted to have the lowest chance of remission (ie, those in 
the <10% group; the red line in the figure, who also have the highest disease activity at baseline) also 
had the greatest change in DAS28-ESR score between baseline and month 6 (Figure 22A). That is, the 
patients who had the worse values of their predictors improved the most but were still the least likely to 
attain remission. A similar pattern was seen for HAQ and EQ-5D scores (Figure 22B and Figure 22C). 
Figure 23 shows the relationship between the categories of predicted response rates from the matrix 
model and the attainment of EULAR response at month 6. EULAR response is a measure of both disease 
state and improvement over time, and it was not related to the predicted probability of remission. 
EULAR response was about 82%, regardless of the rate of remission predicted by the matrix tool.  
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FIG 23: For each category of predicted DAS28-ESR remission rate from the matrix model, percentage of 
patients who attained good or moderate EULAR response after 6 months of GLM treatment.  
 
4.3.5. Discussion  
Tools that determine which patients with RA might benefit from biologic treatment can help make 
value-based decisions. We have developed a tool derived from data collected in a large trial of GLM 
treatment in more than 3000 patients with active RA despite DMARD treatment. The matrix tool 
predicts outcomes of 432 sub-populations of RA patients identified by combinations of 6 characteristics 
(gender, HAQ, presence of comorbidities, age, TJC, and ESR) that are associated with LDA and remission 
in the early treatment phase. It can assist clinicians in identification of patients for treatment, aid in 
establishing a treatment goal for an individual patient, and provide guidance to policy-makers for the 
selection of RA patient populations that are likely to achieve good disease states from anti-TNF 
treatment. The model can be used to predict outcomes at several time points during treatment, and the 
predictions for disease activity are also relevant to physical function and quality-of-life outcomes. A 
similar matrix model approach to visualizing prediction of remission and response has been developed 
for patients with ankylosing spondylitis treated with biologics [14].  
The data are important when considering the implications of treatment recommendations and 
reimbursement criteria on both patient selection criteria and patient outcomes as patients are 
considered for anti-TNF treatment. For example, in the United Kingdom (UK), reimbursement for 
biologic treatment in RA is limited to patients who have a DAS28 >5.1. In Belgium, the threshold for 
reimbursement is DAS28 >3.7. The GO-MORE study included patients from both of these countries, and 
we compared treatment efficacy based on these eligibility criteria. For patients from the UK, 185/263 
(70%) had DAS28ESR >5.1 at baseline. For patients from Belgium, 114/123 (93%) had DAS28ESR >3.7. In 
these subgroups of patients who would have been eligible for reimbursement, the selection-criterion 
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based on DAS28 led to large differences in the HAQ score, ESR, and SJC of selected patients at baseline. 
As a result, remission was obtained by 20% of UK patients and 43% of Belgian patients. LDA was 
obtained by 35% of UK patients and 55% of Belgian patients. In this analysis, because of different policy 
regarding access to treatment in the UK and Belgium, the Belgian population had a doubled rate of 
remission.  
Although patients with lower baseline disease activity were more likely to achieve remission and LDA, 
patients with high baseline disease activity demonstrated greater improvement. The differences in 
remission rates and improvement rates in the different sub-populations counterbalanced each other 
and resulted in nearly equal EULAR response rates across the population (figure 23). This may suggest 
that, at least for some DMARD refractory populations, response is a more appropriate goal of treatment 
than LDA or remission. At the same time, the excellent remission rates that can be obtained in patients 
with moderate disease activity may be a convincing argument to open up that patient population for 
treatment. 
Health Technology Assessments tend to be based on change-scores between 2 treatments compared in 
randomized, controlled trials and resulting in cost of quality-adjusted life-years. However, when 
clinicians make treatment choices or adjustments to treatments, they tend to rely on disease state 
rather than level of improvement. Elevated disease activity in RA patients receiving anti-TNF treatment 
is associated with dose increases [15], and also the other direct and indirect costs of care of RA patients 
are significantly lower in patients with LDA or remission as opposed to those who have moderate or high 
disease activity [16, 17]. Physical function, and to a lesser extent disease activity state, have been shown 
to be the major drivers of cost of RA management. Tables 24 and 25 summarize cost associated with 
different levels of HAQ, DAS28, and SDAI, and indicate that, even for biologic treated patients, function 
and disease activity drive health care utilization costs of patients maintained on treatment. Therefore, 
not only the cost associated with change of disease state but also the disease state that is achieved is of 
importance for value-based decision making. Once the decision to treat is made, the eventual disease 
state achieved will be the driver of cost and further decision making. Even if larger improvements are 
seen in patients with the worst values of predictors at baseline, this may be an argument to value 
achievement of good disease state more than improvement. Another consideration for payers is that 
cost of treatment may be reduced if patients, as per EULAR recommendations, can taper or stop therapy 
after achieving sustained remission (EULAR recommendation 12) [12]. Better selection of patients who 
are likely to achieve remission may increase the likelihood of tapering or stopping therapy. Early 
achievement of remission appears to be an important component to successfully stopping therapy, 
which points to the relevance of the 1- and 3-month time points we chose for prediction of disease state 
in our analysis [18]. 
Most of the factors included in the matrix model are validated by a number of studies that have 
analyzed individual predictors of RA treatment outcomes in studies of other biologics [1, 2], thereby 
increasing the face-validity of the model. Some characteristics, such as smoking, were not predictive in 
this dataset, but may be predictors in the overall RA population. The presence of comorbidities as a 
prognostic indicator has been shown previously [19], and it has also been shown that greater 
comorbidity is associated with greater physical disability in RA patients [3]. Because collection of 
comorbidity data in GO-MORE was not rigorous, and comorbidities were likely to have been 
underreported in this study, future work should further explore the nature of the relationship between 
comorbidities and RA outcomes.  
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Further research will be helpful to validate this model in other populations, improve its predictive ability, 
or expand its usefulness to include prediction of other outcomes. Although AUC in the ROC analysis of 
the prediction models was relatively high, not all factors that may affect response were included in the 
model. For example, patient expectations about effectiveness of treatment have been shown to be 
associated with remission [20].  
4.3.6. Conclusions 
A matrix tool was developed to predict GLM treatment outcomes in patients with RA, based on a 
combination of 6 baseline demographic and disease characteristics of patients. Value of the outcome of 
therapy may be the amount of improvement in disease activity or the eventual disease state achieved. It 
is expected that such a tool will assist physicians, guideline committees, and payers in providing practical 
guidance on identification and selection of appropriate candidates for anti-TNF therapy.  
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4.4. Predicting the outcome of ankylosing spondylitis therapy 
4.4.1. Abstract 
Objectives  
To create a model that provides a potential basis for candidate selection for anti-tumor necrosis factor 
(TNF) treatment by predicting future outcomes relative to the current disease profile of individual 
patients with ankylosing spondylitis (AS).  
Methods  
ASSERT and GO–RAISE trial data (n=635) were analysed to identify baseline predictors for various 
disease-state and disease-activity outcome instruments in AS. Univariate, multivariate, receiver operator 
characteristic and correlation analyses were performed to select final predictors. Their associations with 
outcomes were explored. Matrix and algorithm-based prediction models were created using logistic and 
linear regression, and their accuracies were compared. Numbers needed to treat were calculated to 
compare the effect size of anti-TNF therapy between the AS matrix subpopulations. Data from registry 
populations were applied to study how a daily practice AS population is distributed over the prediction 
model.  
Results  
Age, Bath ankylosing spondylitis functional index (BASFI) score, enthesitis, therapy, C-reactive protein 
(CRP) and HLA-B27 genotype were identified as predictors. Their associations with each outcome 
instrument varied. However, the combination of these factors enabled adequate prediction of each 
outcome studied. The matrix model predicted outcomes as well as algorithm-based models and enabled 
direct comparison of the effect size of anti-TNF treatment outcome in various subpopulations. The trial 
populations reflected the daily practice AS population.  
Conclusion  
Age, BASFI, enthesitis, therapy, CRP and HLA-B27 were associated with outcomes in AS. Their combined 
use enables adequate prediction of outcome resulting from anti-TNF and conventional therapy in 
various AS subpopulations. This may help guide clinicians in making treatment decisions in daily practice.  
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Ankylosing spondylitis (AS) is characterised by back pain caused by inflammation of the sacroiliac joints 
and spine. The management of AS includes non-pharmacological, pharmacological, invasive and surgical 
interventions that should be tailored to each patient's disease manifestations, current symptoms, 
clinical findings and prognostic indicators [1]. Non-steroidal anti-inflammatory drugs (NSAID) are 
recommended as first-line pharmacological treatment, and anti-tumour necrosis factor (TNF) agents are 
recommended in the case of NSAID failure [2–6]. 
Predictors of response to therapy may enable improved patient selection, outcomes and resource 
utilization [7, 8]. The recommendations for anti-TNF use in AS are, however, based primarily on 
inadequate response to conventional therapies and less on the expectation that an anti-TNF agent will 
be effective in a particular patient [2]. The literature continues to establish predictors of response [9–
14], which are also associated with anti-TNF use in AS [15]. Ideally, these may help clinicians to make 
evidence-based decisions that maximise the benefits from treatment by targeting subsets of patients 
most likely to respond [16]; however, single predictors are too weak to be useful for decision-making in 
the individual patient.  
This paper describes the predictor selection and construction of a model that identifies AS 
subpopulations likely to respond optimally to anti-TNF therapy. In the absence of a ‘hard outcome’ 
parameter that can be predicted in AS, such as mortality in cardiovascular disease, the ability and 
robustness of the predictor model to predict the results of a variety of AS outcome instruments were 
explored.  
In addition, the distribution of AS registry populations encountered in daily rheumatology practice over 
the prediction model was evaluated.  
4.4.2. Patients and methods 
This is a post-hoc analysis of the ASSERT and GO–RAISE trials in adult patients with active AS despite 
NSAID or disease-modifying antirheumatic drugs (DMARD) and naive to anti-TNF therapy.  
In ASSERT, patients were randomly assigned to receive infusions of placebo or 5 mg/kg infliximab at 
weeks 0, 2, 6, 12 and 18 and were allowed to receive concurrent NSAID but not DMARD or systemic 
corticosteroids [5]. In GO–RAISE, patients were randomly assigned to receive subcutaneous injections of 
placebo or 50 or 100 mg golimumab every 4 weeks and could continue concurrent NSAID, DMARD and 
systemic corticosteroids. For our analysis, week 16 data from GO–RAISE were carried forward to week 
24 for placebo patients who received golimumab starting at week 16 [4]. Week 24 data were collected 
between November 2002 and September 2003 in ASSERT and between December 2005 and May 2007 
in GO–RAISE.  
4.4.2.1. Outcome instruments 
The Bath ankylosing spondylitis disease activity index (BASDAI) score measures disease activity based on 
six questions on fatigue, spinal pain, joint pain/swelling, areas of localised tenderness and morning 
stiffness [17]. BASDAI50 response is defined as a 50% or greater improvement in the BASDAI score.  
Assessment of spondyloarthritis (ASAS) 20 response is an improvement of 20% or more in the patient 
global assessment (PGA), patient assessment of pain, Bath ankylosing spondylitis functional index 
(BASFI) score and assessment of inflammation. ASAS partial remission is achieved when the value of 
each of these domains is less than 2 cm on a 10-cm visual analogue scale [18]. 
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The ankylosing spondylitis disease activity score (ASDAS) measures disease activity state using an 
algorithm comprising assessment of back pain, morning stiffness duration, joint pain/swelling, PGA and 
C-reactive protein (CRP) [19, 20]. Clinically important and major ASDAS improvements are defined as a 
decrease of 1.1 units or more and 2.0 units or more, respectively. ASDAS less than 1.3 is the threshold 
for an inactive disease state [21]. 
The association of the following characteristics at baseline with BASDAI50 response and partial 
remission was studied: age, gender, HLA-B27 status, disease duration, CRP, BASFI, Bath ankylosing 
spondylitis metrology index (BASMI) score, chest expansion, intermalleolar distance, tragus to wall 
distance, modified Schobers index, lateral spinal flexion, cervical rotation, PGA, pain assessment, 
BASDAI, inflammation score, Berlin enthesitis score index and treatment group. MRI, x-rays of the spine 
and peripheral joint counts were not available for the analysis.  
4.4.2.2. Statistics 
4.4.2.2.1. Study population 
The ASSERT and the GO–RAISE datasets were summarised using means±SD and were also combined into 
a third dataset. 
4.4.2.2.2. Outcome predictor selection 
Predictors of week 12 BASDAI50 response and week 24 partial remission were identified by comparing 
the values of the aforementioned baseline characteristics between responders and non-responders and 
between remitters and non-remitters using Student's t test and χ2 tests. Variables that differed at p=0.1 
were explored further.  
Multivariate regression and stepwise selection procedures were used to narrow the number of 
predictors. The area under the receiver operating characteristics curve (ROC–AUC) and the maximum 
rescaled R² were calculated. The ROC–AUC measures the accuracy of a prediction model as: 90−100% 
excellent prediction; 80−90% good prediction; 70−80% fair prediction; 60−70% poor prediction and 
50−60% failed prediction [22]. The R² compares how competing models fit the dataset [23]. 
Spearman correlation coefficients were calculated for continuous baseline characteristics, and 
associations between variables were explored. A variable was selected for the final prediction model if it 
was retained in stepwise selection in any dataset and for either BASDAI50 response or the partial 
remission model, provided it did not have a correlation coefficient of 0.4 or greater with another 
variable. Final predictors were categorised into tertiles or according to a clinically relevant threshold in 
the matrix model.  
4.4.2.2.3. Associations of predictors with outcomes 
Associations of predictor variables with BASDAI50, ASAS20, ASDAS clinically important and major 
improvement, ASAS partial remission and ASDAS inactive disease state were explored using OR and 95% 
CI of outcomes relative to the categorised predictor variables. OR was interpreted as: 1.5 to 1 weak 
association; 2.5 to 1 moderate association; 4 to 1 strong association and 10 to 1 very strong association 
[24]. 
4.4.2.2.4. Matrix model construction 
Fitted logistic regression was used to calculate the predicted proportion of patients meeting the 
outcome criterion according to each subpopulation's value category for the predictors at baseline. These 
results were organised into a matrix model showing increasing predicted rates of achieving each 
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outcome from left to right, bottom to top [25]. Patient subpopulations with high predicted outcome 
rates are shown in yellow, those with low rates are shown in red, and those with intermediate rates are 
shown in orange. The numbers needed to treat (NNT) to realise a target beneficial outcome following 
anti-TNF treatment was calculated as follows: NNT=1/(predicted outcome rate with anti-TNF–predicted 
outcome rate with conventional therapy) and are presented in matrix models using a white, grey and 
black colour scheme.  
4.4.2.2.5. Algorithm-based models 
For each outcome instrument, logistic regression with stepwise selection was used to calculate the 
model yielding the highest ROC–AUC and R² using numeric values for CRP, BASFI, age and enthesitis 
score; categorical values for treatment and HLA-B27 genotype and their interaction terms. In a similar 
approach using linear regression, models predicting week 12 ASDAS and BASDAI scores were also 
calculated. The multiple correlation coefficient (R), which represents the correlation between the 
observed and the predicted values, and the R² were calculated, with R of 0.1 or less being ‘small’, R of 
0.1−0.3 being ‘medium’, and R of 0.3−0.5 being ‘large’ [26]. The predicted versus the observed change in 
ASDAS and BASDAI scores were plotted.  
4.4.2.2.6. Distribution of two registry AS populations over the prediction model 
The ASPECT and the Regisponser studies [15, 27, 28] conducted in 2004–5 in Belgium and Spain, 
respectively, were used to study the distribution of a daily practice AS population over the model. Cross-
sectional data were used from AS patients who had complete data for BASDAI, BASFI, CRP, the presence 
of enthesitis, age and HLA-B27 status. The percentage of the ASPECT/Regisponser populations falling 
within each of the predictor value categories in the matrix model is shown for all patients, irrespective 
of BASDAI score (total registry population), and only for patients with a BASDAI score of 4 or greater 
(active registry population). The proportion of registry patients corresponding with the NNT categories 
in the matrix models for various outcome instruments is reported. The OR of BASDAI50 response in the 
combined dataset were compared with those reported for AS populations treated with anti-TNF therapy 
in clinical practice [10–12]. 
4.4.3. Results 
4.4.3.1. Study population 
Four hundred and seventy-nine patients treated with anti-TNF agents and 156 treated with placebo in 
ASSERT or GO–RAISE were included. The characteristics of the datasets are presented in Table 26. The 
mean (SD) ASDAS at baseline was 4.0 (0.8) and median ASDAS (IQR) was 3.9 (3.4–4.5).  
 
Variables at baseline ASSERT GO–RAISE Combined 
N 279 356 635 
Male (%) 80.6 71.6 75.6 
Age (years) 39.8±10.2 39.3±12.1 39.5±11.3 
BASDAI score 6.4±1.6 6.7±1.5 6.6±1.5 
BASFI score 5.8±2.0 5.1±2.4 5.4±2.2 
BASMI score 4.0±2.1 3.5±2.2 3.7±2.1 
Cervical rotation (°) 45.8±21.9 48.8±20.3 47.5±21.0 
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Variables at baseline ASSERT GO–RAISE Combined 
Intermalleolar distance (cm) 95.3±30.6 100.8±24.8 98.3±27.7 
Lateral flexion (cm) 11.2±11.0 11.0±5.8 11.1±8.5 
Tragus to wall distance (cm) 17.0±6.3 14.2±5.7 15.4±6.1 
CRP (mg/dl) 2.4±2.7 1.8±2.0 2.1±2.4 
Enthesitis, presence of (%) 63.3 63.7 63.5 
HLA-B27 positive (%) 87.1 83.4 85.0 
PGA (cm) 6.8±1.8 7.0±1.8 6.9±1.8 
Concomitant medications for placebo patients 
NSAID (%) 90.7 92.3 – 
Methotrexate (%) (mean dose (mg/week)) – 19.2 (14.2) – 
Sulphasalazine (%) (mean dose (g/day)) – 30.8 (1.8) – 
Oral corticosteroids (%) (mean dose (mg/day)) – 16.7 (7.2) – 
Anti-inflammatory/antirheumatic drugs (%) 38.5 – – 
TABLE 26: Characteristics at baseline of the ASSERT, the GO–RAISE and the combined datasets. Values 
are mean±SD for continuous variables or percentages for categorical variables unless otherwise 
specified. 
4.4.3.2. Outcome predictor selection 
Age, CRP, HLA-B27, PGA, BASFI, BASDAI, BASMI, cervical rotation, tragus to wall distance, intermalleolar 
distance, Berlin enthesitis score and treatment differed significantly (p<0.1) between BASDAI50 
responders and non-responders and between partial remitters and non-remitters in ASSERT, GO–RAISE 
or the combined dataset (see Table 27).  
   Week-12 BASDAI50 Week-24 ASAS Partial Remission 
 Variables  ASSERT GO-RAISE Combined ASSERT GO-RAISE Combined 
Age <0.0001 0.0371 <0.0001 0.0027 0.0511 0.0007 
BASDAI score >0.1 0.0126 >0.1 >0.1 0.0021 0.0343 
BASFI score  0.0037 <0.0001 <0.0001 0.0143 <0.0001 <0.0001 
BASMI score  >0.1 >0.1 0.0909 0.0006 0.0792 0.0003 
Cervical 
  
0.032 >0.1 0.0983 0.0013 0.0150 <0.0001 
Intermalleolar 
 
0.0172 0.0216 0.0014 0.0234 0.0251 0.0011 
Tragus to wall 
  
>0.1 >0.1 >0.1 0.0046 0.0318 0.0002 
CRP  0.0159 0.0102 0.0004 0.0388 >0.1 >0.1 
Berlin Enthesitis 
 
0.0264 0.0030 0.0002 0.0495 0.0053 0.0007 
PGA >0.1 0.0052 >0.1 >0.1 0.0037 >0.1 
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Treatment 
  
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
HLA-B27  0.0882 0.0106 0.0021 0.0583 >0.1 0.0479 
TABLE 27: Exploration of predictors of BASDAI50 response at week 12 and ASAS partial remission at 
week 24 using Student t-test for continuous variables and χ2 test for categorical variables. 
These variables were further investigated. In stepwise multiple regression analysis (T), age, BASFI, 
enthesitis score, CRP, HLA-B27 and treatment were identified as predictors of BASDAI50 response and 
ASAS partial remission. BASMI and cervical rotation were identified as predictors of partial remission but 
not of BASDAI50 response (Table 28).  
 
ASSERT GO–RAISE Combined 
All Select Final All Select Final All Select Final Final category 
Age √, x √, x √, x √, x 
 
√, x √, x 
 
√, x >/≤40 years 
BASDAI score √, x   √, x   √, x    
BASFI score √, x √ √, x √, x √, x √, x √, x √, x √, x Tertiles 
BASMI score √, x x  √, x   √, x    
Cervical rotation √, x 
  
√, x 
  
√, x x 
  
Intermalleolar 
distance 
√, x 
  
√, x 
  
√, x 
   
Tragus to wall 
distance 
√, x 
  
√, x 
  
√, x 
   
Enthesitis score √, x 
 
√, x √, x x √, x √, x √, x √, x 0/≥1 
CRP √, x √, x √, x √, x √ √, x √, x √, x √, x Tertiles 
PGA √, x 
  
√, x 
  
√, x 
   
HLA-B27 √, x  √, x √, x √ √, x √, x √, x √, x +/− 
Treatment √, x √, x √, x √, x √, x √, x √, x √, x √, x Anti-TNF/placebo 
R2 0.40, 0.34 
0.36, 
0.27 
0.37, 
0.27 
0.27, 
0.24 
0.23, 
0.18 
0.24, 
0.22 
0.29, 
0.26 
0.27, 
0.25 
0.28, 
0.24 0.32, 0.28 
ROC–AUC (95% 
CI) 
0.83, 
0.84 
0.81, 
0.80 
0.82, 
0.80 
0.77, 
0.78 
0.75, 
0.74 
0.75, 
0.77 
0.78, 
0.79 
0.77, 
0.79 
0.77, 
0.78 
0.80 (0.76–0.83), 
0.77 (0.73–0.82) 
TABLE 28: Multivariate regression models for BASDAI50 response and ASAS partial remission using 
variables with p<0.1 on univariate screening, stepwise selection and final selection of variables for both 
the ASSERT and the GO–RAISE datasets. R2 and the area under the receiver operating characteristics 
curve (ROC–AUC) are presented for the different models. √ represents Bath ankylosing spondylitis disease 
activity index (BASDAI) 50, x represents assessment of spondyloarthritis (ASAS) partial remission. R2 and 
ROC–AUC values are presented for BASDAI50 response, ASAS partial remission. 
High correlation was observed between BASMI, its subcomponents and BASFI scores but not when other 
variables were compared (see Table 29).  
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TABLE 29: Spearman correlation coefficients between baseline factors. 
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Age and BASFI score were significantly higher for HLA-B27-negative than HLA-B27-positive patients, but 
numeric differences were small and not clinically significant (see Table 30).  
Variables HLA-B27 N Mean SD P-value 
Age − 95 42.8 12.0 0.0016 
+ 538 38.9 11.1 
Berlin enthesitis 
score     
− 94 2.9 3.2 0.0948 
+ 538 2.4 2.8 
BASFI total score  
− 94 5.8 1.9 0.0427 
+ 536 5.3 2.3 
CRP − 92 2.0 2.5 0.8113 
+ 530 2.1 2.3 
TABLE 30: Relationship between HLA-27 status and continuous variables of interest at baseline in the 
combined dataset. 
Due to the high correlation between BASMI and BASFI and to limit the total number of predictors to six 
(which is a reasonable maximum, considering the total number of patients included in the analysis; 
n=635), BASMI and cervical rotation were not retained in the final model. Age, BASFI, CRP, enthesitis 
score, treatment and HLA-B27 were retained in at least one of the different stepwise selection models 
and were therefore retained in the final model.  
BASFI was categorised into 4.5 or less (35%), 4.5–6.5 (31%) and over 6.5 (34% of patients). CRP was 
categorised into 0.6 mg/dl or less (corresponding with the upper limit of normal (ULN) 32%), ULN to 2 
mg/dl (34%) and over 2 mg/dl (33%). An age cut-off of 40 years yielded the highest ROC–AUC; 46% of 
patients were 40 years old or less and 54% were over 40 years old. Enthesitis was present (enthesitis 
score >0) in 64% and absent (enthesitis score 0) in 36%. Additional information leading to the selection 
of age and enthesitis categories is provided in Table 31.  
 Week-12 BASDAI50 Week-24 ASAS partial remission 
Berlin Enthesitis Index 
Score 
≤0 vs. >0 ≤2 vs. >2 ≤0 vs. >0 ≤2 vs. >2 
Age (yrs) R2 ROC-AUC R
2 ROC-AUC R
2 ROC-AUC R
2 ROC-AUC 
≤30 vs. >30 0.3001 78.8 0.2925 78.2 0.2304 77.2 0.2373 77.5 
≤35 vs. >35 0.3010 78.8 0.2936 78.5 0.2292 77.2 0.2360 77.7 
≤40 vs. >40 0.3168 79.7 0.3117 79.3 0.2370 77.4 0.2439 78.2 
≤45 vs. >45 0.3128 79.4 0.3076 78.8 0.2352 77.4 0.2420 78.0 
≤50 vs. >50 0.3015 79.0 0.2945 78.2 0.2387 77.8 0.2445 78.3 
TABLE 31: Area under the Receiver Operator Characteristic (ROC-AUC) curve and R2 for different 
dichotomous categorizations of Berlin Enthesitis Index score and age. 
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The ROC–AUC and R² of the different models presented in table 2 indicate that the accuracy of the 
predicted BASDAI50 response and predicted partial remission was similar when models with many 
predictor variables were compared with models with few variables. In addition, they show that the final 
set of predictors predicts BASDAI50 response and partial remission in the three datasets reasonably 
well. The relationship between the week 12 BASDAI50 response and week 24 partial remission is shown 
in Table 32.  
 Wk-24 BASDAI50 Wk-24 ASAS partial remission 
No (%) Yes (%) No (%) Yes (%) 
Wk-12 BASDAI50 No  326 (86.0) 53 (14.0) 372 (98.2) 7 (1.9) 
Yes  31 (13.4) 201 (86.6) 122 (52.6) 110 (47.4) 
TABLE 32: 2x2 table relating BASDAI50 response at week 12 to BASDAI50 response and ASAS partial 
remission at week 24.Chi-square test. All p-values <0.0001. 
4.4.3.3. Associations of predictor variables with outcomes 
The OR (95% CI) of achieving an outcome relative to the value category of a predictor variable is 
presented in Table 33.  
HLA-B27 was more strongly associated with large improvements and disease states (BASDAI50, ASDAS 
major improvement, ASAS partial remission, ASDAS inactive disease) than with small improvements 
(ASAS20, ASDAS clinically important improvement). Age was more strongly associated with 
improvement than with disease states. Enthesitis showed weak associations with all outcome 
instruments. The BASFI score was strongly associated with disease state and BASDAI50 improvement 
but less so with ASDAS and ASAS20 improvements. The very strong association between CRP and ASDAS 
improvement is striking, albeit reasonable given that CRP is an intrinsic component of ASDAS. A strong 
association was also seen between CRP and BASDAI50. Finally, very strong associations between anti-
TNF therapy and all outcomes were seen with OR ranging from 5.8 to 46.5.  
4.4.3.4. Matrix model construction 
Matrix models using the six predictor variables were created for all outcome instruments (Figure 24A–F) 
and show a good spread of outcome rates over the different subpopulations defined by the predictor 
value categories. The strength of associations between predictor and outcome instrument is reflected in 
the differences between outcome rates in these subpopulations. Differences of 22% or less were seen 
when rates of large improvement and disease states were compared between similar HLA-B27-positive 
versus negative patients. Differences of 14% or less were seen when small improvements were 
compared between genotypes. Differences in improvement rates were larger than differences in rates 
of disease state when older and younger patients were compared, whereas the association of BASFI led 
to larger differences in disease state. Differences in outcome rates related to the presence of enthesitis 
were small. The association of CRP with ASDAS improvement led to major differences in outcomes; for 
example, ASDAS major improvement in HLA-B27-positive patients aged 40 years or less who had BASFI 
of 4.5 or less and no enthesitis was 81% if their CRP was over 2 mg/dl but only 22% if their CRP was 
normal.  
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ASDAS clinically important 
improvement 3 months ASAS20 response 3 months 
OR Lower 95% 
CI 
Upper 95% 
CI 
OR Lower 95% 
CI 
Upper 95% CI 
Anti-TNF vs conventional 17.7 10.0 31.3 5.8 3.7 9.0 
HLA-27+ vs HLA-27− 1.3 0.7 2.2 1.7 1.1 2.9 
Age ≤40 vs >40 years 2.2 1.5 3.4 1.7 1.2 2.4 
CRP high vs low 9.3 5.5 16.0 2.2 1.4 3.4 
CRP moderate vs low 3.5 2.2 5.7 1.2 0.8 1.9 
Berlin enthesitis score 0 vs >0 0.9 0.6 1.3 1.2 0.8 1.6 
BASFI low vs high 2.2 1.3 3.6 1.5 1.0 2.4 
BASFI moderate vs high 2.2 1.3 3.6 1.9 1.2 3.0 
 
ASDAS major improvement 3 
months 
BASDAI50 response 3 months 
OR Lower 95% 
CI 
Upper 95% 
CI 
OR Lower 95% 
CI 
Upper 95% CI 
Anti-TNF vs conventional 14.2 6.5 31.1 8.7 4.9 15.6 
HLA-27+ vs HLA-27− 2.4 1.2 4.7 2.5 1.4 4.5 
Age ≤40 or >40 years 1.8 1.2 2.9 1.9 1.3 2.8 
CRP high vs low 15.0 7.9 28.6 3.6 2.2 5.8 
CRP moderate vs low 4.1 2.2 7.8 2.3 1.4 3.7 
Berlin enthesitis score 0 vs >0 1.6 1.0 2.5 1.4 1.0 2.1 
BASFI low vs high 1.635 0.9 2.8 3.4 2.1 5.5 
BASFI moderate vs high 1.4 0.8 2.4 3.0 1.8 4.8 
 
ASDAS inactive disease 6 
months 
ASAS partial remission 6 months 
OR 
Lower 95% 
CI 
Upper 95% 
CI OR 
Lower 95% 
CI Upper 95% CI 
Anti-TNF vs conventional 46.5 6.4 339.6 16.8 5.2 54.4 
HLA-27+ vs HLA-27− 2.4 1.0 5.5 2.2 1.0 5.0 
Age ≤40 or >40 years 1.6 1.0 2.6 1.6 1.0 2.6 
CRP high vs low 2.3 1.3 4.2 2.1 1.2 3.7 
CRP moderate vs low 1.6 0.9 3.0 1.3 0.8 2.4 
Berlin enthesitis score 0 vs >0 1.5 0.9 2.4 1.3 0.8 2.1 
BASFI low vs high 3.2 1.7 5.9 4.1 2.2 7.6 
BASFI moderate vs high 1.8 1.0 3.5 2.6 1.4 4.8 
TABLE 33: Associations of predictor variables with selected outcome instruments. 
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FIG 24: Matrix presentation of outcome rates of different patient subpopulations (%) defined by the 
categorised predictor variables: (A) ankylosing spondylitis disease activity score (ASDAS) clinically 
important improvement, (B) ASDAS major improvement, (C) assessment of spondyloarthritis (ASAS) 
partial remission, (D) ASAS 20 response, (E) Bath ankylosing spondylitis disease activity index (BASDAI) 50 
response and (F) ASDAS inactive disease.  
Differences in response rates exceeding 50% were observed when anti-TNF was compared with 
conventional therapy. The robustness of response to anti-TNF therapy is further highlighted by Figure 
25A–F, which indicates that almost all subpopulations have a NNT of less than five to achieve small  
improvements.  
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FIG 25: Matrix presentation of numbers needed to treat for one patient to respond to anti-tumour 
necrosis factor treatment according to different outcome instruments at 12 or 24 weeks: (A) ankylosing 
spondylitis disease activity score (ASDAS) clinically important improvement, (B) ASDAS major 
improvement, (C) assessment of spondyloarthritis (ASAS) partial remission, (D) ASAS 20 response, (E) 
Bath ankylosing spondylitis disease activity index (BASDAI) 50 response, and (F) ASDAS inactive disease.  
High NNT indicate that large improvements and inactive disease states are difficult to achieve in some 
subpopulations. The ROC–AUC (R²) for the matrix model of ASAS20 response, BASDAI50 response, ASAS 
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partial remission, ASDAS clinically important and major improvement, and ASDAS inactive disease was 
0.74 (0.28), 0.80 (0.32), 0.77 (0.28), 0.84 (0.44), 0.84 (0.39) and 0.79 (0.25), respectively.  
4.4.3.5. Algorithm-based models 
The formulae of the models using selected predictor variables and/or their interaction terms are 
presented in Table 34.  
 
Predicted outcome  ROC-
AUC 
R² Prediction formula * 
% ASAS20 response – 
week 12 0.75 0.244 
 P=1/(1+exp(-(β0+ (β1.4)*(X1X4)+(β1.6)*(X1X6)+β2*X2 
+(β2.5)*(X2X5)+ (β3.5)*(X3X5)+ (β4.5)*(X4X5)))) 
% BASDAI50 response – 
week 12 
0.79 0.326 
 P=1/(1+exp(-(β0+ β1*X1+(β1.3)*(X1X3)+(β2.4)*(X2X4) 
+(β2.6)*(X2X6)+ (β3.5)*(X3X5)+ (β3.6)*(X3X6)+ 
(β4.5)*(X4X5)))) 
% ASDAS clinically 
important improvement – 
week 12 
0.86 0.480  P=1/(1+exp(-(β0+ β1*X1+(β1.6)*(X1X6)+β2*X2+ 
(β2.5)*(X2X5)+(β3.5)*(X3X5)+ (β3.6)*(X3X6)))) 
% ASDAS major 
improvement – week 12 0.85 0.427 
 P=1/(1+exp(-(β0+ (β1.4)*(X1X4)+(β1.5)*(X1X5)+ 
(β2.6)*(X2X6)+ (β3.5)*(X3X5)+(β3.6)*(X3X6)+ β4*X4))) 
Unit ASDAS change – week 
12 
0.697¹ 0.486 
Y=β0+ 
β1*X1+(β1.6)*(X1X6)+(β2.6)*(X2X6)+(β3.5)*(X3X5)+ 
(β3.6)*(X3X6)+ (β4.5)*(X4X5)+ (β4.6)*(X4X6)+ β5*X5 
% BASDAI change – week 
12 0.517¹ 0.267 
Y=β0+X1*β1+(X1X6)*(β1.6)+(X2X6)*(β2.6)+(X3X4)*(β3.4)+
(X3X5)*(β3.5) +(X3X6)*(β3.6)  
% ASDAS remission – week 
24 0.78 0.257 
P=1/(1+exp(-(β0+ β1*X1+(β2.3)*(X2X3)+ 
(β3.5)*(X3X5)+β4*X4+β4.6)*(X4X6)))) 
% AS partial remission – 
week 24 0.79 0.254 
P=1/(1+exp(-(β0+ (β1.6)*(X1X6)+(β2.3)*(X2X3) 
+(β3.6)*(X3X6)+ (β4.5)*(X4X5)+β5*X5))) 
TABLE 34: Area under the ROC curve, R², and algorithms for the prediction of different outcome 
instruments.* P = predicted probability of outcome, Y = predicted outcome, X1 = Treatment, X2 = HLA-
B27, X3 = Age, X4 = Enthesitis, X5 = BASFI, X6 = ln(1+CRP). ¹ multiple correlation coefficient (R) is 
provided. 
The values for ROC–AUC and R² were very similar to those of the matrix models. Comparisons of R² 
show that the model to predict week 12 ASDAS fitted the combined dataset best. Values for R indicate 
that the association of the algorithm-based model with week 12 ASDAS was higher than that with 
BASDAI. Figures 26A and B show the predicted versus the observed changes in ASDAS and BASDAI 
scores and also illustrate that the prediction of ASDAS is more accurate than the prediction of BASDAI.  
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FIG.26: Observed versus predicted change in ASDAS score (A) and BASDAI score (B). 
 
4.4.3.6. Distribution of a cross-sectional AS registry population over the model 
Of the 1760 AS patients in the total registry population, 1051 (59.7%) had an elevated BASDAI score of 4 
or greater (ie, the active registry population). The distribution of CRP in the total/active populations, 
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respectively, was: 56.6%/51.0% for patients with CRP less than ULN; 29.8%/33.6% for those with a CRP 
level of ULN to 2 mg/dl; and 13.6%/15.3% for those with CRP greater than 2 mg/dl. The distribution of 
BASFI was: 53.9%/32.9% for patients with a score less than 4.5; 22.5%/30.4% for those with a score of 
4.5–6.5; and 23.6%/36.7% for those with a score greater than 6.5. Approximately 83% of patients were 
HLA-B27 positive, and approximately 33% of patients were 40 years old or younger in both the total and 
the active populations. Enthesitis was present in 16% and 21% of the total and the active registry 
populations, respectively. The percentage of the total and the active registry patients falling into each 
cell of the matrix is shown in Figure 26A , B. The percentage of registry patients falling into the different 
NNT categories for each outcome instrument (Figure 25A–F) is reported in Table 35.  
Total registry 
population 
ASAS20 BASDAI50 ASAS 
partial 
remission 
ASDAS 
clinically 
important 
improvement 
ASDAS major 
improvement 
ASDAS 
inactive 
disease 
NNT<3 
NNT 3-5 
NNT 5-10 
NNT>10 
81.8% 
18.2% 
0.0% 
0.0% 
45.2% 
38.6% 
14.1% 
2.2% 
10.9% 
45.3% 
26.0% 
17.8% 
82.2% 
9.3% 
8.5% 
0.0% 
27.3% 
11.7% 
40.7% 
20.3% 
10.7% 
45.5% 
29.8% 
14.0% 
Active registry 
population 
ASAS20 BASDAI50 ASAS 
partial 
remission 
ASDAS 
clinically 
important 
improvement 
ASDAS major 
improvement 
ASDAS 
inactive 
disease 
NNT<3 
NNT 3-5 
NNT 5-10 
NNT>10 
75.5% 
22.5% 
0.0% 
0.0% 
40.8% 
38.7% 
16.9% 
3.5% 
8.4% 
34.7% 
29.9% 
27.0% 
79.4% 
7.9% 
12.7% 
0.0% 
26.3% 
16.8% 
33.6% 
23.3% 
8.4% 
34.7% 
36.1% 
20.8% 
TABLE 35: Percentages of patients of the total and active registry population that fall within the patient 
subpopulations as categorized by the NNT for each outcome instrument. See also Figures 25A-F. 
For example, for ASDAS clinically important improvement, 82.2%, 9.3% and 8.5% of the active registry 
population fell into the NNT less than three, three to five and five to 10 categories, respectively. NNT 
greater than 10 was not observed for this outcome (F), therefore 0% of registry patients fell into this 
category.  
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FIG. 27: Cross-sectional application of the ASPECT/Regisponser populations over the matrix grid: 
percentage of (A) the total registry population (including all patients irrespective of Bath ankylosing 
spondylitis disease activity index (BASDAI) score), and of (B) the active registry population (including only 
patients with a BASDAI score of ≥4) defined by the categorised predictor variables.  
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A detailed comparison of associations between predictors and outcomes reported from comparable 
analyses performed in AS populations treated with anti-TNF therapy in clinical practice [10-12] is 
provided in Table 36.  
 
Predictor 
Odds of BASDAI50 response at 3 months 
ASSERT/ GO-
RAISE 
Lord et al.[11] Rudwaleit et 
al.[12] 
Glintborg et al.[10]* 
CRP: OR/mg/dL increase 
BASFI: OR/unit increase 
Age: OR/year increase 
HLA-B27: OR + vs. − 
1.21 
0.82 
0.97 
2.47 
1.4 (raised vs. not) 
0.94 
0.97 
- 
1.23 
0.89 
0.97 
1.77 
0.45 (> vs. ≤14 mg/L) 
0.87 
0.98 
- 
TABLE 36: Comparison of associations between predictor variables and BASDAI50 response at 3 months. 
* Response was defined as BASDAI50 improvement or an improvement of at least 2 cm in the BASDAI 
score.  
4.4.4. Discussion 
Our analyses show that CRP, HLA-B27 genotype, BASFI, age, enthesitis and choice of therapy are 
independent predictors of a variety of outcome instruments, and that the combination of these six 
variables adequately predicted clinical improvement following therapy and subsequent disease states in 
the ASSERT and the GO–RAISE datasets separately and combined.  
4.4.4.1. Model validity 
The goal of our analysis was to create a practical, evidence-based model that can help guide clinicians in 
making informed treatment choices for AS patients. The predictive variables identified in these 
randomised studies have been shown to be associated with response and remission in other datasets 
and outside of a randomised controlled setting, which lends support to the external validity of the 
model [8-14]. 
The associations of age, CRP, HLA-B27 and BASFI with BASDAI50 response in ASSERT/GO–RAISE are very 
similar to those in previous reports [10-12]. Figure 27 further indicates that the 72 subpopulations 
characterised by the baseline values for predictors reasonably represent the AS population in clinical 
practice. This may support the value of our model in daily practice.  
There are, however, several weaknesses of our data indicating that validation of the model is necessary. 
The association of the enthesitis score with outcomes was not investigated in previous reports, and 
comparisons between anti-TNF and conventional treatment were not performed. Our algorithms and 
models originate from studies designed and powered to show the superiority of anti-TNF therapy over 
placebo, and identifying predictors of response was not a formal endpoint of those studies. The blinded, 
controlled design of the trials may have led to outcomes different from those observed in clinical 
practice, and other data sources may have led to the development of different models. Finally, the 
cross-sectional registry data do not provide any insight into the model's ability to predict outcomes 
adequately in daily practice.  
The predictors retained in the step-wise selection procedures differed between ASSERT and GO–RAISE 
(Table 28), and enthesitis was not associated with ASAS20 response (Table 33, Table 34). As such, some 
final predictor variables are redundant for certain datasets or for certain outcomes. However, 
independent of the dataset used and the outcome instrument predicted, the ROC–AUC of the six 
selected predictors combined remains close to 0.80, indicating good accuracy of prediction.  
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4.4.4.2. Comparison of different outcome instruments 
Interestingly, although final predictors were selected for their ability to predict BASDAI50 response and 
ASAS partial remission, these predictors were more accurate in predicting week 12 ASDAS improvement 
and inactive disease. Our single component analysis shows that this is due to a stronger association of 
CRP and therapy with the ASDAS scoring system (Table 28). The difference in strength of association 
between predictors and outcome instruments is relevant for trial design in AS. The stronger association 
of anti-TNF therapy with ASDAS than with traditional outcomes indicates that the ASDAS scoring system 
may be a more powerful tool than current outcome instruments in showing the efficacy of biological 
agents. The associations identified may also improve patient selection in studies.  
The inclusion of CRP as a component in the ASDAS formula may explain partly why outcomes assessed 
with ASDAS were very strongly associated with baseline CRP. However, although BASFI is a component 
of ASAS20 response and ASAS partial remission criteria, the association between BASFI and these 
outcomes was not as strong as that between CRP and ASDAS outcomes.  
In subpopulations with normal CRP, BASDAI50 response and ASAS partial remission rates following anti-
TNF treatment were higher than ASDAS major improvement and ASDAS inactive disease rates, and 
absolute differences with response to conventional therapy led to higher NNT. Differences between 
ASAS20 response and ASDAS clinically important improvement were also present but smaller. This may 
indicate that outcomes in patients with normal CRP may be better assessed with an outcome instrument 
based only on patient-reported outcomes. These findings are in concordance with validation sets of the 
ASDAS in which discrimination of ASDAS was better than that of BASDAI in patients with elevated CRP 
and equal to BASDAI in patients with normal CRP [20]. 
4.4.4.3. Selected predictors 
Although BASDAI was not a predictor of response in our datasets, it was in previous reports [8, 11]. This 
may be due to a homogeneous selection of study patients based on elevated BASDAI scores as part of 
the inclusion criteria. BASFI was retained as a predictor in this and previous studies [10-12]. The 
correlation between BASDAI and BASFI is relevant for selecting candidates for anti-TNF therapy in AS, as 
shown in the AS registries. The proportion of patients in the lowest BASFI category is much higher in the 
total than the active registry population. The high correlation between BASFI and BASDAI is due to the 
exclusion of patients with low BASDAI in the active registry population. Patients with a BASDAI less than 
4, however, may still have other clinical characteristics that are associated with response and remission 
in addition to a low BASFI score. For example, 658 (37.4%) of all registry patients were HLA-B27 positive 
and had CRP elevation greater than ULN; of these, 214 (32.5%) had a BASDAI less than 4. These patients 
have not been studied in clinical trials and are currently not recommended for anti-TNF therapy.  
Our data show that somewhat worse outcomes can be expected in patients with an elevated enthesitis 
score. Because of the lack of agreement on how enthesitis should be measured [29], enthesitis was 
assessed only as present or absent and was not scored in the registries. This explains why enthesitis is 
present in the majority of patients in randomised studies but only in a minority of patients in registries. 
The differences in response and remission to anti-TNF therapy were not large when similar patients with 
and without enthesitis were compared. As anti-TNF agents are very effective in patients with well-
defined enthesitis [30] patients with peripheral manifestations having worse enthesitis may be a 
reflection of more severe disease in general [31, 32]. 
HLA-B27-positive patients responded better to anti-TNF treatment in our study and in previous reports 
[8, 12]. It is unclear whether this is a function of HLA-B27 facilitating earlier and correct diagnosis or the 
disease biology differing in HLA-B27-positive versus negative AS patients.  
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Age was an independent predictor of outcome in the ASSERT study, and significant differences were 
seen when age was compared between responders and remitters in the GO–RAISE study and the 
combined dataset. The importance of age in response prediction has been shown previously [8, 10, 11]. 
Although disease duration has been shown to be relevant for outcome prediction [8] disease duration 
was not retained in our dataset because age can be more precisely determined than disease duration 
and may be more useful for prediction.  
Our data confirm the association of elevated CRP levels with good response to anti-TNF therapy [9-14]. 
As the registry data show that AS patients with normal CRP constitute approximately half the AS 
population, recognising suitable candidates for anti-TNF treatment among such patients may be 
challenging. Other inflammatory biomarkers and MRI may help in predicting response to therapy [14, 
29], and may be especially useful in distinguishing responders from non-responders in patients with low 
CRP [14, 33]. 
4.4.4.4. Subpopulations with robust response to anti-TNF treatment 
Anti-TNF therapy is recommended for patients who have sustained elevated disease activity despite 
conventional therapy and should be prescribed based on expert opinion [2]. Our prediction model may 
help guide that expert opinion. The data show that the continuation of conventional therapy in the face 
of sustained elevated disease activity will be unlikely to result in improvement. The differential 
responses in ASAS20 and ASDAS clinically important improvement rates from using anti-TNF versus 
continued conventional treatment and the resulting low NNT indicate that anti-TNF treatment is a 
clinically sound choice in all subpopulations with elevated disease activity. Given the lack of good 
alternatives, the treating physician should therefore consider a defined trial period with an anti-TNF 
agent if disease activity is not controlled with NSAID [2]. Large improvements and remission may, 
however, not be achievable therapeutic goals for all patients.  
In conclusion, our analysis shows that a model combining age, HLA-B27 genotype, CRP level, functional 
status and the presence of enthesitis at baseline enables a good prediction of the response to anti-TNF 
or conventional therapy in AS, as measured by various outcome instruments. This may help clinicians 
choose more appropriate therapies for patients in daily practice and also help improve patient selection 
and protocol design for clinical studies.  
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4.5. ASDAS high disease activity versus BASDAI elevation in 
patientswith ankylosing spondylitis as selection criterion 
for anti-TNF therapy 
4.5.1. Abstract 
Objective 
To investigate which of the 2 ankylosing spondylitis (AS) disease activity instruments identifies better 
those patients with characteristics that have been associated with positive response to anti-TNF 
therapy.  
Methods 
Data from patients with AS in the REGISPONSER registry were analyzed. Patients were categorized by 
disease activity using 3 different selection criteria: elevated Bath Ankylosing Spondylitis Disease Activity 
Index criteria (BASDAI ≥ 4), high Ankylosing Spondylitis Disease Activity Score (ASDAS ≥ 2.1), or very high 
ASDAS (ASDAS ≥ 3.5). To determine which criterion selects for patients most likely to respond to anti-
TNF therapy, the groups of patients selected with each criterion were compared on five disease 
characteristics that are associated with good response to anti-TNF therapy: lower age, lower function 
score, less enthesitis, higher C-reactive protein (CRP), and HLA-B27-positive status.  
Results 
50.9%, 66.3%, and 24.9% of 1156 patients had elevated BASDAI, high ASDAS, or very high ASDAS, 
respectively. Compared to patients selected with elevated BASDAI, more patients selected with high 
ASDAS had characteristics associated with good response to anti-TNF therapy. Patients with very high 
ASDAS had higher CRP and were younger, but more frequently had enthesitis and had higher function 
scores when compared to those with elevated BASDAI.  
Conclusions 
Selection of AS patients with the ASDAS instrument results in patient sub-populations with different 
characteristics than those selected with the BASDAI instrument. Since some of these characteristics have 
been associated with response to anti-TNF therapy, further study should establish if the choice of 
selection instrument improves the outcome of therapy in the selected populations. 
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4.5.2. Introduction 
For patients with axial spondyloarthritis and patients with ankylosing spondylitis (AS) failing 2 or more 
nonsteroidal anti-inflammatory drugs (NSAIDs), recommendations for anti-tumor necrosis factor (anti-
TNF) therapy require presence of elevated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
and positive expert opinion using clinical disease characteristics [1–3]. Even though clinical activity and 
physician judgment are still the main drivers for starting anti-TNF therapy, different studies suggest that 
demographic and disease characteristics, such as age, C-reactive protein (CRP), functionality, and HLA-
B27 genotype may influence response to anti-TNF and therefore could help in the selection of 
candidates for treatment with these drugs [4–9].  
The reason elevated BASDAI is used for patient selection in treatment recommendations is because 
elevated BASDAI has also been used as a selection criterion in efficacy studies [10, 11] How-ever, 
because a higher BASDAI score has been associated with nonresponse and anti-TNF treatment 
discontinuation [5, 7] selection with elevated BASDAI score may be a recipe for poor outcomes. As 
elevated disease activity is indispensable for patient selection, we investigated whether use of the newly 
developed Ankylosing Spondylitis Disease Activity Score (ASDAS) as selection instrument results in a 
different population of patients than those selected with BASDAI, and whether the populations could be 
characterized through characteristics that have been associated with response to anti-TNF therapy in 
published literature [9, 12]. 
4.5.3. Methods  
4.5.3.1. Disease activity instruments.  
The BASDAI measures disease activity using six patient-reported questions pertaining to fatigue, spinal 
pain, joint pain/swelling, areas of localized tenderness and morning stiffness [13]. Patients have an 
elevated disease activity if the BASDAI score is ≥4 on a10-point scale.  
The ASDAS measures disease activity using an algorithm comprising 3 BASDAI questions (spinal pain, 
morning stiffness, and joint pain/swelling), the patient global assessment, and CRP [11]. ASDAS ≥ 1.3 
indicates moderate, ≥2.1 indicates high, and ≥3.5 indicates very high disease activity [14]. 
4.5.3.2. Characteristics associated with treatment outcome  
Lower age, lower Bath Ankylosing Spondylitis Functional Index (BASFI), lower enthesitis score, higher 
CRP, and presence of HLA-B27 have been associated with good outcomes to anti-TNF therapy [3–8]. 
Samples selected with the various disease activity measures/cutoffs were compared for their profile of 
these 5 characteristics.  
4.5.3.3. Patient population  
Patients with AS according to the modified New York criteria included in the Spanish national registry of 
spondyloarthropathies (REGISPONSER), who had complete data for BASDAI, ASDAS, age, CRP, BASFI, 
presence of enthesitis, and HLA-B27 status, were included in this analysis [15].  
4.5.3.4. Analysis 
Two-by-two cross-tabulation reflecting patient samples selected with BASDAI and ASDAS were created. 
Each sample’s characteristics are reported using the following categories: BASFI ≤ 4.5, 4.5–6.5, and >6.5; 
CRP <upper limit of normal (ULN),>ULN but <2 mg/dL, and >2 mg/dL; age ≤40 and >40 years; and 
enthesitis present or absent. The different combinations of these variables and categories allowed the 
identification of 72 subpopulations, which were represented in a matrix grid that situates 
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subpopulations that have been associated with the best outcomes (i.e., high CRP, no enthesitis, HLA-
B27-positive, low age, and low BASFI) in the upper right corner and those associated with lower 
response rates in the lower left corner [8].  
The difference between the numbers of patients selected with ASDAS versus BASDAI is reported for 
each subpopulation. Subpopulations that had a net increase or decrease when selected with ASDAS are 
presented in green and red, respectively. The proportion of patients falling into each of the 72 
subpopulations, relative to the total population selected with BASDAI or ASDAS are reported.  
4.5.4. Results 
A total of 1156 patients had complete data for all variables (mean age: 48 years [SD 13], 74.5% male and 
25.5% female). Mean disease duration was 21.5 years (SD: 13), 84.9% had positive HLA-B27 and 34.6% 
had history of enthesitis. A total of 17.0% was being treated with anti TNF agents, 9.2% was taking 
steroids, 8.6% methotrexate, 14.2% sulphasalazine and 0.6% leflunomide. CRP value was<0.6 mg/dL in 
53.2% of the sample, whilst 11.6% had ≥2.0 mg/dL.  
Table 37 shows the distribution of ASDAS and BASDAI values. Almost all patients had at least moderate 
ASDAS (Table 37A), two-thirds had at least high ASDAS (Table 37B), and one-quarter had very high 
ASDAS (Table 37C). Approximately half of the patients had elevated BASDAI. Among those with high 
ASDAS or high BASDAI, 14.3%and 15.1% were treated with anti TNF drugs respectively. Of 568patients 
with a low BASDAI score, 210 patients had high disease activity as measured by ASDAS (37%, Table 37B), 
and only 16 had very high disease activity on ASDAS (2.8%, Table 37C). Of 390 patients with ASDAS <2.1, 
only 32 had elevated BASDAI (8.2%, Table 37B). There were no patients with ASDAS <1.3 and elevated 
BASDAI (Table 37C). 
A. 
 BASDAI <4 
BASDAI ≥4 
(elevated activity) Total 
ASDAS <1.3 142 0 142 (12.3%) 
ASDAS ≥1.3 (moderate activity) 426 588 1014 (87.7%) 
Total 568 (49.1%) 588 (50.9%) 1156 (100%) 
B. 
 BASDAI <4 
BASDAI ≥4 
(elevated activity) Total 
ASDAS <2.1 358 32 390 (33.7%) 
ASDAS ≥2.1 (high activity) 210 556 766 (66.3%) 
Total 568 (49.1%) 588 (50.9%) 1156 (100%) 
C. 
 BASDAI <4 
BASDAI ≥4 
(elevated activity) Total 
ASDAS <3.5 552 316 868 (75.1%) 
ASDAS ≥3.5 (very high activity) 16 272 288 (24.9%) 
Total 568 (49.1%) 588 (50.9%) 1156 (100%) 
TABLE 37:  Percentage of patients who met each criterion and characteristics of patients selected with 
each criterion. Two-by-two cross-tabulations of disease activity state as determined by the BASDAI 
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criterion for elevated disease activity versus ASDAS criteria for moderate (A), high (B), and very high 
disease activity (C).  
Table 38 shows that more patients selected with high ASDAS have disease characteristics that have been 
associated with positive outcomes of anti-TNF treatment in reported literature (markedly higher CRP 
and lower BASFI; slightly lower age, fewer patients with enthesitis, and more patients with HLA-B27 
positive status) when compared to patients selected with elevated BASDAI. Patients with very high 
ASDAS had much higher CRP levels and were younger (both associated with positive outcomes in 
literature), but more frequently had enthesitis and had markedly higher BASFI scores (inversely 
associated with positive outcomes) when compared to those with elevated BASDAI. Characteristics of 
patients with moderate ASDAS were nearly identical to the total cohort (not shown). 
 
All patients 
(n=1156) 
Patients with High Disease Activity, as Determined 
by Each Selection Criterion 
ASDAS ≥2.1 
(n=766) 
ASDAS ≥3.5 
(n=288) 
BASDAI ≥4 
(n=588) 
Age ≤40 years  
HLA-B27–positive  
Never had enthesitis  
BASFI 
      ≥6.5 
      4.5–6.5 
      <4.5 
CRP (mg/dL) 
      ≥2 
      0.6–2 
      <0.6 
28.6% 
84.9% 
65.4% 
 
19.8% 
20.0% 
60.2% 
 
11.6% 
34.9% 
53.2% 
26.4% 
85.1% 
61.7% 
 
27.3% 
26.1% 
46.6% 
 
17.4% 
45.0% 
37.6% 
24.0% 
83.0% 
53.3% 
 
44.4% 
26.4% 
29.2% 
 
30.2% 
54.9% 
14.9% 
23.1% 
83.5% 
58.2% 
 
34.2% 
28.7% 
37.1% 
 
12.9% 
41.5% 
45.6% 
TABLE 38: Percentage of patients who had each characteristic that has been associated with positive 
anti-TNF treatment outcomes, by patient groups selected with ASDAS or BASDAI criteria. 
Relative to the total population included in this analysis, the pro-portion of patients in subpopulations 
identified with characteristics that have been associated with positive outcomes (i.e. expected to 
respond well and located to the right and top of the matrix grid) increases when selection is done with 
high ASDAS instead of BASDAI (Figure 28B, D, and E). At the same time, few sub-populations are 
numerically decreasing when BASDAI is replaced by high ASDAS. These sub-populations are located at 
the bottom left of the matrix grid (i.e., associated with worse outcomes related to anti-TNF therapy) and 
the size of these subgroups relative to the total population goes down. If BASDAI is replaced by very high 
ASDAS, few subpopulations in the highest CRP category have a small increase, whereas most 
subpopulations show decreases in population size (Figure 28A, C, and D).  
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FIG. 28: Matrix representation of characteristics of patients selected with each criterion. Net numeric 
increase (green) or decrease (red) within each of the various subpopulations when the measure of 
disease activity used to select patients changes from elevated Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) to (A) Ankylosing Spondylitis Disease Activity Score (ASDAS) very high disease 
activity and (B) ASDAS high disease activity. Size of each of the 72 subpopulations, relative to the total 
population selected with the following disease activity measure: (C) very high ASDAS, (D) elevated 
BASDAI, and (E) high ASDAS. 
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4.5.5. Discussion  
This analysis of cross-sectionally evaluated patients with AS in daily clinical practice describes the profile 
of patients who would be selected for anti-TNF therapy if different disease activity instruments were 
used. The purpose of this hypothesis-generating research was to evaluate which disease activity 
measure and threshold criterion would select the population that is most likely to have characteristics 
that have been associated with response to anti-TNF treatment in the literature. The data show that 
more patients have high ASDAS than elevated BASDAI, and compared to those selected with high 
BASDAI, patients selected with high ASDAS more frequently have disease characteristics that have a 
documented association to good response to anti-TNF therapy [9]. 
The selection of patients for anti-TNF therapy is not an easy decision. The BASDAI instrument is currently 
the main driver to select candidates to receive anti-TNF therapy in AS, but positive expert opinion 
clinical based in clinical judgment based on disease characteristics is also very important [1–3] In this 
study, we highlight that the BASDAI instrument may exclude a certain proportion of patients that (1) 
have high disease activity according to another instrument (i.e. the ASDAS activity index), (2) show 
characteristics that have been associated to good outcome to anti-TNF therapy in the literature, and (3) 
may correspond with a patient profile that a clinician may think is appropriate for anti-TNF treatment 
(e.g., a young patient with high disease activity, high CRP, and HLA-B27-positive status). In the current 
study, 37% of patients who had low disease activity according to the BASDAI criterion had high disease 
activity according to the ASDAS; if BASDAI was used as a strict criterion for determining eligibility for 
treatment, none of these patients would be eligible for anti-TNF treatment. The use of high ASDAS as a 
selection criterion instead of elevated BASDAI would increase the number of treatment candidates. 
Patients selected with elevated ASDAS but not elevated BASDAI had a combination of disease 
characteristics that are associated with positive outcomes in published studies (represented in green in 
Figure 28B) [4–9]. Very few patients had high BASDAI and low ASDAS and would not be selected with 
the high ASDAS criterion (represented in red in Figure 28B); these patients tend to have characteristics 
that may not be associated with good outcomes. Good selection criteria for treatment in clinical practice 
would ideally select future responders as treatment candidates, and select against patients who are not 
likely to respond to treatment.  
Whether selection is based on elevated BASDAI or high ASDAS, a number of patients who would be 
selected have combined characteristics that are associated with low probability of response. This 
indicates that the recommendation to use clinical characteristics (in addition to a disease activity 
criterion) to guide choice of therapy remains important. Predictors of response such as the ones 
described can be helpful tools to complement the elevated ASDAS criterion for patient selection. In 
clinical practice, a rheumatologist may wonder whether there is a good reason to use anti-TNF 
treatment in an older HLA-B27-negative patient who reports poor function and high disease activity, 
despite absence of objective signs of inflammation (i.e., CRP < 0.6 mg/dL); this profile corresponds with 
that of 24/1156 REGISPONSER patients. From a societal perspective, payers may want to evaluate 
whether it is worth excluding patients with such characteristics to allow treating a group of HLA-B27-
positive patients younger than 40 years of age with high disease activity and CRP greater than 2 mg/dL 
who still have preserved function (this profile corresponds with 23/1156 REGISPONSER patients). Thus, 
using BASDAI as the only criterion to decide anti-TNF treatment could exclude the latter group to be 
treated with anti-TNF therapy in many European countries, and this is why expert opinion and clinical 
judgment based on patient’s characteristics and biochemical markers like CRP levels or HLA-B27status is 
critical in the decision.  
 126  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
Compared to selection with BASDAI, more patients are selected for anti-TNF treatment when high 
ASDAS is used and fewer patients are selected when very high ASDAS is the selection criterion. Because 
BASDAI and BASFI are highly correlated, selection with high BASDAI automatically leads to a selection of 
patients who fall in the higher categories for BASFI. Replacing BASDAI with ASDAS leads to an increase of 
the proportion of patients in the lower BASFI category, which is associated with better response. The 
advantageous CRP profile (higher CRP is associated with better response) that is seen for a population 
with very high ASDAS is largely offset by the disadvantageous BASFI profile (higher BASFI is associated 
with worse response). The data show that patients with very high ASDAS also have a higher likelihood of 
enthesitis, which is associated with slightly worse outcomes [9]. In addition to leading to a more 
favorable CRP and BASFI profile, selection with high and very high ASDAS also results in a younger 
population, even though age is not an explicit component of the ASDAS. Because younger patients tend 
to respond better, this finding is relevant for patient selection in practice. The overall decrease in 
number of patients who can be treated and the profile of patients no longer selected if BASDAI is 
replaced by very high ASDAS indicates that the latter selection criterion may not be an improvement 
over the former. However, replacing BASDAI with high ASDAS may need to be considered for future 
recommendations. In fact, in a recent study, a small group of patients with high ASDAS and normal 
BASDAI (n = 48) have shown to respond to anti-TNF therapy [16], and these patients would have been 
excluded from anti-TNF therapy if high BASDAI would have been used as strict selection criterion.  
The main limitation of the study is its cross-sectional design with no follow-up, which precludes 
validating the findings of the study by assessing the response to anti-TNF therapy in groups of patients 
with the abovementioned characteristics. We did not get specific information on individual components 
of BASDAI and ASAS indexes; thus, we cannot display BASDAI and ASAS component-per-component 
values to check which items contribute to the discordance in the high ASAS/low BASDAI group. Another 
limitation is that some 15% of patients were already treated with anti-TNF agents, and this may have 
had an influence on BASDAI and ASDAS as well as some of the relevant disease characteristics (e.g. CRP 
and BASFI). It is difficult to say how this has an influence on the results. Although higher ASDAS has been 
associated with better outcomes [8] it is important to emphasize that the database did not allow 
confirmation of whether the response was indeed higher inpatients selected with ASDAS versus BASDAI. 
Because the efficacy of anti-TNF treatment in patients with high ASDAS and BASDAI less than 4 has 
never been studied, except in a small group of patients [16] it is not certain whether the favorable 
disease characteristic profile described here is also related to better outcomes in that patient group. 
Further investigation on the response to anti-TNF in a larger population with high ASDAS/low BASDAI is 
needed.  
In conclusion, in this cross-sectional study, selection of AS patients with the ASDAS instrument results in 
patient sub-populations that have different characteristics than those selected with the BASDAI 
instrument. Since some of these characteristics have been associated with good outcome to anti-TNF 
therapy, the hypothesis generated through this research is that replacing the disease activity measure in 
anti-TNF treatment recommendations from BASDAI to ASDAS may lead to better outcomes of therapy. 
This hypothesis should be tested in prospective studies. 
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Chapter 5: Anti-TNF alpha Treatment 
Discontinuation following Remission 
Includes 3 publications from the ‘Infliximab as First Line Therapy in Patients with Early Active Axial 
Spondyloarthritis Trial’ (INFAST).  
 
Efficacy and safety of infliximab plus naproxen versus 
naproxen alone in patients with early, active axial 
spondyloarthritis: results from the double-blind, placebo-
controlled INFAST study, Part 1. 
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, 
Chitkara D, Vastesaeger N; All INFAST Investigators. 
Ann Rheum Dis. 2014 Jan; 73(1):101-7. Epub 2013 May 21. 
Maintenance of biologic-free remission with naproxen or no 
treatment in patients with early, active axial 
spondyloarthritis: results from a 6-month, randomised, open-
label follow-up study, INFAST Part 2. 
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, 
Chitkara D, Vastesaeger N; All INFAST Investigators. 
Ann Rheum Dis. 2014 Jan; 73(1):108-13. Epub 2013 Jun 5. 
Partial Remission in Ankylosing Spondylitis and Non-
Radiographic Axial Spondyloarthritis and Associations 
between Partial Remission and Baseline Disease 
Characteristics during Treatment with Infliximab plus 
Naproxen or Naproxen alone. 
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, 
Chitkara D, Vastesaeger N; All INFAST Investigators. 
Submitted manuscript. 
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5.1. Efficacy and safety of infliximab plus naproxen versus 
naproxen alone in patients with early, active axial 
spondyloarthritis: results from the double-blind, placebo-
controlled INFAST study, Part 1 
5.1.1. Abstract 
Objectives  
To assess whether combination therapy with infliximab (IFX) plus nonsteroidal anti-inflammatory drugs 
(NSAIDs) is superior to NSAID monotherapy for reaching Assessment of SpondyloArthritis international 
Society (ASAS) partial remission in patients with early, active axial spondyloarthritis (SpA) who were 
naïve to NSAIDs or received a submaximal dose of NSAIDs.  
Methods  
Patients were randomised (2 : 1 ratio) to receive naproxen (NPX) 1000 mg daily plus either IFX 5 mg/kg 
or placebo (PBO) at weeks 0, 2, 6, 12, 18 and 24. The primary efficacy measure was the percentage of 
patients who met ASAS partial remission criteria at week 28. Several other measures of disease activity, 
clinical symptoms and patient-rated outcomes were evaluated. Treatment group differences were 
analysed with Fisher exact tests or analysis of covariance.  
Results  
A greater percentage of patients achieved ASAS partial remission in the IFX+NPX group (61.9%; 65/105) 
than in the PBO+NPX group (35.3%; 18/51) at week 28 (p=0.002) and at all other visits (p<0.05, all 
comparisons). Results of most other disease activity and patient-reported endpoints (including 
Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index, Bath 
Ankylosing Spondylitis Functional Index, multiple quality of life measures and pain measures) showed 
greater improvement in the IFX+NPX group than the PBO+NPX group, with several measures 
demonstrating early and consistent improvement over 28 weeks of treatment.  
Conclusions  
Patients with early, active axial SpA who received IFX+NPX combination treatment were twice as likely 
to achieve clinical remission as patients who received NPX alone. NPX alone led to clinical remission in a 
third of patients.  
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5.1.2. Introduction 
The term axial spondyloarthritis (SpA) is the umbrella term for patients with ankylosing spondylitis (AS) 
according to the modified New York criteria [1] and for patients who do not yet show signs of structural 
damage in the sacroiliac (SI) joint that are visible as radiographic sacroiliitis and, therefore, categorised 
as non-radiographic axial SpA. Recently, new classification criteria for axial SpA have been developed, 
which cover both subgroups [2]. There are currently only two treatments with proven efficacy available 
for these patients with axial SpA: nonsteroidal anti-inflammatory drugs (NSAIDs) and tumour necrosis 
factor (TNF)-α–targeted therapy [3].  Until now, TNF antagonists have only been investigated and are 
only recommended for patients with axial SpA who fail previous NSAID therapy [3 , 4]. Although data are 
limited, studies have demonstrated up to 50% remission rate with TNF-α antagonist therapy in NSAID-
refractory patients with axial SpA who are treated in the first 3–5 years of their disease [5-7]. This raises 
the question of whether even earlier treatment of axial SpA in patients who are not refractory to NSAID 
therapy would result in even higher response rates and potentially even in biologic drug-free remission, 
as has been recently investigated in great detail in patients with rheumatoid arthritis [8, 9]. 
The Infliximab (IFX) as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial 
(INFAST) evaluated whether combination therapy with the TNF antagonist IFX and naproxen (NPX) was 
superior to treatment with NPX alone in patients who had active moderate-to-severe axial SpA and who 
were naïve to NSAIDs or had only been treated with a submaximal dose of NSAIDs. All patients had to 
fulfil the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA, 
thus including patients both with AS and with non-radiographic axial SpA; had to have a disease duration 
≤3 years; and had to have evidence of inflammatory SI lesions on MRI at baseline. Thus, this study is the 
first investigation of the potential benefits of early TNF-antagonist treatment in active axial SpA patients 
who are not yet refractory to NSAID therapy.  
5.1.3. Methods 
5.1.3.1. Design and patients 
INFAST was a Phase 3b, randomised, parallel-group, multisite, double-blind, placebo (PBO)-controlled 
study of IFX in adults with moderate-to-severe, active axial SpA who were not refractory to NSAIDs 
(Protocol P05336, NCT00844805). Patients were recruited consecutively by rheumatologists in hospitals 
or private practice settings. Patients were enrolled in 47 centres in nine countries (Austria, Belgium, 
Denmark, France, Germany, Hungary, Russia, South Korea and Ukraine). The study protocol was 
reviewed by appropriate institutional review boards for each study site. All patients gave written 
informed consent to participate. Data were collected between 22 October 2009, and 20 September 
2011.  
Patients were 18–48 years of age with a diagnosis of active axial SpA according to the local investigator 
and disease duration of ≤3 years. All patients had to fulfil the imaging portion of the ASAS criteria for 
axial SpA,2 with active inflammation of the SI joints (defined as bone oedema within or adjacent to the 
SI joints) as shown by short tau inversion recovery MRI. For inclusion into the study, the MRI scans were 
read locally. All patients had active disease at screening and baseline, defined as a total back pain 
evaluation of ≥40 mm (visual analogue scale (VAS) of 0–100 mm) and a Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) score of ≥4 cm (0–10 cm VAS). Patients were either NSAID-naïve at 
baseline or had been treated with not more than two-thirds of the maximal recommended dose10 
during the 2 weeks prior to screening and had undergone a washout period of ≥3 days before baseline, 
during which they had an increase in total back pain of ≥30%.  
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5.1.3.2. Study treatment 
During Part 1 of INFAST patients were randomised in double-blind fashion at a 2 : 1 ratio to receive 
either intravenous (IV) IFX 5 mg/kg or IV PBO at weeks 0, 2, 6, 12, 18, and 24 (Figure 29). Both groups 
also received oral NPX 1000 mg daily. A computer-generated randomisation list was created by the 
sponsor and held by the central randomisation centre, which was contacted by the site to assign 
treatment to each patient as he or she enrolled. Patients who met ASAS partial remission criteria at 
week 28 were eligible to participate in Part 2 of INFAST, which compared maintenance of partial 
remission with two follow-up regimens (NPX alone or no treatment); this portion of the study is 
reported separately.  
 
FIG. 29: INFAST study design. 
5.1.3.3. Outcome measures 
The primary efficacy measure was the percentage of patients in each treatment group who met ASAS 
partial remission criteria at week 28. A number of secondary measures of disease activity, clinical signs 
and symptoms, inflammatory markers, and patient-reported outcomes were also assessed.  
Adherence to NPX treatment was measured as the percentage of days in the study that the daily dose 
was taken as reported on patient diary cards. Adherence to IFX and placebo was measured as the 
number of doses infused of the number of scheduled doses.  
Adverse events (AEs) and several other safety measures were also collected. 
5.1.3.4. Statistical analyses 
The targeted sample size was 150 patients (100 receiving IFX+NPX and 50 receiving PBO+NPX) for 90% 
power to detect a 30% difference in ASAS partial remission between treatment groups, assuming a 15% 
withdrawal rate.  
The intention-to-treat (ITT) population was used for efficacy analyses and included all patients who were 
randomised, received at least one dose of study medication and had at least one efficacy evaluation 
after baseline. Analyses included observed data. For the primary efficacy analysis, patients who 
withdrew before week 28 were categorised as not achieving partial remission.  
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Treatment group differences in categorical efficacy measures were analysed with Fisher exact tests at a 
two-sided significance level of 0.05. Treatment group differences in continuous measures were analysed 
with analysis of covariance, with baseline values as covariates.  
The safety population included all patients who received at least one dose of study medication. Adverse 
events were analysed descriptively.  
5.1.4. Results 
5.1.4.1. Patient disposition 
Of the 158 randomised patients, 106 were assigned to IFX+NPX and 52 to PBO+NPX (Figure 30). The ITT 
population included 105 patients in the IFX+NPX group (one patient did not receive study medication) 
and 51 in the PBO+NPX group (one patient had no post-baseline efficacy assessment). The majority of 
patients completed the study through week 28 (90.6% in the IFX+NPX group and 86.5% in the PBO+NPX 
group).  
 
FIG. 30: Patient disposition. IFX, infliximab; ITT, intention-to-treat; NPX, naproxen; PBO, placebo. 
5.1.4.2. Baseline characteristics 
Baseline characteristics were similar in the two treatment groups (Table 39). Most patients had high or 
very high disease activity, as measured by Ankylosing Spondylitis Disease Activity Score (ASDAS), and 
mean time since axial SpA diagnosis was less than 1 year. The mean number of baseline SpA 
manifestations was comparable between treatment groups (3.8 vs 4.0). The incidence of arthritis 
appeared to be greater for the IFX+NPX arm than the PBO+NPX arm (45.3% vs 26.9%, respectively), but 
in both groups few joints were swollen (means, 1.49 vs 0.78, respectively) or tender (means 4.06 vs 3.80, 
respectively). Approximately 60% of patients had x-ray findings that met the modified New York 
radiographic criteria for AS (bilateral ≥grade 2 or unilateral ≥grade 3) at baseline, according to the x-ray 
reading by the local investigator.  
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5.1.4.3. Exposure and adherence 
Most patients received all six infusions of IFX or PBO (90.5% and 88.5% of patients, respectively). The 
mean doses per infusion of IFX and PBO were 367 and 372 mg, respectively. Treatment adherence with 
NPX, based on total number of doses taken regardless of dosage amount, was a mean of 99.0% for 
IFX+NPX and 99.5% for PBO+NPX; the mean daily doses were 960.5 and 978.1 mg, respectively.  
Baseline characteristics IFX+NPX PBO+NPX 
Demographic characteristics N=105 N=51 
 Gender (male), n (%) 72 (68.6) 40 (78.4) 
 Age (years), mean (SD) 31.7 (8.51) 30.7 (7.34) 
Race, n (%) 
  White 91 (86.7) 45 (88.2) 
  Asian 14 (13.3) 5 (9.8) 
  Multiracial 0 1 (2.0) 
 Body mass index (kg/m2), mean (SD)  24.1 (4.35) 24.1 (3.40) 
Clinical characteristics N=106 N=52 
 Years since diagnosis of axial SpA, mean (SD) 0.84 (0.814) 0.69 (0.647) 
 Years since onset of axial SpA symptoms, mean (SD) 1.76 (0.896) 1.91 (1.439) 
 Number of SpA manifestations, mean (SD) 3.8 (1.4) 4.0 (1.23) 
  Inflammatory back pain, n (%) 95 (89.6) 48 (92.3) 
  Arthritis, n (%) 48 (45.3) 14 (26.9) 
  Dactylitis, n (%) 3 (2.8) 1 (1.9) 
  Psoriasis, n (%) 6 (5.7) 2 (3.8) 
  Family history of SpA, n (%) 16 (15.1) 11 (21.2) 
  Uveitis, n (%) 6 (5.7) 6 (11.5) 
  History of CD/UC, n (%) 0 0 
  Enthesitis (heel), n (%) 15 (14.2) 10 (19.2) 
 ASDAS, n (%) n=105 n=51 
  Inactive disease: <1.3 0 0 
  Moderate disease activity: 1.3 to <2.1 3 (2.9) 0 
  High disease activity: 2.1 to ≤3.5 34 (32.4) 15 (29.4) 
  Very high disease activity: >3.5 63 (60.0) 34 (66.7) 
 HLA-B27–positive status, n (%) 87 (82.1) 47 (90.4) 
 X-ray sacroiliitis, according to the modified New York criteria* n (%) 61 (57.5) 33 (63.5) 
 Previous good response to NSAIDs, n (%) 73 (68.9) 36 (69.2) 
 Patients who had prior NSAID treatment, n (%) 100 (94.3) 44 (84.6) 
TABLE 39: Baseline demographic and disease characteristics. *Bilateral ≥grade 2 or unilateral ≥grade 3, 
as assessed by the local investigator. 
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5.1.4.4. Efficacy results 
The primary endpoint was met. A greater percentage of patients achieved ASAS partial remission in the 
IFX+NPX group (61.9% [65/105], 95% CI 52.4% to 70.6%) than in the PBO+NPX group (35.3% [18/51], 
95% CI 23.6% to 49.0%; p=0.002) at week 28 (Figure 31A). The greater partial remission in the IFX+NPX 
group than the PBO+NPX group was statistically significant as early as week 2 and at each visit until 
week 28. The number of patients with partial remission increased steadily in both treatment groups 
over the 28 weeks. A similar pattern of treatment group differences occurred with the percentage of 
patients achieving 40% response in ASAS criteria (ASAS-40) (Figure 31B). The percentage of patients who 
achieved ASAS-20 was numerically greater in the IFX+NPX group than the PBO+NPX group, but the 
treatment group differences were smaller and not statistically significant after week 2 (Figure 31C).  
 
FIG.31: Percentage of patients who achieved ASAS partial remission (A), ASAS-40 response (B), ASAS-20 
response (C), ASDAS major improvement (D), ASDAS clinically important improvement (E) and ASDAS 
inactive disease (F). p Values are from analysis of treatment group differences in change from baseline at 
each visit. aASAS partial remission at week 28 was the primary endpoint of the study. Subjects who 
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withdrew prior to week 28 were not considered to be in partial remission. Patients who were missing 
more than two ASAS components at week 28 were considered not in partial remission. If a patient had 
data for at least two ASAS domains at week 28, missing data for the remaining ASAS domains were 
imputed using a last-observation-carried-forward approach 
ASDAS major improvement (≥2.0-point improvement from baseline) and ASDAS clinically important 
improvement (≥1.1-point improvement from baseline) also showed a pattern of greater improvement in 
the IFX+NPX group than the PBO+NPX group at each visit (Figure 32D and E). The percentage of patients 
with ASDAS-inactive disease (ASDAS-C <1.3, using C-reactive protein (CRP) in the calculation) in the 
IFX+NPX group (51.4%) was much greater than in the PBO+IFX group (19.6%) at week 28 (p<0.001) 
(Figure 32F).  
Efficacy 
measures 
IFX+NPX =105 PBO+NPX N=51 p Value for 
treatment 
group 
difference 
Baseline 
(BL), 
mean 
Week 
28, 
mean 
Change 
from BL, 
mean (SD) 
% 
Change 
Baseline, 
mean 
Week 
28, 
mean 
Change 
from BL, 
mean (SD) 
% 
Change 
PhGADA (100 
mm VAS) 66.6 15.6 
–51.3 
(23.00) –76.5 63.3 30.6 
–33.0 
(22.44) –51.7 <0.001 
PtGADA (100 
mm VAS) 
73.5 18.8 –54.5 
(25.71) 
–74.4 72.3 34.4 –38.1 
(29.02) 
–52.4 <0.001 
Patient's total 
back pain (100 
mm VAS) 
76.7 18.6 
–58.0 
(25.61) –75.7 76.6 30.8 
–45.2 
(29.27) –59.8 0.005 
Patient's 
nocturnal pain 
(100 mm VAS) 
70.6 16.7 
–54.0 
(26.03) –76.4 69.3 31.4 
–37.4 
(30.66) –54.7 <0.001 
EQ-5D index 
score* 
0.38 0.75 0.37 
(0.303) 
95.4 0.33 0.60 0.27 
(0.313) 
81.6 0.003 
EQ-5D global 
health status* 46.8 76.8 
30.0 
(29.23) 64.2 40.0 58.9 
18.5 
(23.11) 47.0 <0.001 
SF-36 physical 
component* 34.0 46.6 
12.6 
(10.31) 42.5 32.4 40.3 8.6 (8.93) 29.4 0.003 
SF-36 mental 
component* 
40.0 49.0 9.0 (10.96) 33.5 37.7 45.7 7.6 (11.10) 27.1 0.16 
BASMI 3.1 2.0 –1.1 (1.13) –34.6 3.1 2.5 –0.6(0.72) –18.7 <0.001 
ESR (mm/h) 23.0 7.1 –16.0 (16.11) –54.7 28.3 19.0 
–9.4 
(13.18) –13.0 <0.001 
CRP (mg/dL) 2.02 0.91 –1.24 
(6.209) 
–55.1 1.65 1.15 –0.55 
(1.315) 
–30.5 0.59 
66-joint SJC, 
mean (SD) 
1.49 0.15 –1.44 
(4.131) 
–89.6 0.78 0.40 –0.42 
(0.917) 
–49.0 0.06 
68-joint TJC, 
mean (SD) 4.06 0.94 
–3.29 
(6.385) –76.9 3.80 1.07 
–2.93 
(5.101) –72.0 0.73 
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Patients who met criterion 
at week 28, % 
Patients who met criterion 
at week 28, %  
BASDAI≥50% 
improvement 77.3 51.1 0.003 
BASDAI<3 76.3 53.3 0.01 
TABLE 32: Secondary efficacy outcomes from baseline to week 28. *An increase in scores indicates 
improvement on these measures. For all other measures, a decrease in score indicates improvement.  
As shown in Table 40, the IFX+NPX group had significantly greater improvement than the PBO+NPX 
group in most other measures of disease activity, clinical signs and symptoms and patient-reported 
outcomes at almost all visits. For all of the patient-reported outcomes, including quality of life and 
assessments of pain, both treatment groups improved substantially after baseline, with the IFX+NPX 
group showing significantly greater improvement at week 28 on all but one of the eight measures. 
5.1.4.5. Safety 
Overall, IFX was well tolerated, and the pattern of AEs in the IFX+NPX group was similar to that reported 
previously for TNF antagonists in comparable populations (Table 41). The AEs that occurred in ≥5% of 
patients in either the IFX+NPX (N=105) or PBO+NPX (N=52) group were nasopharyngitis (10.5% and 
7.7%, respectively), upper abdominal pain (7.6% and 1.9%, respectively), headache (6.7% and 3.8%, 
respectively) and dyspepsia (2.9% and 5.8%, respectively).  
No deaths occurred. Serious AEs were reported in five patients (4.8%) in the IFX+NPX group and three 
patients (5.8%) in the PBO+NPX group. In the IFX+NPX group, one patient experienced chest discomfort, 
dizziness and dyspnea; one patient had increased hepatic enzymes (alkaline phosphatase 2 times the 
upper limit of normal (ULN) and gamma glutamyl transpeptidase elevated greater than 10 times the 
ULN; at a follow-up 7 months after study discontinuation, liver enzymes were within normal range with 
a slight increase in GGT); one patient had breast cancer (diagnosed 6 months after start of treatment); 
and one patient had pneumonia and tuberculosis (patient was from the Russian Federation and had a 
negative tuberculin test and normal chest x-ray at screening; hospitalised for tuberculosis 5 months 
after the start of treatment). In addition, one case of fetal distress syndrome and uterine hypotonus 
occurred in a patient in the IFX+NPX group who reported pregnancy and was discontinued from the 
study; the baby was reported as born healthy after caesarean section. In the PBO+NPX group, one 
patient had anaemia and ovarian cyst rupture, one patient had worsening of AS and one patient had 
atopic dermatitis.  
AEs leading to withdrawal from the study occurred in four patients (3.8%) in the IFX+NPX group and one 
patient (1.9%) in the PBO+NPX group (see details in Table 41).  
Treatment-emergent infections and infestations occurred in 27/105 patients (25.7%) in the IFX+NPX 
group and 9/52 patients (17.3%) in the PBO+NPX group (see details in Table 41). In both treatment 
groups, 1.9% of patients had an increase in hepatic enzymes, including the one serious event already 
mentioned above in the IFX+NPX group.  
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Treatment-emergent AE category, n (%) 
IFX+NPX 
N=105 
PBO+NPX 
N=52 
Any AE 61 (58.1) 26 (50.0) 
Any serious AE 5 (4.8) 3 (5.8) 
AE related to study medication 36 (34.3) 12 (23.1) 
AE leading to early withdrawal 4 (3.8) 1 (1.9) 
 Dyspepsia 1 (1.0) 0 
 Tuberculosis 1 (1.0) 0 
 Hepatic enzyme increased 1 (1.0) 0 
 Worsening of ankylosing spondylitis 0 1 (1.9) 
 Breast cancer 1 (1.0) 0 
Infections and infestations occurring in >1 patient in either group 
 Nasopharyngitis 11 (10.5) 4 (7.7) 
 Localised infection 2 (1.9) 2 (3.8) 
 Cystitis 1 (1.0) 2 (3.8) 
 Bronchitis 2 (1.9) 1 (1.9) 
 Gastroenteritis 3 (2.9) 0 
 Oral herpes 2 (1.9) 0 
 Tonsillitis 2 (1.9) 0 
TABLE 41: Patients with treatment-emergent adverse events (AEs) 
5.1.5. Discussion 
This is the first study comparing the efficacy of a combination of a TNF antagonist and an NSAID versus 
an NSAID alone in patients with active axial SpA who are not refractory to NSAID therapy. Nearly two-
thirds of patients who received IFX+NPX combination treatment achieved ASAS partial remission at 
week 28, compared with about one-third of the group who received NPX alone. This pattern of greater 
improvement in the IFX+NPX group was apparent as early as week 2; and continued, steady 
improvement occurred up to week 28.  
The good results in the group receiving NSAIDs alone (35% partial remission) were rather surprising. NPX 
and other NSAIDs have been shown to be similarly effective in AS patients [11-14] and most of these 
NSAID trials used a flare design similar to the design used in INFAST (ie, patients using NSAIDs before 
inclusion must stop treatment and demonstrate worsening symptoms to be included in the study). 
However, none of these trials found ASAS partial remission rates greater than about 15% [11-13]. 
Although the controlled phase of these studies was usually shorter (12 weeks rather than 28 weeks), 
response rates did not increase during trials with longer, open-label periods [12] One possible reason for 
the good response in the PBO+NPX group in the INFAST study may be the short symptom duration 
required for study entry (≤3 years, with actual mean duration <2 years) and, therefore, a mixture of 
patients with AS and patients with non-radiographic axial SpA; other studies have used populations with 
longstanding AS. In addition, all patients in INFAST had lesions seen on MRI at study entry, which was 
not a selection criterion for the NSAID studies. Although placebo response in the PBO+NPX group cannot 
be excluded, another study of patients with active axial SpA (refractory to previous NSAID therapy) with 
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a symptom duration of <3 years found a placebo response rate of only 12.5%.6 Our data suggest that 
axial SpA patients respond better to a full NSAID dose if they are treated early.  
Within the first 2 weeks of NSAID therapy for patients in the PBO+NPX group, a strong improvement in 
disease activity was seen; mean BASDAI decreased from 6.3 to 4.4, with a continued, slower decrease up 
to week 28 (mean, 3.2). These data suggest that response to NSAIDs can be judged in the first 2–4 weeks 
of treatment, as noted in the ASAS treatment guidelines,3 and that further improvement may occur with 
continued treatment. Similar to the results for BASDAI, a reduction of about 50% from baseline was seen 
in the other continuous outcomes (Figure 32; Table 40), including CRP concentration, which has 
previously been shown to improve during NSAID treatment in patients with AS [13, 14] 
 
FIG.32: Efficacy measures from baseline to week 28: BASDAI (A), BASFI (B), and ASDAS (C). p Values are 
from analysis of treatment group differences in change from baseline at each visit.  
Despite the better-than-expected response in the PBO+NPX group, a greater improvement in disease 
activity was observed in those patients who received IFX+NPX. The superiority of treatment with 
IFX+NPX was most obvious in the binary outcome parameters, which measured low disease activity 
status or major response rates (eg, ASAS partial remission and ASDAS inactive disease rate, followed by 
ASAS-40 response). Interestingly, there was no clear difference between the treatment groups for minor 
response levels such as ASAS-20. For nearly all the continuous efficacy measures, approximately 75% 
reductions from baseline were seen in the IFX+NPX group, and approximately 50% reductions were seen 
in the NPX-alone group. Whether a combination of IFX+NSAID would be superior to IFX alone cannot be 
determined from the INFAST study because no IFX-alone group was included. However, information 
about a potentially additive effect of NSAIDs and TNF antagonists for improvement of signs and 
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symptoms would be of interest, especially given the reported inhibitory effect of NSAIDs on radiographic 
progression in AS (15, 16).  
The response rates in the IFX+NPX group of INFAST are comparable to those from a smaller, placebo-
controlled IFX trial in active axial SpA patients with symptom duration of <3 years [6]: ASAS partial 
remission rates were 61.9% vs 55.6%, and ASAS-40 response rates were 67.6% vs 61.1% in the two trials, 
respectively. No detailed information was given in the smaller trial on the status of NSAID treatment, 
but these patients are likely to have been NSAID failures. The comparable response rates in the two 
trials and the good response rate to NSAIDs in the INFAST study support an early step-up treatment 
approach, with early diagnosis and treatment with NSAIDs, escalating to combination treatment after an 
insufficient response [3], although such an approach was not specifically tested in our trial. Currently, 
these two IFX studies are the only ones that limited symptom duration of axial SpA to 3 years and 
included a blinded control group. In a recent trial of etanercept in axial SpA, symptom duration at 
inclusion was limited to 5 years, and the two treatment groups, etanercept versus sulfasalazine, were 
not blinded for the clinical outcome assessments [7]. At week 48, ASAS partial remission was reached in 
50% of the etanercept group versus 19% of the sulfasalazine group. In two trials of adalimumab in 
patients with non-radiographic axial SpA with no limit on symptom duration, a better response rate was 
reported in a subgroup of patients who had shorter symptom duration [5, 17] 
Fulfillment of the ASAS criteria for axial SpA and positive MRI findings of the SI joint were, according to 
the ASAS definition, mandatory for inclusion into the INFAST trial. Local investigators judged whether 
patients had radiographic sacroiliitis according to the modified New York criteria, but these judgments 
were irrelevant for inclusion in the study. The percentage of patients with radiographic sacroiliitis in 
INFAST (59%), based on the local reading of the x-rays, was relatively high compared to the other IFX 
trial described above that had a similar symptom duration (12% [6]), but the percentage was not so 
different from other analyses of patients with axial SpA in the first 3–5 years of their disease (50% [7, 
18]). Some of the variability across studies may be due to the challenge of reading x-rays of patients with 
early sacroiliitis; rather low sensitivity and specificity have been reported in some studies [19, 20] 
Overall, the current study results, combined with evidence from other studies in which patients were 
already optimised on NSAID treatment, suggest that response to anti-TNF therapy may be improved 
with selection of patients who are young, have short disease duration and have objective evidence of 
inflammation (as demonstrated by MRI and elevated CRP). Evaluation of the best strategy for 
maintenance and/or continued improvement in patients who had achieved partial remission after 28 
weeks of therapy with either IFX+NPX or NPX alone was the subject of a follow-up phase of the INFAST 
study that continued to week 52. Predictors of maintenance of remission were evaluated in that study, 
and the data will be reported in a separate manuscript.  
The AE profiles for each treatment arm were as expected in patients receiving TNF-α–targeted therapy 
and NSAID therapy. Both treatments appeared to be well tolerated, and no new safety signals were 
identified. Good tolerability appears to have been reflected in the drug adherence rates, which were 
close to 100% in both treatment groups. Safety and good drug tolerability are especially important in 
this young patient population in the early phase of their disease.  
In conclusion, results of the INFAST study demonstrated better outcomes on a variety of efficacy 
measures in patients with early axial SpA who were treated with IFX+NPX than in those treated with NPX 
alone. Overall, available evidence supports early diagnosis and treatment of SpA with a full dose of 
NSAIDs first, escalating to combination NSAID+TNF antagonist treatment in patients who have 
insufficient response.  
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5.2. Maintenance of biologic-free remission with naproxen or 
no treatment in patients with early, active axial 
spondyloarthritis: results from a 6-month, randomised, 
open-label follow-up study, INFAST Part 2  
5.2.1. Abstract 
Objective  
To investigate whether biologic-free remission can be achieved in patients with early, active axial 
spondyloarthritis (SpA) who were in partial remission after 28 weeks of infliximab (IFX)+naproxen (NPX) 
or placebo (PBO)+NPX treatment and whether treatment with NPX was superior to no treatment to 
maintain disease control.  
Method  
Infliximab as First-Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial (INFAST) Part 1 
was a double-blind, randomised, controlled trial in biologic-naïve patients with early, active, moderate-
to-severe axial SpA treated with either IFX 5 mg/kg+NPX 1000 mg/d or PBO+NPX 1000 mg/d for 28 
weeks. Patients achieving Assessment of SpondyloArthritis international Society (ASAS) partial remission 
at week 28 continued to Part 2 and were randomised (1:1) to NPX or no treatment until week 52. 
Treatment group differences in ASAS partial remission and other efficacy variables were assessed 
through week 52 with Fisher exact tests.  
Results  
At week 52, similar percentages of patients in the NPX group (47.5%, 19/40) and the no-treatment 
group (40.0%, 16/40) maintained partial remission, p=0.65. Median duration of partial remission was 23 
weeks in the NPX group and 12.6 weeks in the no-treatment group (p=0.38). Mean Bath Ankylosing 
Spondylitis Disease Activity Index scores were low at week 28, the start of follow-up treatment (NPX, 
0.7; no treatment, 0.6), and remained low at week 52 (NPX, 1.2; no treatment, 1.7).  
Conclusions  
In axial SpA patients who reached partial remission after treatment with either IFX+NPX or NPX alone, 
disease activity remained low, and about half of patients remained in remission during 6 months in 
which NPX was continued or all treatments were stopped.  
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5.2.2. Introduction 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line treatments for patients with axial 
spondyloarthritis (SpA) or ankylosing spondylitis (AS). For patients who fail NSAID treatment or cannot 
tolerate it, tumour necrosis factor (TNF) α blockers are recommended [1] because they reduce 
inflammation, control disease activity and improve patient functioning and quality of life [2–5] In the 
Infliximab as First-Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial (INFAST) study 
[6] patients with axial SpA who had not failed NSAIDs or were NSAID-naïve showed substantial benefit 
from combined treatment with NSAIDs and the TNF-antagonist infliximab (IFX). At month 6, partial 
remission was achieved in 62% and 35% of patients treated with IFX+naproxen (NPX) or placebo 
(PBO)+NPX, respectively.  
For patients with axial SpA who have achieved remission, the best strategy for maintenance of remission 
is not known. In patients with rheumatoid arthritis (RA), several studies have shown that biologic-free 
remission, either with or without continuous treatment with methotrexate, can be achieved if patients 
are treated early enough in the course of the disease [7–9]. In patients with AS, studies have found that 
response to TNF antagonists may be sustained over several years, but that response is lost soon after 
cessation of treatment [10, 11]. Few studies have evaluated the long-term effects of TNF-antagonist 
treatment in patients with early axial SpA, and it is unclear how long biologic-free remission is likely to 
be maintained or whether NSAID treatment might aid in maintenance of remission after anti-TNF 
treatment is discontinued.  
The primary goals of INFAST Part 2, the 6-month follow-up study reported here, were to explore 
whether biologic-free remission can be achieved in patients with early axial SpA and to determine 
whether continued treatment with NPX was superior to discontinuing all treatments in order to 
maintain disease control for 6 months.  
5.2.3. Methods 
5.2.3.1. Study design and patients 
Part 1 of INFAST (Protocol P05336, NCT00844805) was a multicentre, double-blind, randomised, 
controlled trial of IFX+NPX vs PBO+NPX treatment in patients aged 18–48 years with early, moderate-to-
severe axial SpA (see online supplementary figure S1). The design of Part 1 of the INFAST study has been 
reported elsewhere.6 Briefly, patients enrolled in INFAST Part 1 had been diagnosed with axial SpA of 
less than 3 years’ duration, were naïve to biologics and were either NSAID-naïve at baseline or had been 
treated with not more than two-thirds of the maximal recommended dose during the 2 weeks prior to 
the screening visit. Patients were randomised (2:1) to receive 28 weeks of treatment with either 
intravenous (IV) IFX 5 mg/kg (weeks 0, 2, 6, 12, 18 and 24)+NPX 1000 mg/d or IV PBO+NPX 1000 mg/d.  
In Part 2, the follow-up period of INFAST that is the focus of this report, patients who had achieved 
Assessment of SpondyloArthritis international Society (ASAS) partial remission at week 28 (defined as 
reaching ≤20 mm on a scale of 100 mm in all four ASAS domains) were eligible to continue to the follow-
up phase. IFX treatment was stopped, and patients were randomised to receive either NPX or no 
treatment (1:1 ratio) until week 52. For the NPX group, open-label NPX was administered at the dose 
each patient had received prior to week 28 (1000 mg/d or 500 mg/d if the higher dose was not 
tolerated). A computer-generated randomisation list was created by the sponsor and held by the central 
randomisation centre, which was contacted by the site to assign treatment to each patient as they 
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enrolled. Randomisation in Part 2 was stratified by randomised treatment assignment in INFAST Part 1. 
Data were collected from October 2009 to September 2011.  
Patients with flares, defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥3 cm on a 
10-cm visual analogue scale during two consecutive visits within 1–3 weeks of each other between 
weeks 28 and 52, had a final MRI and were discontinued from the study.  
5.2.3.2. Outcome measures 
The primary outcome of INFAST Part 2 was the percentage of patients who maintained ASAS partial 
remission until week 52. Secondary outcomes included the percentage of patients with disease flare (as 
defined above) and several other measures of disease activity, inflammation, clinical symptoms, 
functioning and quality of life (Ankylosing Spondylitis Disease Activity Score (ASDAS), BASDAI, 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Functional 
Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and EuroQoL 5D Health 
Questionnaire (EQ-5D)) were assessed at several points throughout the study.  
Adverse events and other safety measures were also collected. 
5.2.3.3. Statistical analysis 
No sample size calculation was done for this exploratory follow-up study because the sample was 
determined by the number of patients in remission at the end of Part 1 of INFAST. Anticipating that 
approximately 60 patients would be in remission at the end of Part 1, with 30 patients per group, the 
study had an estimated 87% power to detect a 42% absolute difference between the treatment groups 
in the percentage of patients with ASAS partial remission at week 52 using a Fisher exact test with α set 
at 0.05. This was considered acceptable because a small effect of NPX would probably not justify 
continued use of NPX to maintain remission after stopping a biologic treatment.  
The intent-to-treat (ITT) population for INFAST Part 2 included all subjects who were randomised in the 
follow-up phase and had at least one efficacy assessment after week 28. The safety population included 
all patients who were randomised in the follow-up phase. Adverse events were analysed descriptively.  
Treatment group differences in categorical efficacy measures, including the primary efficacy outcome, 
were analysed using Fisher exact tests. α was set at 0.05. Patients who discontinued early were 
considered to be non-responders in the analysis of ASAS partial remission. No other data were imputed. 
Continuous measures were analysed using analysis of covariance with baseline values as covariates. 
Duration of ASAS partial remission (in weeks) was assessed using the Kaplan–Meier method with a log-
rank test of the difference between treatment groups. Predictors of duration of remission were 
explored using Cox regression models.  
5.2.4. Results 
5.2.4.1. Patient disposition 
In Part 1 of INFAST, 158 patients were randomised, and 141 completed the study to week 28. In Part 2, 
the follow-up phase that included only patients who achieved ASAS partial remission at week 28, 41 
patients were randomised to NPX and 41 to no treatment (Figure 1). The ITT population included 40 
patients in each treatment group; 1 patient was excluded from each treatment group because they had 
no efficacy data after week 28. Each treatment group in Part 2 had 31 patients from the IFX+NPX arm 
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and 9 patients from the PBO+NPX arm in Part 1; the greater number of patients from the IFX+NPX arm 
reflected the 2:1 randomisation ratio to IFX+NPX vs PBO+NPX in Part 1, and also the greater number of 
patients who reached partial remission in the IFX+NPX arm in Part 1. Most patients (32/41, 78%) in each 
of the treatment arms in Part 2 completed week 52 of the trial.  
 
FIG. 33: Patient disposition for INFAST Part 2.  
5.2.4.2. Baseline characteristics 
For patients who entered INFAST Part 2, the treatment groups were similar in demographic and clinical 
characteristics at baseline of INFAST Part 1 (week 0) and clinical characteristics at baseline of INFAST 
Part 2 (week 28) (Table 42). Patients were selected for INFAST Part 2 only if they had reached partial 
remission in INFAST Part 1, and therefore, disease activity at the beginning of the follow-up phase was 
low. For example, mean BASDAI scores were 0.7 and 0.6 in the NPX and no-treatment groups, 
respectively, at week 28, an improvement from a mean of approximately 6.0 at baseline of INFAST Part 
1 (week 0).  
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Patient characteristics at baseline of INFAST Part 1 (week 0) NPX No treatment 
Baseline demographic characteristics N=41 N=41 
 Gender (male), n (%) 34 (82.9) 30 (73.2) 
 Age (years), mean (SD) 29.3 (7.02) 29.5 (7.82) 
 Race, n (%) 
  White 31 (75.6) 38 (92.7) 
  Asian 10 (24.4) 3 (7.3) 
 Body mass index (kg/m2), mean (SD)  23.6 (3.52) 23.3 (4.19) 
Clinical characteristics at baseline of INFAST Part 2 (week 28) N=41 N=41 
 TJC68, mean (SD) 0.2 (0.95) 0.1 (0.40) 
 SJC66, mean (SD) 0.0 (0.00) 0.0 (0.16) 
 Patient Global Assessment of Disease Activity (0–100 mm), mean (SD) 5.7 (5.82) 5.7 (6.63) 
 Back pain (0–100 mm), mean (SD) 6.1 (5.64) 6.5 (6.69) 
 Physician Global Assessment of Disease Activity (0–100 mm) 8.9 (8.61) 8.7 (8.72) 
 Chest expansion (cm) 5.5 (1.64) 5.4 (1.97) 
 BASDAI (10 cm VAS), mean (SD) 0.7 (0.66) 0.6 (0.70) 
 BASMI, (10 cm VAS), mean (SD) 1.5 (1.05) 1.7 (1.13) 
 BASFI (10 cm VAS), mean (SD) 0.6 (0.60) 0.7 (1.00) 
 CRP (mg/dl), mean (SD) 0.39 (0.786) 0.58 (0.747) 
 ESR (mm/h), mean (SD) 7.2 (8.25) 9.1 (8.27) 
TABLE 42: Demographic and baseline characteristics for patients in INFAST Part 2 (all randomised 
patients). 
5.2.4.3. Exposure and adherence 
In the NPX group, the average daily dose of NPX was 936.6 mg, with 99.4% adherence to the number of 
doses, regardless of dose amount.  
5.2.4.4. Efficacy 
At week 52, similar percentages of patients in the NPX group (47.5%, 19/40) and the no-treatment 
group (40.0%, 16/40) met the ASAS partial remission criteria, p=0.65 (Figure 34A). Overall, the 
percentage of patients in partial remission decreased steadily during the 6-month follow-up period. At 
each assessment point, similar percentages of patients in the NPX group and the no-treatment group 
maintained ASAS partial remission (p>0.05 at each time point). The median duration of partial remission 
was 23 weeks (95% CI 14.43 to 25.14) in the NPX treatment arm and 12.6 weeks (95% CI 10.71, upper 
bound not estimable) in the no-treatment group, a difference that was not statistically significant 
(p=0.38).  
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FIG. 34: Percentage of patients in INFAST Part 2 who had ASAS partial remission (A) and low disease 
activity (BASDAI<3 in patients with non-missing data) (B) at each visit.  
Although the percentage of patients in partial remission decreased steadily over the 6-month follow-up 
period, few patients in either treatment group met the criteria for disease flare (NPX, 1/40, 2.5% and no 
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treatment, 3/40, 7.5%; p=0.62) and the vast majority of patients (83% to 94%) in both groups 
maintained a state of low disease activity (BASDAI<3) at all visits (Figure 34B).  
All efficacy measures indicated some worsening from week 28 to week 52, but overall disease activity, 
as measured by BASDAI and ASDAS, remained very low in both the NPX and no-treatment groups (Table 
43). BASMI, BASFI, ESR, CRP and EQ-5D showed similar patterns (Table 43), with no statistically 
significant differences between the treatment groups.  
Efficacy 
measures 
NPX 
N=40 
No treatment 
N=40 p Value for 
treatment 
group 
difference 
Week 
28, 
mean 
Week 
52, 
mean 
Change, 
mean (SD) 
% 
Change 
Week 
28, 
mean 
Week 
52, 
mean 
Change, 
mean (SD) 
% 
change 
ASDAS 0.9 1.5 0.6 (0.71) 145.8 1.0 1.6 0.6 (0.63) 95.5 0.84 
BASDAI (10 
cm VAS) 
0.7 1.2 0.6 (1.06) 71.3 0.5 1.7 1.1 (1.37) 214.5 0.11 
BASMI (10 
cm VAS) 
1.5 1.8 0.3 (0.47) 30.2 1.6 1.7 0.3 (0.63) 19.6 0.89 
BASFI (10 cm 
VAS) 
0.6 1.0 0.5 (0.79) 73.5 0.6 1.5 0.9 (1.41) 144.1 0.30 
CRP (mg/dl) 0.37 0.69 
0.29 
(0.924) 
85.0 0.53 0.72 
0.26 
(0.707) 
34.3 0.99 
ESR (mm/h) 7.1 14.7 
7.6 
(11.63) 
209.8 9.4 13.6 
5.1 
(10.10) 
134.0 0.46 
EQ-5D index 
score* 
0.85 0.73 
−0.12 
(0.228) 
−13.9 0.84 0.74 
−0.12 
(0.232) 
−12.0 0.95 
TABLE 43: Efficacy outcomes by treatment group. *An increase in this score indicates improvement. For 
all other measures, a decrease in score indicates improvement. 
Figure 35 illustrates the gains that were made in the first 28 weeks and maintained over the 6-month 
follow-up period by showing the data over the full-year study period for the group of patients who 
participated in Part 2. For example, BASDAI scores decreased substantially for patients at the start of 
treatment in INFAST Part 1. In Part 2, after patients were randomised to NPX or no treatment, the NPX 
group appeared to have a slightly lower BASDAI at each visit. Patterns were similar for ASDAS based on 
CRP (ASDAS-C), CRP and BASFI.  
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FIG. 35: Mean BASDAI (A), ASDAS-C (B), CRP (C) and BASFI (D) from baseline to week 52 for patients who 
participated in INFAST Part 2. aDuring the follow-up period, patients with ASAS partial remission were 
assigned to either NPX or no treatment, with assignments stratified by initial treatment group.  
Figure 36 shows BASDAI and ASDAS-C scores for the Part 2 participants, grouped according to their 
randomised assignments in both Part 1 and Part 2. Patients receiving IFX+NPX in Part 1 showed greater 
improvement than patients receiving PBO through week 34. By week 52, differences were no longer 
evident between the groups. Although it is useful to see the overall patterns across groups in Part 2, it 
should be noted that the numbers of subjects in these four groups are small.  
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FIG. 36: BASDAI (A) and ASDAS-C (B) by treatment sequence and visit for patients who participated in 
Part 2. aDuring the follow-up period, patients with ASAS partial remission were assigned to either NPX or 
no treatment, with assignments stratified by initial treatment group. 
Single and two-factor logistic regression analyses examined predictors of sustained remission at week 
52. Regardless of treatment in Part 1 of INFAST, disease duration in years was the only characteristic 
that had a robust association with remission at week 52. In the single-variable analysis, the estimate was 
−1.673 (SE=0.572, p=0.03), indicating that patients with shorter disease duration were more likely to 
have sustained remission than patients with longer disease duration.  
5.2.4.5. Safety 
During the follow-up period, the percentage of patients with treatment-emergent adverse events 
(TEAEs) was higher in the no-treatment arm (41.5%; 17/41) than in the NPX arm (26.8%; 11/41). The 
most frequently reported TEAEs in the NPX group were rhinitis and intervertebral disc protrusion (each 
in two patients). The most frequently reported TEAEs in the no-treatment group were nasopharyngitis 
(three patients), bronchitis (two patients) and respiratory tract infection (two patients). During the 
follow-up period, one serious TEAE (carcinoma in situ) was reported in the no-treatment group (the 
patient had received IFX+NPX in INFAST Part I), and one TEAE leading to early withdrawal (fatigue) 
occurred in the NPX group. No deaths occurred.  
5.2.5. Discussion 
In this study of patients with early, active, moderate-to-severe axial SpA who had reached ASAS partial 
remission following 28 weeks of treatment with IFX+NPX or PBO+NPX, remission was maintained at 
week 52 by similar percentages of patients who either stayed on NPX therapy (47.5%) or in whom all 
treatments were stopped between weeks 28 and 52 (40.0%). Although the rate of partial remission, a 
stringent criterion for disease activity, decreased steadily over the follow-up period, other measures of 
disease activity indicated that most of the substantial improvement achieved over the first 28 weeks of 
treatment was well maintained during the follow-up period. For example, mean BASDAI across 
treatment groups was approximately 6 at baseline of INFAST Part 1, approximately 0.6 at baseline of 
INFAST Part 2 (week 28) and approximately 1.5 at week 52. Approximately 90% of patients had 
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BASDAI<3 at week 52. As assessed by several other measures of disease activity, inflammation and 
functioning (eg, ASDAS-C, CRP and BASFI) improvements achieved during the initial treatment phase of 
INFAST were generally maintained during the 6-month follow-up period, and very few flares were 
observed.  
One issue of importance to patients, clinicians and payers is whether patients with axial SpA who are 
treated with TNF-α antagonists can stop therapy without experiencing disease flare. Although studies in 
AS populations have shown that patients continue to respond to TNF-antagonist treatment over periods 
of several years, available evidence indicates that nearly all patients will flare once treatment is stopped 
[10, 11] suggesting that the biologic-free remission rates found in INFAST would be unlikely in patients 
with established AS and longer disease duration. In the current study's population of patients with early 
disease, 78% of the patients in the follow-up study had received IFX+NPX in the initial treatment phase 
of INFAST. When all IFX treatment was stopped at week 28, almost half of the patients maintained 
partial remission to week 52. Overall, the data suggest that both combination treatments with IFX+NPX 
and NPX monotherapy in the first 6 months had long-lasting benefits in those patients who reached 
partial remission, with few patients in any treatment group experiencing disease flares.  
The initial positive responses to treatment in INFAST Part 1 and the well-maintained response shown in 
INFAST Part 2 are among the highest rates of response for studies of TNF-α antagonist treatment in 
patients with axial SpA [5, 12-14]. The high response rates are possibly due to the very short disease 
duration of the population, patient selection for signs of inflammation on MRI and the intensified 
treatment during Part 1 (either a full dose of NPX or NPX+IFX) in a population of patients that had not 
yet failed NSAIDs or were naïve to NSAIDs at study entry. Patients in INFAST reported a mean of fewer 
than 2 years since the onset of symptoms, and previous studies [4, 12, 15] have shown that short 
disease duration is a predictor of better response to TNF-α antagonists in patients with axial SpA and AS. 
Shorter disease duration was associated with sustained remission in our study, which may indicate the 
existence of a window of opportunity for treatment of axial SpA early in the course of disease, as has 
been described in early RA [16]. This is the first trial in axial SpA demonstrating that a remission-
induction strategy in patients with very early disease can actually keep these patients in a state of low 
disease activity, even without medication. One limitation of this study is that it is not known whether 
these results could be achieved after stopping medication in a population of patients who had already 
failed NSAIDs.  
Although there was a tendency for slightly numerically better outcomes in patients who received NPX 
rather than no treatment during the follow-up period, none of these differences were statistically 
significant. It is difficult to draw any conclusions about the possible superiority of NPX because the 
follow-up phase of INFAST was an exploratory study that was underpowered to detect smaller 
differences between the NPX and no-treatment groups. Although significant clinically relevant 
differences could have been missed because of the small sample size, the small differences between the 
two groups detected here are likely to be too small to be of clinical significance even if a statistically 
significant difference had been shown in a study with greater power. The open-label nature of the study 
might be considered a weakness that could bias the results in favour of the NPX group, but the NPX 
group was not superior to the no-treatment group, suggesting that the open-label design should not 
influence the overall interpretation of the data.  
The results of the INFAST follow-up study demonstrated that patients with early, active, moderate-to-
severe axial SpA who achieved partial remission during 28 weeks of IFX+NPX or PBO+NPX treatment had 
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similar rates of partial remission whether they received NPX or no treatment during 6-months of follow-
up. Overall, patients had low disease activity and very few flares during the follow-up period, whether 
they received NPX or no treatment at all. Whether such a low level of disease activity could be 
maintained beyond 6 months is an important question for future studies.  
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5.3. Partial Remission in Ankylosing Spondylitis and Non-
Radiographic Axial Spondyloarthritis and Associations 
Between Partial Remission and Baseline Disease 
Characteristics During Treatment With Infliximab Plus 
Naproxen or Naproxen Alone 
5.3.1. Abstract  
Objectives  
To evaluate partial remission during treatment with infliximab (IFX [Remicade])+naproxen (NPX) vs NPX 
alone in patients from the 2 subgroups of axial spondyloarthritis (SpA) and explore baseline predictors of 
partial remission. 
Methods 
INFAST was a double-blind, randomized controlled trial of IFX in biologic-naïve patients with early, active 
axial SpA. Patients were randomized (2:1) to receive 28 weeks of treatment with IV IFX 5 mg/kg (weeks 
0, 2, 6, 12, 18, and 24)+NPX 1000 mg/d or IV placebo (PBO)+NPX 1000 mg/d. The current post hoc 
analysis evaluated outcomes in patients who did or did not meet modified New York x-ray criteria for 
ankylosing spondylitis (AS).  
Results  
The analysis included 94 patients who met AS criteria and 56 with nonradiographic axial SpA (nr-axSpA). 
At week 28, Assessments in Ankylosing Spondylitis (ASAS) partial remission was greater with IFX+NPX 
than PBO+NPX for both the AS group (70.5% vs 33.3%, respectively) and the nr-axSpA group (50.0% vs 
37.5%, respectively). A similar pattern occurred with several efficacy measures. Larger treatment effects 
occurred in the AS group than the nr-axSpA group, possibly due to baseline differences in disease 
characteristics. Multivariable analyses identified type of treatment, age, and HLA-B27 status as 
predictors of ASAS partial remission in the total study population. MRI SI scores were associated with 
partial remission during IFX+NPX treatment. 
Conclusions  
Patients with AS had greater partial remission to IFX+NSAID than NSAID therapy alone; 
patients with nr-axSpA had a smaller treatment effect. Baseline disease characteristics and age 
were associated with partial remission to IFX therapy. 
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5.3.2. Introduction 
For patients with axial spondyloarthritis (SpA), only 2 types of treatments have proven efficacy: 
nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor (TNF)-α–targeted therapies 
(1). NSAIDs are considered first-line treatment, and patients who fail 2 NSAIDs are considered 
candidates for TNF antagonist treatment (1). Clinical trial results have shown good response to TNF 
antagonists in both patients with ankylosing spondylitis (AS) and patients with nonradiographic axial SpA 
(nr-axSpA) (2-7). Recently, 3 TNF- blocking agents (adalimumab [8], certolizumab pegol [9], and 
etanercept [10]) have been approved for treatment of nr-axSpA in the European Union. Good outcomes 
of anti-TNF therapy have been associated with better function at baseline, human leukocyte antigen 
(HLA)-B27 genotype, elevated C-reactive protein (CRP), male gender, higher inflammation score on 
magnetic resonance imaging (MRI), and younger age in patients with AS (11-15). In patients with nr-
axSpA, elevated CRP and MRI scores, shorter disease duration, and younger age also have been shown 
to predict better outcomes (3, 16). 
In the Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial (INFAST) 
study, patients with early, active axial SpA who had been treated with suboptimal doses of NSAIDs were 
treated with naproxen (NPX) at the maximally recommended and/or tolerated dose with either 
infliximab (IFX [Remicade®, Janssen, Titusville, NJ]) or placebo (PBO) for 28 weeks (17). This study 
included both AS and nr-axSpA patients with moderate to severe disease with a disease duration of ≤3 
years. The combination of NSAID and IFX treatment resulted in better rates of Assessment in Ankylosing 
Spondylitis (ASAS) partial remission than NSAID treatment alone (61.9% vs 35.3%, respectively) (17). In 
this post hoc analysis of INFAST, we describe the results for the subgroups of patients who had AS versus 
nr-axSpA, and we explore predictors of partial remission in this patient population that had early 
disease. 
5.3.3. Patients and methods 
5.3.3.1. Design and Patients. 
INFAST was a randomized, double-blind, PBO-controlled study of IFX in adults with moderate to severe, 
active axial SpA who were not refractory to NSAIDs (Protocol P05336, NCT00844805). Details of the 
study methods have been previously reported (17). The study was conducted in accordance with the 
Declaration of Helsinki and standards of good clinical research practice. Written informed consent was 
required to participate, and the study protocol was reviewed by appropriate institutional review boards 
for each study site. Patients were enrolled in 9 countries (Austria, Belgium, Denmark, France, Germany, 
Hungary, Russia, South Korea, and Ukraine). Data collection occurred from 22 October 2009 to 20 
September 2011. Patients who achieved partial remission criteria at week 28 were eligible to participate 
in a follow-up study of NPX vs no treatment up to week 52; data from this portion of the study are 
reported in Sieper et al. (18) and are not used in the analysis reported here.  
Patients in INFAST were 18 to 48 years of age, had a diagnosis of axial SpA, and had disease duration of 
≤3 years. All patients had inflammation of the sacroiliac (SI) joints (per ASAS criteria for axial SpA [19]) as 
determined by MRI read by local investigators. All patients had active disease, defined as a total back 
pain evaluation of ≥40 mm (visual analog scale [VAS] of 0–100 mm), and a Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) score of ≥4 cm (0–10 cm VAS). Patients were either NSAID-naïve or had 
been treated with not more than two thirds of the maximal recommended NSAID dose during the 2 
weeks prior to screening. 
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For the current subgroup analysis, the patients were divided into 2 groups: those who met the New York 
modified radiographic criteria for AS (bilateral ≥ grade 2 or unilateral ≥ grade 3 lesions, as assessed by 
the local investigator) and those who had nr-axSpA. 
5.3.3.2. Study Treatment.  
During Part I (28 weeks) of INFAST, patients were randomized at a 2:1 ratio to receive either intravenous 
(IV) IFX 5 mg/kg or IV PBO at weeks 0, 2, 6, 12, 18, and 24. Both groups also received oral NPX at the 
maximum dose of 1000 mg daily, if tolerated. Randomization was not stratified by whether patients met 
AS radiographic criteria. 
5.3.3.3. Outcome Measures.  
The primary efficacy measure was the percentage of patients in each treatment group who met ASAS 
partial remission criteria at week 28. A number of secondary measures of disease activity, clinical signs 
and symptoms, and patient-reported outcomes were also assessed at each study visit. MRI lesions in 
spine and SI joints were assessed at baseline and week 28. Adverse events (AEs) and several other safety 
measures were also collected at each visit. 
5.3.3.4. Statistical Analyses.  
The originally targeted sample size for INFAST was 150 patients (100 receiving IFX+NPX and 50 receiving 
PBO+NPX) for 90% power to detect a 30% difference in ASAS partial remission between treatment 
groups, assuming a 15% withdrawal rate. The study was not powered for evaluation of treatment effects 
in the subgroups of patients analyzed here. 
This post hoc analysis included patients who were randomized, received at least 1 dose of study 
medication, had at least 1 efficacy evaluation after baseline, and had baseline radiographs for 
determination of AS versus nr-axSpA status. For the main efficacy measure, ASAS partial remission, 
Fisher’s exact tests were used to compare treatment arms within the AS and nr-axSpA groups. Other 
efficacy measures were analyzed descriptively. 
To evaluate predictors of ASAS partial remission, a multivariable logistic regression model was used with 
stepwise selection of covariates with an entry criterion of P = 0.25 and a retention criterion of P = 0.15. 
Patients with AS and nr-axSpA were combined for this analysis. Variables of specific interest were 
explored further in the individual treatment groups using multivariable analyses. 
5.3.4. Results 
5.3.4.1. Patient Disposition  
Of the 156 randomized patients in the INFAST intention-to-treat population, 93% of patients in the 
IFX+NPX group and 89.3% in the PBO+NPX group completed the study through week 28 (17). At 
baseline, 94 patients met the criteria for AS (IFX+NPX, 61; PBO+NPX, 33), 56 had nr-axSpA (IFX+NPX, 40; 
PBO+NPX, 16) according to local reading of the SI joint x-rays, and 6 patients were excluded from the 
analyses reported here because they were missing baseline radiographs and could not be classified 
accurately. 
5.3.4.2. Baseline Characteristics  
For each radiographic group, most baseline characteristics were similar in the IFX+NPX and PBO+NPX 
groups (Table 44). Compared with the nr-axSpA group, the AS group appeared to have greater 
concentrations of inflammatory markers, greater Berlin MRI scores, a greater percentage of patients 
with HLA-B27–positive status, and a greater percentage of males. 
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Baseline Characteristics 
Patients with AS 
Patients with  
Nr-axSpA 
IFX+NPX 
(N = 61) 
PBO+NPX 
(N = 33) 
IFX+NPX 
(N = 40) 
PBO+NPX 
(N = 16) 
Gender (male), n (%) 51 (83.6) 28 (84.8) 19 (47.5) 10 (62.5) 
Age (years), mean (SD) 31.2 (8.19) 31.0 (7.55) 31.8 (8.89) 30.9 (7.28) 
Race, n (%) 
    White 
    Asian 
    Multiracial 
52 (85.2) 
9 (14.8) 
0 
29 (87.9) 
4 (12.1) 
0 
36 (90.0)  
4 (10.0) 
0 
14 (87.5) 
1 (6.3) 
1 (6.3) 
Body mass index (kg/m2), mean (SD) 23.8 (4.08) 24.0 (3.22) 24.7 (4.89) 24.1 (4.02) 
Diagnosis duration years, mean (SD) 1.06 (0.891) 0.74 (0.701) 0.53 (0.587) 0.50 (0.417) 
Symptom duration years, mean (SD) 2.01 (0.868) 1.84 (0.927) 1.44 (0.855) 1.54 (0.898) 
BASDAI, mean (SD) 65.99 (15.17) 63.98 (16.28) 64.10 (16.34) 61.25 (13.90) 
Nr of SpA manifestations, mean (SD)  4.1 (1.45) 4.1 (1.34) 3.4 (1.27) 3.9 (1.06) 
Inflammatory back pain, n (%) 53 (86.9) 30 (90.9) 37 (92.5) 15 (93.8) 
Arthritis, n (%) 34 (55.7) 10 (30.3) 13 (32.5) 4 (25.0) 
Dactylitis, n (%) 3 (4.9) 1 (3.0) 0 0 
Psoriasis, n (%) 1 (3.0) 2 (6.1) 2 (5.0) 0 
Family history of SpA, n (%) 9 (14.8) 4 (12.1) 6 (15.0) 6 (37.5) 
Uveitis, n (%) 4 (6.6) 4 (12.1) 2 (5.0) 2 (12.5) 
History of CD/UC, n (%) 0 0 0 0 
Enthesitis (heel), n (%) 9 (14.8) 5 (15.2) 4 (10.0) 5 (31.3) 
HLA-B27–positive status, n (%) 54 (88.5) 32 (97.0) 31 (77.5) 12 (75.0) 
CRP (mg/dL), mean (SD) 2.75 (7.335) 2.13 (1.514) 0.98 (1.221) 0.74 (0.698) 
ESR (mm/h), mean (SD) 26.8 (17.56) 33.8 (17.65) 18.1 (16.06) 18.8 (11.57) 
Overall MRI SI score at screening, 
median 
 
4.0 6.5 3.3 6.5 
Overall Berlin MRI spine score at 
screening, median  1.5 3.0 0.5 0.5 
Previous good response to NSAIDs, n 
(%)* 43 (70.5) 21 (63.6) 26 (65.0) 12 (75.0) 
TABLE 44: Baseline Demographic and Disease Characteristics in Patients With AS or Nr-axSpA. 
5.3.4.3. Efficacy  
ASAS partial remission. For both the AS and the nr-axSpA groups, ASAS partial remission rates at week 
28 were greater in the IFX+NPX group than the PBO+NPX group (Table 45; Figure 37). The treatment 
effect favoring IFX+NPX in the AS group (70.5% for IFX+NPX vs 33.3% for NPX alone, P = 0.0009) was 
greater than the treatment effect favoring IFX+NPX in the nr-axSpA group (50.0% for IFX+NPX vs 37.5% 
for NPX alone, P = 0.55).   
Secondary efficacy outcomes. For several other clinical and patient-reported outcomes at week 28, 
including BASDAI, ASDAS, BASFI, and EQ-5D, improvement was greater for patients who received 
IFX+NPX than NPX alone in the 2 subgroups (Table 45). The advantage of IFX+NPX over NPX alone was 
generally smaller in the nr-axSpA group than the AS group.  
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FIG.37: Percentage of patients who achieved ASAS partial remission at week 28 (observed data) 
by radiographic status and type of treatment.  
 
Efficacy Measure 
Patients with AS  
Patients with  
nr-axSpA 
IFX+NPX 
(N = 61) 
PBO+NPX 
(N = 33) 
IFX+NPX 
(N = 40) 
PBO+NPX 
(N = 16) 
ASAS partial remission at week 
28, n (%) 43 (70.5)  11 (33.3) 20 (50.0) 6 (37.5) 
ASAS40 at week 28, n (%) 53 (86.9) 18 (54.5) 24 (60.0) 9 (56.3) 
ASAS20 at week 28, n (%) 53 (86.9) 24 (72.7) 29 (72.5) 11 (68.8) 
BASDAI, mean (SD) 
Baseline 
Week 28 
6.50 (1.517) )                                               
1.38 (1.861)             
6.40 (1.628) 
3.54 (2.468)                        
6.41 (1.634) 
2.50 (2.436)             
6.13 (1.389) 2.82 
(2.906)                        
BASDAI < 3 cm, n (%) 
Baseline 
Week 28 
1 (1.6) 
50 (86.2)                 
0 
15 (50.0)                        
1 (2.5) 
22 (61.1)                  
0 
7 (53.8)                        
BASFI , mean (SD) 
Baseline 
Week 28 
51.7 (23.26) 
15.2 (19.61)             
59.2 (21.09) 
32.9 (23.98)                        
55.4 (20.85) 
20.5 (23.12)             
45.2 (21.01) 16.1 
(17.77)                         
ASDAS-C, mean (SD) 
Baseline 
Week 28 
 
3.950 (0.9231) 
1.417 (1.1919)           
4.106 (0.7828) 
2.549 (1.2115)                 
3.607 (0.8842) 
1.434 (1.0708)           
3.399 (0.7116)  
2.023 (1.1072)                 
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ASDAS-C < 1.3, n/N (%) 
Baseline 
Week 28 
0 
33/57 (57.9)                  
0 
5/30 (16.7)       
0 
19/36 (52.8)                  
0 
4/13 (30.8)       
EQ-5D Index score, mean 
Baseline 
Week 28  
0.38  
0.76 
0.28 
0.55  
0.37  
0.71 
0.43 
0.69 
Overall MRI SI score, median 
Screening 
Week 28 (or ET) 
Median change 
IQR of change 
Percent change 
 
4.0 
1.0 
–3.0  
(–7.5, –0.5)  
–75.0 
6.5  
2.0 
–3.0  
(–6.5, –0.5) 
–46.2 
3.3 
0.5 
–2.0  
(–5.0, 0.0) 
–61.5 
6.5 
2.5 
-3.5  
(–4.5, –1.0) 
–53.8 
Overall Berlin MRI score, 
median  
Screening 
Week 28 (or ET) 
Median change 
IQR of change 
Percent change 
1.5 
0.0 
–1.0 
(–6.0, 0.0) 
–66.7 
3.0 
1.0 
–1.0 
(–6.0, 0.0) 
–33.3 
0.5 
0.0 
0 
(–2.0, 0.0) 
0 
0.5 
1.0 
0 
(–0.5, 0.5) 
0 
CRP (mg/dL), median (Q1, Q3) 
Baseline 
 
Week 28 
 
 
1.21  
(0.53, 2.10) 
0.36  
(0.10, 0.60) 
1.87  
(0.78, 3.05) 
1.23  
(0.35, 1.58) 
0.48 
(0.10, 1.43) 
0.10  
(0.05, 0.34) 
0.62 
(0.10, 1.02) 
0.43  
(0.29, 1.00) 
ESR (mm/h), median (Q1, Q3) 
Baseline 
 
Week 28 
 
 
26.0 
(14.0, 39.0) 
6.0 
(4.0, 10.0) 
35.0 
(29.0, 38.0) 
18.5 
(12.0, 28.0) 
13.0  
(7.0, 25.0) 
4.0  
(2.0, 7.0) 
18.0  
(9.0, 27.0) 
17.5 
(8.5, 27.0) 
TABLE 45: Secondary Efficacy Outcomes in Patients With AS or Nr-axSpA. 
Associations between baseline factors and ASAS partial remission. The multivariable logistic regression 
model used to explore factors associated with partial remission for the full group of axial SpA patients 
included the following factors: type of treatment (IFX+NPX vs PBO+NPX), age (continuous), gender (male 
vs female), HLA-B27 status (positive vs negative), baseline CRP (continuous and log-transformed), and 
MRI SI joint score (continuous and log-transformed). Factors significantly associated with greater 
likelihood of ASAS partial remission were IFX+NPX treatment (odds ratio [OR] = 5.786; confidence 
interval [CI] = 2.477, 13.516; P < 0.0001), positive HLA-B27 status (OR = 3.209; CI = 1.014, 10.150; P = 
0.0472), and younger age (OR = 0.937; CI = 0.892, 0.985; P = 0.0100) (Figure 38). 
CRP and MRI SI-joint score at baseline were not associated with ASAS partial remission in this logistic 
regression analysis that included the total population. However, in the group of patients who received 
IFX+NPX, patients with CRP ≥ ULN had a higher ASAS partial remission rate than those with CRP < ULN 
(88.1% vs 53.1%, respectively; P values for the difference were not calculated because of low statistical 
power). Within the group treated with NPX alone, remission rates were similar for those with and 
without elevated CRP (34.4% vs 35.3%, respectively). A similar pattern occurred in the relationship 
between MRI scores and partial remission; in patients treated with IFX+NPX, patients with an elevated 
MRI SI-joint score (≥3.9) had a higher remission rate than those without elevated MRI score (78.4% vs 
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46%, respectively). In patients treated with NPX alone, partial remission rates were similar whether or 
not MRI score was elevated (34.5% vs 35%, respectively). 
 
FIG. 38: Predicted probabilities of achieving ASAS partial remission according to treatment group, HLA-
B27 status, and age in logistic regression model. Note: Model includes both patients with AS and nr-
axSpA. 
The AS and nr-axSpA groups differed in some baseline characteristics; mean CRP concentration was 
greater in the AS group, and to a lesser extent, MRI scores were greater in the AS group (Table 45). 
Because CRP (3, 11, 12, 14-16, 20, 21) and MRI (3, 13, 21) have been shown to be predictive of outcomes 
during TNF antagonist treatment, 2 logistic regression models were performed in the IFX+NPX treatment 
group. The first explored the effects of baseline CRP and axial SpA diagnosis (AS vs nr-axSpA) on ASAS 
partial remission, and the second explored the effects of baseline MRI SI joint score and axial SpA 
diagnosis (AS vs nr-axSpA) on ASAS partial remission. The logistic regression analysis for the PBO+NPX 
treatment arm was not performed because of the small number of subjects. 
CRP values were not predictive of clinical remission in patients treated with IFX+NPX, as evidenced by 
the shallow slopes in Figure 39A. Both the AS and nr-axSpA subgroups had high remission rates, but the 
odds of ASAS partial remission were 2.4 times higher in the AS group than the nr-axSpA group, 
controlling for baseline CRP. Thus, the lower CRP values in the nr-axSpA group were not a sufficient 
explanation for the difference in partial remission between the nr-axSpA and AS groups.  
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Figure 39B shows that baseline MRI scores were associated with increased likelihood of ASAS partial 
remission (P = 0.006). However, again similar levels of MRI inflammation resulted in a higher partial 
remission rate in patients with AS than nr-axSpA (P = 0.04). The odds of ASAS partial remission were 2.5 
times higher in the AS group than the nr-axSpA group (P < 0.05).  
 
FIG. 39: Predicted probability of achieving ASAS partial remission from logistic regression 
models according to baseline CRP concentration (A) or baseline MRI SI joint score (B) in 
patients with AS or nr-axSpA who were treated with IFX+NPX. 
5.3.5. Discussion 
The strongest predictor of attaining remission in the INFAST trial was treatment with the TNF-
antagonist, infliximab. HLA-B27 positivity and young age were also positive predictors, as has been 
reported before in patients with AS (11, 12, 14, 15, 20) and also in patients with nr-axSpA, although 
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often with a weaker association (3 ,16). Interestingly, CRP levels and active bony inflammation on MRI 
were not significantly associated with remission in this multivariable logistic regression analysis. 
Nonetheless, within the patient group treated with IFX+NPX, those with elevated CRP and those with 
elevated MRI SI-joint scores did have numerically higher partial remission rates than patients with lesser 
CRP and MRI scores. Both of these factors have been predictive of outcomes in other TNF-blocker trials 
in axial SpA (3, 20, 21).  
The clinical outcome was clearly better in patients with AS than in patients with nr-axSpA. The INFAST 
population is unique from previous studies in that the patients had short disease duration and were 
selected if they were naïve to NSAIDs or were using a suboptimal dose of NSAIDs. This selection of 
patients may help explain why the 70.5% partial remission rate in the AS group was considerably greater 
than the 15% to 20% rates of partial remission typically reported in patients with longstanding, 
established AS (5 ,6, 22). In contrast, in a study of patients with axial SpA (both AS and nr-axSpA) who 
had symptom duration of less than 5 years and were treated with etanercept, partial remission rates 
were approximately 50% during unblinded treatment (23). In another study of patients with AS and nr-
axSpA with symptom duration < 3 years who were treated with infliximab, partial remission rate was 
56% (24). 
Recent evidence suggests that patients with AS and patients with nr-axSpA respond similarly well to TNF 
antagonists (3, 4, 7, 23-25). In INFAST, however, the nr-axSpA group did not appear to benefit as much 
from IFX+NPX as the AS group. Major differences in the baseline characteristics of the AS versus nr-
axSpA groups included higher CRP concentrations and MRI SI scores, a higher percentage of HLA-B27 
positivity, and a higher proportion of male patients. In addition, CRP concentrations were lower in the 
PBO+NPX group than the IFX+NPX group, whereas MRI SI scores were comparable in the 2 treatment 
groups.  
The relatively flat slopes in Figure 39A indicate that estimated probability of ASAS partial remission did 
not increase with increasing baseline CRP in this study population. Thus, higher CRP values at baseline in 
the AS patients could not explain the better partial remission rate in this group. The steeper slope in 
Figure 39B indicates that higher baseline MRI SI scores were associated with greater probability of ASAS 
partial remission in the IFX+NPX group, but that at similar levels of MRI inflammation, partial remission 
was better in AS patients than nr-axSpA patients. The most important baseline differences that might 
explain the difference in the clinical response rate between the AS and nr-axSpA groups are the higher 
HLA-B27-positivity in the AS group at baseline (Table 44). HLA-B27-positivity was indeed predictive of a 
better partial remission rate in the multivariable logistic regression analysis while gender, CRP, and MRI 
were not.  
As noted earlier, the population in INFAST was unique in that patients had not failed NSAIDs before 
starting biologic treatment and patients had a short mean disease duration (≤2 years). Some of the 
results presented here probably can be generalized, such as the very good clinical response to NSAIDs 
when treatment begins early for patients with either AS or nr-axSpA. In INFAST, ASAS partial remission 
was achieved with NPX treatment by 33.3% of patients with AS and 37.5% of patients with nr-axSpA. 
However, the high partial remission rate to IFX+NPX in this population that is not refractory to NSAIDs 
cannot automatically be generalized to all axial SpA patients who are refractory to NSAIDs. 
A limitation of this study is that the analysis of the AS population was not planned, and the study was 
not powered for analysis of subgroups of patients; therefore, inferences about the differences between 
the 2 subsets of the populations should be made with caution. Another limitation is that the 
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classification of patients in the AS group was based on x-ray readings performed by the local 
investigator, and they were not independently confirmed by a central reading. 
5.3.6. Conclusions 
Patients with early axial SpA had better outcomes when treated with IFX+NPX than NPX alone, but also 
showed good outcomes when receiving NPX alone. Other predictors of partial remission were HLA-B27 
positivity and young age. Objective signs of inflammation, such as CRP and MRI-inflammation, were less 
predictive in this early axial SpA cohort. Thus, early diagnosis seems to be important to achieve a good 
treatment effect, including in patients who already fulfil the modified New York criteria for AS. Patients 
with nr-axSpA had lesser response to IFX than patients with AS, which may partly be explained by 
differences in baseline disease characteristics.  
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Chapter 6: Outcome-based Treatment 
Decisions in RA and Axial SpA Treatment 
recommendations  
- Discussion - 
A critical review of the RA and Axial SpA management recommendations is done and specific proposals 
on how the clinical tools and data presented in Chapter 4 and Chapter 5 may help refine guidelines are 
formulated. 
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6.1. Relevance of outcome-based patient selection in RA  
Combination therapy with more than one synthetic disease modifying agent (DMARD) or with DMARDs 
and biologics or corticosteroids has better disease activity suppressing effects and slows progression 
more than a single DMARD [1-5]. The use of combination therapy comes with increased complexity and 
toxicity and in the case of biological agents increased cost. Fact is also that DMARDs show response in a 
significant proportion of patients even if used as single agent [6] and they slow down the progression of 
the disease [7-12].  Intensive treatment regimens are thus not needed for all patients and should be 
reserved for those in whom single agents do not allow to achieve treatment goals. In practice this often 
means that clinicians will try less intensive treatment first, will see that disease activity is not sufficiently 
controlled and will only then proceed with the next, more intensive/expensive treatment step. 
Inadequate treatment during the early ‘window of opportunity’ however, may mean that an opportunity 
to change the course of the disease on the long run is missed [13-15].  
Tools that provide insight on patients or sub-populations at risk of developing significant morbidity 
under specific treatments such as MTX mono-therapy allow selecting the more appropriate treatment 
regimen for such patient or sub-population without going through a trial and error phase first. Each 
unnecessary step allows continued uncontrolled disease activity to lead to disability and progression of 
organ damage, which a better initial treatment choice would avoid. For use in daily clinic, such tools 
should be user-friendly, simple and based on demographic, diagnostic or disease related characteristics 
that are readily available in practice. It is equally important that the outcome parameter is important 
enough to counterbalance potential incremental toxicity or risk for side-effects that can be anticipated 
from combining multiple agents in a more intensive treatment regimen. Finally these tools should be 
reliable in predicting the outcome.   
6.1.1. Predicting and preventing poor prognosis in RA 
Models for risk of bad outcome of cardiovascular disease (CVD) and osteoporosis (OP) are well known 
and the build-up of these models was the inspiration for the RA poor prognosis model [16, 17]. These 
models use readily-available characteristics to predict an unambiguous event that is important from a 
health perspective and a socio-economical perspective. Risk is quantified as the proportion of patients 
within a sub-population that dies or incurs a major osteoporotic fracture. The result does not highlight 
‘black and white’ who will certainly die or have a fracture vs. who will live or not have a fracture. 
Instead, the tools present an increasing gradient of probability of an event which implicitly provides 
insights where treatment should be envisioned and where not (e.g. bisphosphonate use for OP, lipid-
lowering drugs for CVD). They do not show however the potential of that treatment to reduce an event. 
The model we introduced for RA in Section 4.1. directly compares the ability of different therapies to 
reduce the risk of poor prognosis [18]. The advantage is that it allows going beyond the question 
whether to treat but it quantifies the likelihood of a treatment to avoid poor prognosis. Directly 
comparing 2 treatments facilitates physicians’ choice as he selects a preferred treatment for a specific 
patient. We also introduced numbers needed to treat (NNT) to avoid rapid radiographic progression 
(RRP) in RA sub-populations which facilitates treatment choice from a societal and health-economical 
perspective.     
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6.1.1.1. Outcome predictors 
The factors that were retained in the poor prognosis model for RA are well established in the 
rheumatology literature and are valued and recognized as predictors of radiographic progression in RA 
[19-23]. It is however interesting to see different datasets bring forth different predictors and models 
(Section 4.2.) [18, 24-26]. The summary provided in Table 46 shows this and raises the question which 
‘final’ model a physician should use.  
 
 
TABLE 46: Summary of characteristics identified as predictor of poor prognosis in models. 
Some differences are caused by whether a predictor-characteristic was measured in the study or not. 
Anti-CCP and smoking for example were not collected in ASPIRE and their use as predictor could thus 
not be investigated. A characteristic like SJC was measured and predictive in ASPIRE but not BeSt. One 
can further wonder whether associations established in a population have any relevance for an 
individual; e.g. a patient with high CRP may not develop erosions. These situations may mimic clinical 
practice where treatment decisions are made even if not all information is available (e.g. anti-CCP not 
reimbursed and therefore not done). Since literature heavily supports the association of factors such as 
RF, Anti-CCP, ESR and CRP with radiographic progression they have high face-validity for use in poor-
prognosis prediction models in RA [19-23]. 
Categorization of variables such as SJC, CRP and ESR in these publications was done pragmatically based 
on the tertiles in the individual database, allowing an even distribution over the dataset of a study. 
Other and/or more cut offs could have been chosen and could have led to slight differences in the 
reported RRP rates. As an example, if a different cut-off for SJC would results in a slight change of the 
percentages in the grid (e.g. risk of RRP of 46% goes down to 42%). This will likely not have an impact on 
clinical decision making for an individual RA patient. 
If used for policy and reimbursement decisions, a slight change in percentage may mean that society will 
or will not pay for the treatment of a patient with RA (e.g. treatment reimbursed if risk of RRP is >45%). 
This explains why rheumatologists have expressed concern with our model. Decisions ruling some 
patient sub-populations out of benefitting from treatment are however already made by authorities. 
The Guideline Development Group of the National Institute for Clinical Excellence (NICE) in the UK for 
example, developed RA treatment recommendations in which TNF alpha inhibitors should only be used 
in adults who have high disease activity (DAS28>5.1) and who have undergone trials of two DMARDs, 
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including MTX [27]. As the goal for this recommendation is preventing joint damage, one can argue why 
a patient who has failed 2 DMARDs and has high RF, high anti-CCP levels, erosions within 6 months after 
diagnosis and a DAS28 = 4.8 would not be recommended, whereas a patient who has a DAS28 of 5.2 
who is anti-CCP and RF negative and has no erosions would be eligible for treatment with a biologic 
after failing 2 DMARDs. 
6.1.1.2. Poor prognosis as outcome parameter 
The outcome parameter chosen to reflect prognosis of the disease must be relevant enough to weigh on 
treatment choice. Is rapid radiographic progression in RA an unambiguous event that is important from 
a health perspective and a socio-economical perspective? Clinicians, patients and payers may think 
differently about this. 
For the RA model the annual progression rate of at least 5 SHS was a pragmatic definition for RRP. 
Radiographic progression stratified for risk of RRP at baseline in the BeSt study in Figure 40 nicely shows 
that about half of patients with risk of RRP >=50% progressed with 20 or more SHS units during 5 years 
in spite of intensive management targeting remission [24].  
 
FIG.40: Radiographic progression over 1 and 5 year based on predicted risk of progression. Modified 
from: Visser et al. Ann Rheum Dis;2010, 69(7):1333-7 [24]. 
None of the patient-subgroups randomized to initial therapy with corticosteroids or infliximab had a risk 
>=50% (see Section 4.1) and nearly all the patients highlighted in red are patients who started with 
mono-therapy. Progression with 20 or more on the SHS score is deterioration equivalent to at least 4 
completely destructed joints over 5 years which could have been avoided with intensive treatment 
based on predicted risk. 
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It is well established that radiographic damage has an important effect on long-term functionality [28-
31]. In the BeSt study patients with RRP had worse functional ability over a course of 8 years compared 
to those who did not have RRP; Figure 41 [32]. The tables of Section 1.5 highlight the financial impact of 
these HAQ score findings. 
 
FIG.41: Mean HAQ in patients stratified by the occurrence of RRP from baseline to year 1. From: van den 
Broek et al. Ann Rheum Dis 2012; 71:1530–1533 [31]. 
These data confirm that joint damage over a 1-year time-frame as predicted outcome is a good 
surrogate of the consequences of disease activity as the driver of destruction and long-term disability.  
6.1.1.3. Predictive capacity, NPV, PPV and NNT 
The predictive capacity of the poor prognosis models developed from RCTs (Section 4.1 and 4.2) in 
clinical practice has been investigated in nice work from Belgium, France and the US [34-36]. Disease 
duration, disease activity, treatment, X-ray readers, proportion of RRP in the overall cohort and the 
number of patients between the RCTs and clinical practice cohorts might have contributed to the 
somewhat disappointing findings in 2 reports [32-34] even if adequate performance and good validity is 
shown in 1 report [35]. 
Risk of RRP remains at the lower end of the potential range between 0% and 100% (4% to 47% in the 
ASPIRE study, 1% to 78% in the BeSt study, 12% to 63% in the SWEFOT study) [18, 24, 26]. As such the 
negative predictive value (NPV) is better than the positive predictive value (PPV).  Cut-offs for NPV and 
PPV can be used to define thresholds for treatment decisions. Risk of RRP <20% in the BeSt study has 
high NPV and can be used as guidance in the clinic as threshold below which combination therapy 
should not be used to prevent damage to joints. The NNT to prevent one case of RRP using intensive 
compared with less intensive therapy can also help determine a threshold below which a patient should 
not receive intensive therapy. The negative predictive value of the NNT to prevent RRP from occurring of 
9.17 was 100% in the report from Belgium (sensitivity 100%, specificity 53.3%) [33].  
The more difficult argument to make is at which point the risk of RRP is high enough to start intensive 
therapy early. Only patient sub-groups who were treated with initial MTX in the ASPIRE study or initial 
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monotherapy in the Best study had a risk of RRP of 30% or more and 50% or more respectively (Section 
4.1 and Section 4.2) [18, 24]. The risk of RRP of patient sub-populations initially treated with 
combination therapy with either anti-TNFα or corticosteroids and DMARDs always remained below 
these percentages which can thus be envisioned as thresholds at which moment initial treatment with 
combination therapy would be recommended.  
Figure 42 could be an example of a model to guide treatment recommendations based on NNT of the 
ASPIRE model. The area in red corresponds with patient-subgroups in ASPIRE that have a predicted risk 
higher than 30% when treated with MTX alone and for which combination therapy may be considered 
[18]. The green area has patients in whom the NNT to prevent one case of RRP with monotherapy is 
lower than 9.17 at which time MTX can be recommended. The choice for the sub-populations 
represented in white is not clear and a trial and error strategy could here be default. 
 
FIG.42: hypothetical model based on the ASPIRE data. Area in red is where initial intensive therapy is 
recommended, area in green is where initial monotherapy with MTX is advisable. 
Even if the predicted capacity is modest at best, the important question is whether such models are an 
improvement over what is done in practice and whether advocating their use would have an 
incremental benefit over current treatment recommendations to help reduce progression of 
radiographic damage in the long run.  
A collaborative group has been set up with the aim of creating one ‘final’ poor prognosis model. And this 
resulting model will, without a doubt, still have its weaknesses as also the models for CVD and OP have 
their shortcomings even if they are more widely used than the one for RRP. Clinicians should be aware 
of the strengths and weakness of the information they use for decisions. 
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6.1.2. Response to 'Feasibility of tailored treatment based on risk 
stratification in patients with early rheumatoid arthritis'. 
Markusse et al. recently investigated whether RA patient-subgroups formed according to the presence 
of poor prognostic factors respond differently to initial monotherapy or combination therapy [36]. Since 
both subgroups experienced a better response to initial combination therapy, the authors concluded 
that patient tailored treatment based on prognosis as suggested by the EULAR recommendations  [37] is 
currently not feasible.  
As a general remark, the authors should be reminded that the EULAR recommendations primarily 
suggest combination of MTX with low dose glucocorticoids as its efficacy is not surpassed by biologicals 
and it prevents overtreatment in 20-25% of patients [60]; delaying TNF-inhibitor initiation by 6 months 
does not affect outcomes [61]. Moreover, the definitions of poor prognosis (PP) used by Markusse 
contrast with the stratification suggested by EULAR which, as this paper’s supplementary files highlight, 
influences outcomes [37]. We therefore recommend that its readers look at the supplementary 
information before drawing conclusions.   
Markusse proposes presence of 3 of 4 characteristics as definition of PP (erosions, RF/ACPA 
combination, SJC, elevated DAS). In contrast, the definition of PP established by Visser in the same trial 
population (sic!) uses a different approach, namely CRP, erosion-score and RF/ACPA-combination to 
determine who had >50% chance of rapid radiographic progression (RRP; ≥5 SHS units/year) [24]. 
Median SHS progression between initial combination and initial monotherapy in PP patients differed 
only 1.5 SHS units in Markusse’s model, but 3.5 units in Visser’s. Of initial monotherapy patients, 64% 
and 26%, respectively, had RRP whereas this was only 12% and 10% for initial combination therapy by 
these models. This highlights that the definition of PP used by Visser (provided only as supplement) in 
line with other work [18] is much better at identifying a PP population.  
 
In line, the odds of response to initial combination versus initial monotherapy in the PP versus non-PP 
populations were much higher when using Visser’s versus Markusse’s approach (OR of ACR20/50/70: 
10.0, 9.74, 9.33 versus 2.72, 5.39, 4.22, respectively).  Separation of the HAQ score between PP and non-
PP patients treated with initial combination therapy is only seen with Visser’s definition.  This highlights 
that definition of poor prognosis influences the effect of clinical outcomes.  
 
In accordance with the EULAR research agenda [37], we also believe it is important to study what effect 
patient stratification based on poor prognosis parameters has on clinical outcomes. Alas, we feel that 
Markusse’s study did not address the question appropriately and therefore does not provide a good 
answer. 
6.1.3. Predicting achievement of remission & low disease activity in RA 
Radiographic progression seen in practice is much less extensive than what it was a decade ago due to 
earlier diagnosis, earlier treatment and better use of DMARDs and biologics. Even if studies have 
suggested that there may be an uncoupling of persistence of elevated disease activity and progression 
of radiographic damage of the joints, a lag time between disease activity state and X-ray damage may be 
an explanation and the risk of major radiographic progression in the absence of measurable synovitis is 
very slim [39, 40]. Treatment of RA should be aimed at reaching a target of remission or low disease 
activity (LDA) in every patient [37]. As such, in addition to identifying who will have radiographic 
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damage, an equally relevant question is to identify who will achieve remission or LDA and what 
treatment would get a patient there. Assuming that this disease state will prevent radiographic 
progression as well, one could argue that identifying patients who achieve controlled disease state may 
be more relevant than identifying who will have joint damage. 
Work presented in Section 4.3 highlights how several characteristics that are associated with 
improvement are inversely associated with achievement of a controlled disease state. This observation 
makes the use of predictors for solid decision making (i.e. who to treat and who not) difficult.  
6.1.3.1. Predictors of remission 
Katchamart et al. nicely summarized the literature on predictors of remission in rheumatoid arthritis 
therapy with DMARDs and biologics [41]. They report that the following characteristics predict remission 
with biologics: gender, age, smoking, comorbidities, disease activity at baseline, HAQ score at baseline, 
concomitant treatment, previous treatment, RF, serum RANKL, CRP and radiographic damage at 
baseline. Several of these characteristics were also predicting remission with DMARDs and the following 
predictors were retained only in DMARD studies: age at onset of disease, pain, time to treatment, ACPA, 
shared epitope and other genetic markers and serum IL-2. There was heterogeneity in the nature of the 
predictors, the effect size of the characteristics to predict, the moment at which remission was 
measured and the assessment instrument for measuring predictors and remission which affects the 
interpretation. Most predictors represent the disease severity of RA at baseline (e.g., disease activity, 
functional status, history of failed DMARDs, the presence of RF and anti-CCP, acute-phase reactant, or 
evidence of radiographic damage) and it can be concluded that these factors should be associated with 
RA outcome. Smoking as predictor seems to be associated with the presence and titer of ACPA and the 
authors note that these results need further confirmation [41]. Since this publication which appeared in 
2010, a number of additional studies report on these characteristics but also imaging with MRI, 
ultrasound and additional genetic markers are identified as predictors of remission [42-47].  
The same caveats that were noted for selection of predictors and categorization into a poor prediction 
model apply here. The described literature again indicates face-validity of the selected characteristics 
and supports use in our model. We report reasonable predictive capacity of a combination of these 
characteristics to predict remission and LDA within the GO-MORE dataset (Section 4.3). Even if the study 
was large and the clinical characteristics are similar to those of RA patients in clinical practice, validation 
in other datasets will be important to understand its reliability and relevance to clinical practice.  
The remission prediction model was created from an uncontrolled dataset and this did not allow us to 
introduce therapy as predictor of outcome. As such, NNT to achieve remission or LDA for different 
treatment options could not be compared. Figure 43 indicates that differences in patient selection lead 
to different outcome rates of both biologicals and comparator agents in clinical trials. It seems however 
that the outcomes of both the biologic treatment group and the comparator group (in this case MTX 
monotherapy) evolve in the same way so that the delta between biologic and MTX remains quite similar 
[48]. In patients who have had inadequate response to MTX, biological + MTX combination therapy had 
NNT to achieve ACR20, 50 and 70 that were 3.2, 4.2 and 7.7 respectively compared to MTX alone. The 
NNT to achieve DAS28 remission at 6 months was 9.1 [49]. It is not clear whether introduction of an 
alternative treatment possibility in the prediction model would help identify patient sub-populations in 
which a biologic would result in a greater proportion of patients in remission vs comparator than in 
another sub-population (resulting in NNT that increase from the top right to the left bottom of a model). 
Such information would help to better understand the context of a treatment choice especially from a 
societal and payer’s perspective. 
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FIG.43: ACR 20, 50 and 70 response rates in clinical trials which compare TNF inhibitors versus MTX 
monotherapy in DMARD naïve early RA patients. From: Smolen et al. Lancet 2007; 370: 1861–74 [48].  
The below Figures 44A-D highlight how selected characteristics that predict remission also relate to sick 
leave and disability [50].  
    
FIG.44A-D: association of gender, age, HAQ and DAS28 with sick leave in Sweden. From: Olofsson et al. 
Ann Rheum Dis. 2014; 73(5):845-53 [50]. 
This adds to the information already presented in Section 1.5 on the relationship of disease activity state 
with cost and supports the relevance of our model for health economical decision making. 
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6.1.3.2. Is disease activity state the relevant outcome to predict in RA? 
In Section 3.2 it is shown that disease activity state as measured by DAS28 best reflects the decision of a 
rheumatologist. Prevention of poor prognosis and of function deterioration can be assumed as long as 
disease activity is suppressed well enough [51-57]. Moderate disease activity is tolerated in clinical 
practice for patients with long-standing DMARD refractory disease [57]. LDA however leads to much 
better functional and structural outcomes than moderate or high disease activity and is a good 
alternative goal for most patients in clinical practice with long-standing disease that cannot attain 
remission [37, 54-55]. More stringent criteria than DAS28 remission allow achieving even better 
functional improvement and radiographic results [37, 51]. The definition of the disease activity state is 
also affecting the identified predictors [58].  
Our data show that the same set of well-selected predictors of outcomes of disease state predicts both 
LDA (not stringent) and remission (more stringent) as assessed with different outcome instruments 
(DAS28-ESR, SDAI, DAS28-CRP) (Section 4.3). It can be expected that a higher probability of achieving a 
disease state like DAS28 remission will increase the likelihood of achieving an even more stringent 
disease state like the Boolean ACR/EULAR remission definition (Figure 45).  
 
FIG.45: Proportion of patients meeting different criteria for disease state in the GO-MORE study. From 
Combe et al. Submitted manuscript. 
If the goal is to make value based decisions, it is important to repeat that especially health assessment 
and the disease activity state to a lesser extent are correlated with the mean annual cost of care in RA 
(see also table 5 of Section 1.5). When the information of the GO-MORE remission prediction model is 
directly linked to the data from recently published Canadian analyses on the cost of treatment for 
patients on biologics, it becomes clear that the disease state achieved will continue determine the cost 
of patients maintained on a biologic agent; see Figures 46 and 47.  
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FIG.46: Change in DAS28 score and corresponding estimate of the mean annual cost. 
 
FIG.47: Change in HAQ score and corresponding estimate of mean annual cost. 
The Canadian reports in which the vast majority of patients were treated with anti-TNF, show that the 
cost of care was highest in patients who switch from one to another biological agent due to absence of 
or insufficient response. This was followed nonbiologic DMARD control patients and nonbiologic DMARD 
patients going on to anti-TNF therapy. Patients on a biologic who are in sustained response had the 
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lowest total annual health care costs. The magnitude of the healthcare cost savings varied according to 
the remission definition but was significantly lower for patients in sustained remission versus those who 
were not in sustained remission The in-hospital and outpatient clinic costs were the drivers of the 
differences observed [58, 59]. 
As Figure 48 highlights, good disease activity state is not a guarantee for good health nor is good health 
always coinciding with control of the disease activity. One could thus argue that if HAQ has a better 
association with cost, HAQ rather than DAS28 remission should be the outcome to predict.  
 
FIG.48: Proportion of patients achieving different health states as measured by HAQ<0.5, DAS28 
remission (left figure) or LDA (right figure) or EQ-5D≥0.8 (left figure) or EQ-5D≥078 (right figure) in the 
GO-MORE study. From Combe B et al. Submitted manuscript. 
In Section 4.3 we highlighted that selected predictors of remission were also associated with HAQ state 
(i.e. age, gender, HAQ score at baseline and comorbidity). It has been described as well that disease 
state as measured by DAS28 is directly related to radiographic progression and that remission prevents 
progress of joint damage in nearly all patients. Remission or LDA is finally still the goal of therapy 
according to international guidelines which makes it the outcome of choice for a prediction model 
aimed to help making choices in practice.  
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6.1.4. Conclusion: Improving treatment recommendations of RA 
6.1.4.1. Better define poor prognosis and risk 
Risk stratification using high disease activity state and/or autoantibody positivity (rheumatoid factor 
and/or antibodies to citrullinated proteins) and/or the early presence of joint damage is advocated for 
the therapeutic approach to RA. The EULAR recommendations are very clear on which DMARD strategy 
is to be considered in case of ‘low risk of poor RA outcome’ or ‘patients with a high risk’. Yet ‘low risk’, 
‘high risk’ and ‘poor prognosis’ have not been defined nor is it very clear how the risk characteristics 
should be interpreted. Since the use of poor prognosis for therapeutic choice is highly valued by the 
EULAR Task Force, more specifics on the definition of risk (e.g. rapid radiographic progression) and a 
better definition of high and low risk based on the proportion that is at risk of developing may need to 
be provided to help clinicians. Even if the predictive capacity of the currently available models is 
moderate at best they may still be an improvement over what is currently recommended. 
6.1.4.2. Avoid conflict between characteristics of poor prognosis and good outcomes 
Predictors associated with achievement of a good disease state may be inversely associated with good 
improvements of disease activity and high disease activity as predictor of poor prognosis is inversely 
associated with achieving a good disease state. This highlights that patient stratification for treatment 
choices in RA is complex.  To avoid such conflicts, it seems essential to establish consensus on a goal of 
treatment which reflects superior value for patients, physicians and payers and use patient stratification 
to maximize the likelihood of achieving that goal. Clinical disease state determined with a disease 
activity instrument like DAS28 can be considered to directly affect both health state (measured with an 
instrument like HAQ or EQ-5D) and prognosis based on radiography even if there is no complete 
overlap. This which makes it an appropriate goal and recommendations should maximize the likelihood 
that it is achieved. Risk stratification for poor prognosis using high disease activity may preclude patients 
from attaining LDA or remission. If the goal for RA management continues to be disease state, one may 
wonder whether a characteristic like high disease activity for stratification for poor prognosis should 
thus not be omitted in future recommendations.   
6.1.4.3. Move towards a stratification that is aimed at achieving remission or LDA 
Radiographic progression seen in practice is much less than what it was a decade ago due to earlier 
diagnosis and intervention and better use of DMARDs and biologics. As the cause of radiographic 
progression is synovitis, it can be questioned whether poor prognosis should still be considered when 
making a treatment choice. As ‘Treatment [of RA] should be aimed at reaching a target of remission or 
low disease activity in every patient.’, the more relevant question may be what this patient who will 
achieve remission looks like and what treatment would be needed to get that patient into remission 
(thus preventing radiographic progression as well). The data that is introduced through our work 
highlights how patients can be selected for treatment based on a predicted likelihood of achieving the 
treatment goal. The relevance of treatment choices from the economical perspective are described and 
indicate how treating different patient sub-populations translates in different financial consequences for 
payers.  
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6.2. Relevance of outcome-based patient selection in Axial 
SpA 
In axial spondyloarthritis, the treatment options for axial disease are limited to NSAIDs and anti-TNFα 
agents [1].  Ankylosis progresses very slowly and there are a few reports that identify characteristics of 
progression [2-5]. One such report used the poor prognosis prediction methodology we used in RA to 
highlight the association of baseline syndesmophytes, acute-phase reactants, and smoking status with 
spinal radiographic progression over 2 years in patients with axial spondyloarthritis (Figure 49) [5]. The 
percentages in the figure represent patients with any spinal radiographic progression according to the 
modified Stoke Ankylosing Spondylitis Spine Score units over 2 years. 
 
  
FIG. 49: Poor prognosis model for ankylosis as stratified by predictors of ankylosis progression. From 
Poddubnyy D et al. Arthritis Rheum. 2012; 64(5):1388-98 [5]. 
 
At present there is no definite evidence that anti-TNFα treatment can halt progression of ankylosis in AS 
or Axial SpA [6-8]. Such evidence for NSAIDs exists but is limited to one report [9]. Unlike RA, treatment 
recommendations in this disease are therefore not guided by the use of characteristics that indicate 
poor prognosis [1, 10, 11]. As such, not progression of ankylosis (or poor prognosis) but good outcomes 
of therapy can be assumed to be the treatment goal. Stratification for poor prognosis is still important 
for patient selection in clinical studies that are aimed at proving the effect of therapy on progression of 
ankylosis. For use in clinical practice and for guidelines however, prediction of good outcomes to 
therapy is more relevant, particularly for selecting candidates for treatment with a biologic. 
6.2.1. Predicting response and disease state in AS and Axial SpA 
When the ASAS/EULAR recommendations for management of AS were issued, there were no good 
predictors for treatment response. Anti-TNFα was recommended for patients who fail NSAIDs and who 
have an elevated disease activity since most such patients were thought to benefit from it [10-13]. 
Experts who treat axial SpA patients with an anti-TNFα agent should consider clinical features (history 
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and examination) as well as either serum acute phase reactant levels or imaging results, such as 
radiographs demonstrating rapid progression or MRI scans indicating inflammation [12]. It is however 
not specified how these characteristics need to be considered by the clinicians.  
6.2.1.1. Outcome predictors 
Several reports on predictors of good clinical outcomes of AS have been published in the past years [13-
16]. Acute phase reactants, disease activity measured with BASDAI, functional status measured with 
BASFI, age, and HLA-B27 were identified as independent baseline predictors of clinical response. Some 
of these characteristics were repeatedly identified as independent baseline predictors of anti-TNFα 
treatment continuation as well. Single predictors have only moderate capacity to predict treatment 
response in the individual patient whereas models that allow to combine these predictors may lead to 
more robust prediction instruments to support physicians in decision making on TNFα blocking therapy 
in AS in daily clinical practice [16].  
In Section 4.3 we present a model that combines these clinical characteristics with enthesitis score to 
predict response to and disease state following either continued use of NSAIDs or anti-TNF alpha 
treatment as measured with different AS outcome instruments. The advantage of this way of 
representing the data is that it allows clinicians in practice to easily understand how they should 
‘consider clinical features (history and examination) as well as either serum acute phase reactant levels’ 
as is indicated in the ASAS/EULAR recommendations [12] when they make a decision to treat. The 
absence or low value of one of the characteristics does not mean that response will not occur since the 
presence or value of another characteristic also has an influence on outcome. 
Some of the same practical issues related to the selection of predictors that were described for the RA 
models apply in this AS prediction model as well. As an example, the predictors identified are not always 
retained in all studies; HLA-B27 highlighted in the supplementary table 8 of Section 4.3, was a predictor 
in 2 studies but was not retained as a predictor even though studied in 2 other studies. Enthesitis score 
was only investigated in our ASSERT/GO-RAISE analysis and this is thus the only study that could retain 
that variable. This may affect the confidence in these prediction models and may influence the extent 
with which they are used for decision making. As with RA however, also for Axial SpA we would argue 
that our model is more straightforward for clinicians to interpret than the advice currently provided by 
ASAS/EULAR and that its use in practice may help clinicians move from an intuitive choice towards an 
empirical, individualized selection of individuals for treatment based on more precise knowledge about 
therapeutic outcome. 
MRI results were not investigated as predictor for inclusion in the ASSERT/GO-RAISE model and MRI 
imaging may be particularly useful to evaluate whether patients who have low values for CRP need 
treatment. The presented model however indicates that MRI imaging, which is costly, time-consuming 
and rather cumbersome for patients may not be necessary for all AS patients which are evaluated for 
treatment. If the clinical characteristics indicate that the probability of response is really high, MRI 
information may not alter the likelihood of response to that extent that anti-TNFα treatment would 
suddenly no longer be started. Similarly, if the likelihood of response is very low based on clinical 
characteristics, it would be useful to know whether inflammation visible on MRI would significantly 
increase the likelihood that a patient would respond to therapy. As such, similar to the approach in 
osteoporosis where DEXA scanning to assess the bone mineral content is only recommended when the 
extra information it will provide is relevant for the decision to treat a patient – see Figure 50 [17], the 
color coding of future models predicting response to therapy may indicate when an MRI would not be 
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needed and when it would be helpful to determine whether anti TNF alpha therapy would be indicated 
in Axial SpA.  
 
FIG. 50: Prediction model in osteoporosis uses color coding relevant for treatment decisions. From: 
Compston J et al. Maturitas. 2013 Aug; 75(4):392-6 [12]. 
6.2.1.2. Response and disease state as outcome  
When comparing the response / remission prediction model in AS to the remission / LDA model in RA 
the advantage is that the selected predictors have the same direction of association with improvement 
as with disease state. AS patients who have a low likelihood of achieving a good disease state following 
anti-TNFα therapy will also have a low likelihood to improve whereas in RA, patients who had high 
likelihood to achieve remission had less improvement and vice-versa. Since the AS model thus clearly 
highlights patient sub-populations who will not benefit from treatment this may make this model more 
straightforward to include in treatment recommendations than the RA model.  
6.2.1.3. Selection of AS patients for treatment 
The BASDAI score has been used for patient selection in clinical studies and the ASAS/EULAR treatment 
recommendations reflect this [1, 12]. Section 4.5 shows that patient selection using elevated disease 
activity measured with BASDAI, makes approximately 50% of AS patients followed in rheumatology 
practice in 2005 eligible for treatment independent of the likelihood that this is the proportion of 
patients who will do well with therapy. The ASDAS instrument contains CRP which the BASDAI does not 
and this disease activity instrument thus allows selecting different profiles of Axial SpA patients. If the 
ASDAS would be used for patient selection in treatment recommendations, more patients would be 
eligible for treatment with anti-TNFα alpha which could have budget consequences in countries where 
such treatment is fully reimbursed. Should restrictions on patient eligibility be needed for budget 
reasons, the prediction analyses using NNT combined with elevated disease activity measured with 
ASDAS rather than BASDAI can help establish treatment eligibility based on good treatment outcome.  
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From a health care provider or payer perspective, currently an ‘all or nothing’ methodology is usually 
applied: either you get full reimbursement or no reimbursement at all. An alternative choice of selection 
criteria could result in a setting where ‘the payer’ reimburses in an equal total number of AS patients 
but with a better return due to better overall outcomes in the population treated. If patients would be 
selected based on ASDAS>=2.1 rather than BASDAI>=4, this would mean an increase of about 16% on 
the treatment eligible population (Section 4.5). If at the same time only patients who have a NNT to 
have BASDAI50 response <=5 would be selected (Section 4.4), about 16% of patients who have a 
relatively low likelihood of response compared to NSAIDs would not remain eligible. The return for 
society would be better with the same proportion of patients treated. Using the NNT also alternative 
approaches can be conceived. If resources are limited and payers would want to limit the budget spent 
on the treatment of AS, the expected outcome could determine the extent of co-pay for a patient; e.g. a 
patient who has a NNT to achieve ASDAS clinically important improvement <3 does not co-pay, a patient 
who has NNT of 3-5 has a 10% co-pay, a patient with NNT >5 has 50% co-pay. Indeed, if more than 5 
patients need to be treated with an anti-TNFα agent to have one more patient achieving a clinically 
important improvement than when they are treated with NSAIDs, one can consider this to be too 
limited return of value for money. 
It is probably also important to emphasize that not being eligible for anti-TNFα does not mean that 
patients will not be cared for. Our modeling highlights that the likelihood of good treatment outcomes 
(meeting response criteria as well as achieving good disease state) with anti-TNFα is low for certain 
patient subgroups. The NNTs indicate that in that case the difference in outcomes between anti-TNFα 
and continued NSAID treatment is not large which highlights that continuing NSAIDs may be the 
preferred management option at that moment. The results of the INFAST study presented in Section 5.1 
are highlighting the effect of increasing NSAID to the maximally recommended dose. Maximizing the 
potential of NSAIDs in this disease will always remain a valid patient management option [18, 19]. 
6.2.1.4. Selection of Axial SpA patients for treatment 
The prediction model originates from patient populations with established AS and it is not certain that it 
is useful for patients in whom ankylosis is not visible on conventional X-rays. Even if there seems to be 
similarity in the characteristics that predict outcomes of AS and non-radiographic Axial SpA [20, 21, 
Section 5.3], research to establish the value of the model in a non-radiographic population is needed. 
The objective of the new ASAS classification for Axial SpA described in Section 1.1 has as a goal to 
increase the sensitivity and specificity to diagnose the condition in an early phase of disease so that it 
can be treated early. In this context of early intervention, appropriate patient selection for therapy may 
be even more important than in the setting of more established disease when a key irreversible disease 
feature like ankylosis is present.  
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Conclusion: Improving treatment recommendations of Axial SpA 
6.2.1.5. Change the selection instrument for elevated disease activity 
The disease activity instrument currently recommended for patient selection in treatment 
recommendations is the BASDAI. The BASDAI score is however inversely correlated with good outcome 
of therapy. Since CRP is a component of the ASDAS and a predictor of anti-TNFα therapy outcome it 
better allows selecting patients who are likely to respond. In addition, ASDAS has a greater sensitivity 
than BASDAI to distinct response to placebo (or continued treatment with NSAIDs) from response to 
anti-TNFα treatment. This is another reason why ASDAS would be a better patient selection instrument 
than BASDAI to use in clinical practice.  
6.2.1.6. Include information on predictors of outcome as foundation for treatment 
Experts who treat axial SpA patients with an anti-TNFα agent should consider clinical features (history 
and examination) as well as either serum acute phase reactant levels or imaging results, such as 
radiographs demonstrating rapid progression or MRI scans indicating inflammation [12]. An expert 
should be a doctor, usually a rheumatologist, with expertise in inflammatory back pain and the use of 
biological agents. Experts should be locally defined. 
The literature support of the selected predictors indicates that there now is a large enough basis to use 
predictors to guide the choice of treatment with an anti-TNFα agent. The AS prediction model helps to 
establish how these characteristics can be used by clinicians and provides an evidence-based foundation 
for patient selection.  The current recommendation which is based largely on how an expert intuitively 
uses a number of clinical features can thus be restated as a more empiric recommendation which could 
read something like ‘The threshold of response-rate or remission-rate at which treatment should be 
initiated should be locally defined’ rather than that ‘Expert should be locally defined’. The local 
definition could be established based on AS outcome prediction. 
It is also clear that MRI has a much more prominent role in establishing a diagnosis than it previously 
did. Data highlights that inflammation identified by this imaging technique is associated with clinical 
outcomes and MRI thus has a role in Axial SpA patient selection for treatment as well. Further 
refinement of the prediction model may help establish when an MRI would be needed for anti-TNF 
alpha treatment initiation. 
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6.3. Anti-TNF Treatment discontinuation as treatment goal  
6.3.1. Rheumatoid Arthritis 
If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering a 
biological, especially if this treatment is combined with a DMARD. This is how recommendation 12 of the 
EULAR guidelines reads [1]. Tapering the anti-TNFα inhibitor dose in case of remission (i.e. DAS28<2.6) 
shows good results in early [2] and established RA [3, 4]. More profound and persistent responses 
increase the likelihood of successful discontinuation of a biological [7]. However, most established RA 
patients will flare upon withdrawal of a TNFα inhibitor [5-8] and when needed, reinstitution of a 
biological can be done without safety concerns and with an expectation that a good outcome can be 
achieved again [7, 9, 10]. RA has a fluctuating disease course in some patients and these findings 
indicate that treatment may be used during episodes when disease activity is present in such cases.  
Data from registries in the Nordic countries is highlighting that the population receiving a first anti-TNFα 
inhibitor has changed over time [11-13]. The disease activity of the population treated has gradually 
gone down from high activity at baseline early 2000 to moderate activity 10 years later. This coincides 
with a more than twofold increase in the proportion of patients achieving remission. In the patients 
most recently treated with a biologic, the treatment goal of LDA or remission is achieved in more than 
half of the population [11, 12]. The proportion of patients who achieve sustained remission however, 
remains lower than 20% [13]. Yet, several of the predictors of achievement of sustained remission (i.e. 
the calendar year of treatment start, low HAQ and DAS28 at the treatment start) indicate that the 
changing population characteristics should lead to an increase in the proportion of treated patients who 
will achieve sustained remission [13].  
It thus only seems a matter of time before more patients will start asking their clinician about the 
possibility of treatment discontinuation upon sustained disease control. Rapid induction of remission 
(i.e. at approximately 4 months versus later in the disease course) increases the likelihood of successful 
tapering and discontinuation of anti-TNFα therapy in practice [14]. The tool that we established which 
identifies patients who will go into remission fast can help install remission off biologic as a future 
treatment goal (Section 4.2). One can imagine that a proactive approach aiming for remission in 
selected patients may lead to a revisited treatment recommendation 12 (see first sentence of the first 
paragraph in this section) that starts with the word ‘When’ instead of ‘If’. Communicating this more 
ambitious treatment goal to patients may further increase the likelihood of achieving it. Since it is built 
on the premises of first establishing treatment success (i.e. remission as treatment goal is achieved) the 
financial consequences of treatment optimization through tapering and intermittent use may compete 
quite well with other cost containment efforts that the payers of these medicines introduce (e.g. 
mandatory price decreases, facilitating use of biosimilar agents).  
6.3.2. Axial Spondyloarthritis 
The ASAS/EULAR recommendations advise to assess patients with the measures included in the ASAS 
core set for daily practice and the BASDAI. A specific treatment goal for the treatment of Axial SpA is 
currently not established [15, 16]. Anti-TNFα treatment discontinuation in established AS has been tried 
without much success [17] and ASAS/EULAR has thus not included it either as a recommendation [16].  
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The INFLIXISPINE trial was the first study to show that patient selection for treatment with an anti-TNFα 
agent in early Axial SpA allowed achieving remission rates that were more than double than what could 
be achieved within AS [18, 19-22]. Whereas the data shown in Section 4.3 shows that patient selection 
allows to come to much higher remission rates in selected AS populations, information presented in 
Section 5.1 establishes that ASAS partial remission and ASDAS remission are attainable treatment goals 
for the early Axial SpA population and Section 5.3 helps understand which patient characteristics can 
further refine the selection for biologic use aiming at remission in Axial SpA.  
The lack of breadth in therapeutic options for Axial SpA and the absence of well-established thresholds 
for disease activity states may have been the reasons why treatment goals and treat-to-target approach 
is not established the way it is in RA. The ASDAS is a new instrument that allows to better distinct 
disease activity states in the Axial SpA population and provides a solid basis for a treatment goal. The 
still limited number of medicines that have proven effects on axial disease remains a reason why the 
appetite to run through the options fast in pursuit of remission may still not be there. Yet, as Axial SpA is 
known to have a more relapsing-remitting disease course [24], the possibility of discontinuation may be 
an argument to introduce therapy at an earlier stage. In addition, as several anti-TNFα agents are now 
approved in non-radiographic Axial SpA [23], the possibility to discontinue treatment in patients who 
have not had the disease for a long time and who go into remission rapidly will become a more common 
situation in clinical practices that may require guidance from groups like ASAS/EULAR. 
With the approval of anti-TNF agents in non-radiographic Axial SpA [23], manufacturers of these agents 
made post-approval commitments to perform randomized studies evaluating the possibility to 
discontinue / interrupt treatment. The European Medicines Agency (EMA) states that there is very 
limited knowledge on how long treatment should be continued in subjects in whom there is no disease 
activity following treatment, or the efficacy (and safety) of retreatment after disease flare. The market 
authorization holders are thus commended to conduct blinded withdrawal trials that will provide 
information on how long treatment should be continued in responders; what proportion of patients 
treated early in their disease achieve remission and also provide data on the efficacy and safety of re-
treatment in this setting.  Section 5.2 provides information of the first of such studies which highlights, 
similar to RA, that treatment discontinuation can be considered when remission is achieved in Axial SpA. 
The additional evidence that can be anticipated from the stop-studies in non-radiographic SpA with 
other anti-TNFα agents will likely allow for a significantly altered treatment strategy in which life-long 
treatment with anti-TNFα may be replaced by treatment episodes in case remission (as treatment goal) 
is not present. 
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6.3.3. Conclusion: Proactive approach towards biologic-free disease 
control  
The approach towards use of biologics in both the EULAR recommendations for treatment of RA and the 
ASAS/EULAR recommendations for treatment of Axial SpA are currently founded on the principle that 
cheaper non-biological agents first need to fail. This has been a very successful approach that 
significantly changed the profile of patients currently seen in rheumatology practice versus roughly 15 
years ago in Western countries. In order to continue to make progress in the coming decades, it is very 
likely that more patients will need to be treated with more expensive treatment options. Cost of therapy 
and health-care budget management of rheumatic diseases therefore becomes an even greater concern 
and challenge. Scientists continue to search for genetic and other markers that predict treatment 
response to further optimize treatment and avoid waste due to non-response. While this quest 
continues to go on, clinical models like the ones presented in this thesis should allow improving patient 
selection based on the anticipated outcomes.  
Treatment recommendations that strive for a proactive disease management approach which 
maximizes the likelihood to achieve a disease state that allows successful treatment tapering and 
discontinuation is a way to continue to improve the treatment of RA and Axial SpA patients while 
optimizing the treatment costs.  
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6.4. Models to select Rheumatoid Arthritis and Axial 
Spondyloarthritis patients for Anti-TNFα treatment:  is it 
time to introduce personalized medicine into clinical 
practice? 
 
 
6.4.1. Abstract  
Objectives 
Recommended use of biologic agents in clinical practice should be guided by presence of poor 
prognostic factors in Rheumatoid Arthritis (RA) but use of outcome-predictors is not yet recommended 
in Axial Spondyloarthritis (SpA). We review user-friendly models combining individual treatment 
outcome-predictors to increase the predictive capacity beyond that of single predictors and argument 
why their use can facilitate rational anti-TNF treatment decisions of RA and Axial SpA in clinical practice.  
Methods 
Published models that combine characteristics which are readily-available in the clinic and are 
associated with RA and Axial SpA outcomes are described. Literature-search was done with PubMed.Gov 
for RA and Axial SpA  separately and outcomes of interest were radiographic deterioration (poor 
prognosis), response and low disease activity / remission (good outcomes). 
  Results 
For RA, 8 models predicting poor prognosis and 4 predicting good treatment outcomes were identified. 
One model predicting poor prognosis and one predicting good outcomes were found for Axial SpA. 
Some heterogeneity in the retained predictors and differences in model build-up explain the nuances 
between the models. Models originating from randomized studies allow directly comparing outcomes of 
different therapeutic choices which increases its value and predictive capacity. Models containing 
characteristics that predict multiple outcomes and using characteristics that can be easily applied in 
practice may be preferred for clinical decision making.  
Conclusions  
We describe a number of practical models predicting outcomes of RA and Axial SpA and present 
arguments on how their use in RA and axial SpA treatment recommendations could result in better 
treatment outcomes.  
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6.4.2. Introduction  
The Rheumatoid arthritis (RA) and Axial Spondyloarthritis (SpA) classification criteria help 
rheumatologists to diagnose and treat patients at an early stage (1-3).  
According to the American treatment recommendations, use of an anti-TNF agent with or without MTX 
can be envisioned as first-line therapy in patients who have high disease activity and poor prognostic 
features (4). If Low Disease Activity (LDA) or remission is not achieved with Methotrexate (MTX) with or 
without corticosteroids, in the absence of poor prognostic factors, change to another Disease Modifying 
Anti-Rheumatic Drug (DMARD) strategy should be considered according to the European RA 
management-recommendations. When poor prognostic factors are present, biological agents can be 
added and biologicals should also be considered when alternative DMARD strategies fail (5).  
Experts who treat Axial SpA are recommended to use clinical features, serum acute phase reactant 
levels and imaging results when starting an anti-TNF agent. Patient-stratification based on predicted 
outcome is however not part of the Axial SpA treatment-recommendations and anti-TNF-agents are 
recommended for patients who fail Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and have elevated 
disease activity (6).  
Even if society has paid for the benefits of biologics in RA and Axial-SpA, increasing healthcare costs is an 
issue which better patient selection and personalized treatment may help solve. Efficient use of genetics 
and biomarkers identified with new technology as predictors may require redefining of the taxonomy of 
the diseases into distinct genetic, molecular and cellular groups. Additionally, since the associations of 
biomarkers with outcomes may differ with the outcomes they predict and a variety of outcome-
instruments determine the result of therapy, finding ‘universal’ predictors that have good Positive and 
Negative Predictive Values for all relevant outcomes may be an illusion. 
Several models that combine readily-available disease characteristics predicting treatment-outcomes 
have been published.  In this report we review models predicting poor prognosis and good results of RA 
and Axial SpA treatment. We present arguments how these tools can help clinicians in daily clinical 
practice to move from intuitive patient selection, usually based on severity, to more rational selection 
based on the knowledge of the anticipated treatment-outcome.  
6.4.3. Methods  
Literature-searches were done with PubMed.Gov using medical subject headings and other relevant 
keywords. Searches were done separately for RA and Axial SpA / Ankylosing Spondylitis (AS) and 
included randomized controlled clinical studies (RCT) and prospective studies on populations treated 
with approved anti-TNF agents, without restriction on sample size. Worsening of radiographic outcomes 
measured with conventional X-rays and scored with validated methods and improvement in clinical 
outcomes assessed with validated methods to measure response and disease state were used as 
definitions of poor prognosis and good treatment outcomes respectively.  
Most literature describe the process of identifying predictors and reports associations of genetic, 
biological, clinical and/or demographic characteristics with outcomes in terms of odds or risk ratios with 
95% confidence intervals, regression analyses or means of an independent variable, broken out per 
dependent variable categories. Whereas such data supports the validity of one or more predictors, its 
representation is not useful in the clinic. Description of predictors of anti-TNF therapy outcome has been 
done and was not within the scope of this report. Manuscripts identified through the literature-search 
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were reviewed with the aim to look for reports in which individual predictors were combined in practical 
models or tools that increase the predictive capacity beyond that of single predictors and that facilitates 
management decisions in clinical practice without the need for technology that is not readily available to 
clinicians.  
6.4.4. Results  
6.4.4.1. Prediction tools in Rheumatoid Arthritis  
6.4.4.1.1. Poor prognosis prediction in RA 
A very large body of evidence supports the association of a variety of clinical characteristics, imaging 
findings, genetic and biomarkers with progression of radiographic damage of the joints as measured by 
validated scoring methods.  This is nicely summarized by Smolen et al (7).  
Eight models originating from randomized controlled trials (RCTs) or non-interventional cohort studies 
were identified and are summarized in Table 47 (8-13). They predict the probability of poor prognosis 
using a combination of usually 3 to 4 of the following characteristics: Swollen Joint Count (SJC), C-
reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), Erosions on X-rays, Rheumatoid Factor 
(RF) with or without Anti-Citrullinated Protein Antigen (ACPA), smoking status and the disease activity 
score (DAS). In all models except 2, poor prognosis defined as deterioration with ≥5 units per year on the 
Modified van der Heijde Sharp X-ray scoring method was used as definition of rapid radiographic 
progression (RRP) or poor prognosis. All models identified patient sub-populations with worse 
radiographic prognosis than that observed in the total study-population. Models in which categorical 
(Models 1-3, 6, 7) rather than dichotomous variables (Model 4, 8) were used, allowed identifying 
patient-subpopulations with higher likelihood of poor prognosis. Models 1 to 7 have a similar ‘Matrix-
model’ approach but use different predictors. 
Model 1 and 2 are shown in Figures 51A and 51D and represent models predicting poor prognosis in 
(early) DMARD-naïve and DMARD refractory populations. Sub-populations with increasingly worse 
prognosis as defined by categorized predictors of radiographic progression are shown in green, yellow 
and red (9). Resulting from RCTs, Figures 51B and 51C illustrate how early combination therapy reduces 
the likelihood of progression in patient populations with different prognosis as stratified by their 
predictors compared to MTX alone.  
In Model 8, dichotomized risk characteristics allow counting the predictors rather than categorizing 
them. C-statistics of described models validated in different datasets are shown in the bottom of Table 
47 (8-17). 
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TABLE 47: Prediction models combining disease characteristics to predict radiographic progression in RA.  
The table gives information on the dataset that the model originates from, a brief description of the 
model and the range of predicted progression rates. The bottom of the table describes the performance 
of the model to predict radiographic progression in the original dataset and other datasets.  
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FIG.51: Prediction of Poor Prognosis in RA. The model presents 27 RA patient sub-populations 
characterized by the combination of 4 predictors of rapid radiographic progression:  Rheumatoid Factor 
(RF) level, Swollen Joint Count (SJC) and C-Reactive Protein (CRP, Fig 51A) or Erythrocyte Sedimentation 
Rate (ESR, Fig. 1D).  Figure 51A compares methotrexate (MTX)-naïve patients who either receive initial 
MTX or initial combination of MTX plus infliximab in the ASPIRE study. Figure 51D compares MTX-
refractory patients who either continue MTX or who receive infliximab in addition to MTX in the ATTRACT 
study. The percentages in Figure 51A and D represent the proportion and 95% Confidence Interval (95% 
CI) of patients within the sub-population that will progress with at least 5 Units of the Sharp van der 
Heijde Score (SHS) in one year (defined as rapid radiographic progression, RPP). Figures 51B and C 
represent cumulative probability plots of progression from baseline to 1 year in 3 patient-subpopulations 
representative for a high, medium or low risk population treated with MTX alone or infliximab + MTX. 
Figures 51A-C are modified from Ann Rheum Dis. 2010 Jul;69(7):1333-7).  
6.4.4.1.2. Prediction of Good Outcomes in RA  
As for radiographic progression, quite some evidence on predictors of response and remission exists and 
this is summarized by Katchamart et al (18). We found 4 models that present the information in a 
practical way (Table 2) (19-21). Variations of predictor-associations with the investigated outcomes is 
the main reason why predictors like DAS28 or its subcomponents, age, smoking habits and comorbidity 
were retained in the final model or not. Stratification using predictors of response or remission leads to 
a magnitude of 9 times the probability of favorable outcomes between sub-populations. C-statistics 
were only reported for one model and validation in independent datasets was not done for any study. 
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Table 48: Prediction models combining disease characteristics to predict response or remission in RA.  
The table gives information on the dataset that the model originates from, a brief description of the 
model and the range of predicted outcome rates.  
6.4.4.2. Prediction of poor prognosis and good outcomes in Axial SpA 
When recommendations were issued in 2010, there were no good predictors for treatment response 
and anti-TNFα was recommended for patients failing NSAIDs with elevated disease activity measured 
with the BASDAI instrument (5, 22-23). Several reports have since highlighted that acute phase 
reactants, disease activity, functional status, age and HLA-B27 have moderate capacity to predict 
outcomes of Axial SpA (24-28). Also enthesitis-score and MRI are recognized as response-predictor (28-
30). A regression-model combining elevated CRP, short disease duration and MRI-inflammation in the 
spine predicted BASDAI50 response better than the individual characteristics (29). The clinical 
characteristics were combined in prediction Model 13 shown in Table 49. The same set of predictors 
allows accurately predicting a variety of clinical response and disease states at 3 and 6 months. One of 
those outcomes, ASDAS major improvement is shown in Figure 52 (28).  The predictive capacity of these 
Axial SpA prediction models has not been validated in other datasets. 
We identified one report in which imaging results, inflammatory markers and smoking status were 
combined to predict ankylosis-progression (Model 14, Table 49) (31).  
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Table 49: Prediction models combining disease characteristics to predict response/remission and 
progression of Axial SpA.  The table gives information on the dataset that the model originates from, a 
brief description of the model and the range of predicted outcome rates. 
 
Figure 52: Prediction of Good Treatment Outcome in Axial SpA. The model presents 72 AS patient sub-
populations characterized by predictors of response and remission (C-Reactive Protein, Bath Ankylosing 
Spondylitis Functional Index, enthesitis score, age and Human Leucocyte Antigen-B27 Status) for 
biologic-naïve patients who either continue Non-Steroidal Anti-Inflammatory Drugs or who receive anti-
Tumor Necrosis Factor in the ASSERT and GO-RAISE studies. The percentages represent the proportion 
within each the sub-population that achieves the outcome of interest. Figure 2A shows the Ankylosing 
Spondylitis Disease Activity Score major improvement rates after 3 months per treatment group; color 
coding applies standard fill colors in Microsoft Excel from red to purple with each increase of 10% 
probability of response. Figure 2B shows the Numbers Needed to Treat (NNT) with anti-TNF to achieve 
ASDAS major improvement after 3 months when compared to patients receiving placebo. Color codes are 
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arbitrary: GREEN = NNT less than 5; YELLOW = NNT 5-12; RED = NNT>12. Figures are modified from Ann 
Rheum Dis. 2011 Jun;70(6):973-81. 
6.4.5. Discussion 
Disease characteristics associated with treatment outcomes can help individualize management of RA 
and Axial SpA, thereby optimizing treatment results, minimizing risks and maximizing cost-effectiveness. 
Whereas a large body of evidence supporting several predictors exists, there is only limited 
understanding and guidance on how they should be used in practice. This paper describes 14 published 
models that combine outcome-predictors to stratify the RA and Axial SpA population into sub-
populations with different outcomes. We believe that the use of such models in treatment-
recommendations, which currently do not go much farther than just listing predictors, may help 
introduce personalized medicine in daily rheumatology practice.  
6.4.5.1. Outcome prediction models 
Originating from RCTs, Models 1, 2, 3 and 13 allow directly comparing predicted prognosis of different 
therapeutic choices.  In a situation where the clinician tries to identify the appropriate treatment option 
(i.e. choosing MTX or MTX+anti-TNF as first-line therapy for RA, adding anti-TNF to NSAIDs in AS), this 
helps establishing for which patient incremental value of anti-TNF versus comparator can be expected. 
This presents an important advantage of these models versus those that were established in databases 
that had no control group due to which treatment options cannot be compared.  
Different datasets bring forth different predictors and models. The question thus becomes which model 
is the right one. Some differences exist because a variable was measured in the study or not. This mimics 
clinical practice where treatment decisions are made even if not all information is available (e.g. anti-
CCP not reimbursed and therefore not done). In other occasions the characteristic was explored but did 
not contribute to the model. The wealth of data supporting the predictors retained in these models and 
their mentioning in existing treatment-recommendations, establishes a high face-validity for their use in 
prediction tools aimed to help make choices in clinical practice. Initiatives to better understand the 
validity of these models for practice are ongoing for both diseases and are needed. 
Categorization of variables was done pragmatically allowing an even distribution of the study-dataset 
over the predictor-grids. Other and/or more cut-offs could have been chosen and would lead to slight 
differences in the reported outcome rates. Similarly, adding predictors to improve models would lead to 
altered percentages. As long as treatment-restrictions are not imposed based on these models, small 
changes in predicted outcome-rate would likely not have management consequences for an individual 
patient.   
The contribution of predictors to the predicted probability of an outcome differs and depends on the 
nature of the outcome. When predicting good treatment outcome, models containing characteristics 
that predict multiple outcomes (e.g. Model 13) may increase its relevance in the clinic.  
Finally, the nature of the predictor affects the usefulness of the model to clinical practice. Use of 
treatment history in Model 9 and 10 may be clinician-dependent and models that have only ‘biologic’ 
predictors may be preferred. Formal erosion scoring is not done in clinical practice which makes Model 3 
and 4 difficult to use. ‘Presence of erosions’ on the contrary can be assessed in practice and is more 
easily implemented in the clinic. 
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6.4.5.2. Outcome prediction in Rheumatoid Arthritis  
European and American RA management recommendations advise rheumatologists to use biologics in 
case of presence of one or more of 3 or one or more of 4 poor-prognostic factors respectively (4, 5). 
Patient-eligibility to studies like ASPIRE and BeSt was based on similar selection criteria (32, 33). Even if 
radiographic progression in the overall study population of these studies was substantial, prediction-
modeling still allowed identifying patient populations with a risk of radiographic progression that 
exceeded that of the total study population. This highlights that how predictors are used, influences the 
extent to which they achieve their purpose; i.e. identifying poor prognosis patients. 
The European recommendations use the terms ‘low & high risk’ and ‘poor prognosis’ which are however 
not defined (5). Most models presented in Table 47 used progression with >=5 SHS units in a year or 
Rapid Radiographic Progression (RRP) as definition of poor prognosis. It has been shown that patients 
predicted to have RPP have much more progression over 5 years (10) and those who progress with 5 
SHS units in a given year, have more functional limitations throughout 7 years following that year (14). It 
is furthermore a practical definition that can be explained to decision-makers and even patients (i.e. 
“Progression equivalent to one destructed joint per year”). A pragmatic definition for ‘high risk’ to 
recommend biologics could be based on the percentage above which prediction-models only predict 
occurrence of RRP in the monotherapy population but not the more intensive regimen. Models 1-3 are 
referenced in the European recommendations (5), but also Model 5-8 can be used to establish 
meaningful definitions for ‘high risk’. Model 4 is inferior to the others as it yields lower probabilities of 
poor prognosis (34). In Figure 51, the color coding for ‘high risk’ (red) was chosen so that any level for 
the lower 95% CI of the proportion with RRP when treated with MTX did not overlap with any upper 
95% CI of proportion with RRP occurring in MTX + anti-TNF treated patients. As such a risk of RRP of 20% 
with MTX can be considered ‘high risk’ and none of the patients treated with anti-TNF had a risk above 
this threshold. Epidemiological data used also to create Model 6 indicates that this would make about 
13% of patients newly diagnosed with RA to have a high risk of poor prognosis (i.e. 13% had a predicted 
risk equal to or larger than 20% to progress with >=5 SHS units in one year).  
The predictive capacity for these models in datasets that are not randomized is moderate only (15-17). It 
can thus be questioned whether it would be premature to introduce such models in recommendations. 
It should first be noted that therapy, which is one of the most important predictors, could not be studied 
as predictor due to the un-randomized nature of these validation studies. Omitting this predictor from a 
model will naturally result in reduced predictive power. It is also worth mentioning that, even though 
there is good evidence for the predictors of radiographic progression itself, the manner in which poor 
prognosis is introduced for treatment-choice in the most recent European and American treatment 
recommendations is also not backed by studies in which treatment choice stratified and directed by 
prognostic factors was compared to non-stratified and -directed treatment. Table 47 highlights how the 
prediction tools are superior to using the ‘1 of 3 predictors’ or ‘1 of 4 predictors’ approach that the 
current treatment recommendations advise to use for establishing poor prognosis. We would thus argue 
that these models represent a more solid basis for patient-stratification than what supports the current 
RA recommendations even if the value of patient-tailored treatment choices still needs to be 
established.  
Five-year X-ray results and health-state over 8 years stratified by RPP suggest that avoiding rapid 
progression matters (9, 14). One may still wonder whether it represents an unambiguous event that is 
important at the moment the treatment-decision is made. When patients expect pain-relief (35), 
clinicians aim for remission (4, 5) and payers want the most value at a minimum cost, it is not so obvious 
that prognosis is a decision-making element. Prevention of poor prognosis and of function-deterioration 
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can be assumed as long as disease activity is suppressed well enough (36-40). LDA leads to better 
functional and structural outcomes than moderate or high disease activity and is an alternative goal for 
patients with long-standing disease (38, 39). Arguably, identifying patients who achieve controlled 
disease state may thus be more relevant than identifying who will have joint damage.  
There is a wealth of evidence as well supporting readily available predictors of response and remission 
(18). Remission-predictors frequently have an inverse association with disease activity improvement and 
with poor prognosis (41-43).  Improvement of disease activity in patients with high disease activity is 
larger than improvement in patients with lower disease activity even if the likelihood of attaining LDA or 
remission is smaller in the former group. Rigorously applying selection-models using predictors of 
remission would thus exclude patients with high disease activity or poor prognosis from treatment. 
Selection of patients for Anti-TNF treatment using disease activity thresholds (e.g. DAS28>=5.1 in the 
United Kingdom) is at the same time predestined to lead to lower remission rates and also excludes 
patients from using therapy. To avoid this conflict, it seems essential to establish consensus on a goal of 
treatment which reflects superior value for patients, physicians and payers and use patient-stratification 
to maximize the likelihood of achieving that goal. Since patient-stratification in the RA recommendations 
aims for poor prognosis while the goal of treatment is remission (4, 5), this is currently not the case. 
Clinical disease state determined with a composite disease activity instrument directly affects both 
health state and radiographic prognosis. Rather than adjusting the treatment target based on the 
prognosis of a patient as has been proposed using model 8 (44), we believe that remission should 
remain the target and predicting who will achieve it (thus preventing radiographic progression as well) 
may be more important than prediction who will have poor prognosis. Tools that allow doing this in 
practice now exist (Table 48) but they were not created in RCTs and their value has not been validated 
in other cohorts. Validation of these tools will be important and further investigation to establish better 
RA treatment recommendations also needs a RCT that compares treatment choice stratified and 
directed by predictors of poor-prognosis versus treatment choice stratified and directed by predictors of 
achieving good disease state   
6.4.5.3. Outcome prediction in Axial Spondyloarthritis 
There is some evidence that NSAIDs suppress progression of ankylosis (45) but it is undecided whether 
anti-TNFα-treatment halts progression (46-49). The pathophysiological mechanism behind ankylosis is 
not well understood and we believe it is too early to use predictors of poor prognosis in treatment 
recommendations.  
Recently, TNF-blockers received European Commission approval for the indication of non-radiographic 
axial SpA and their use should be guided by presence of objective signs of inflammation by elevated CRP 
and/or MRI, based on better response rates in analyses of the CRP- and/or MRI-positive subgroups (50). 
Most predictors identified in patients with established AS are also predicting outcomes in non-
radiographic disease (50-54). Unlike RA, the direction of association of predictors with outcomes is the 
same for improvement and disease state in Axial SpA. This makes it more straightforward to include 
models predicting good outcomes in Axial SpA treatment recommendations.  
As these models also identify patient-subgroups that have a low likelihood of response, a major concern 
is that they would lead to exclusion of patients from treatment. Personalized medicine is about making 
such choices but does not mean that a patient will not be cared for. If the likelihood of response is low 
for anti-TNFα and continued NSAID treatment (resulting in high NNT), rheumatologists should consider 
reevaluating a patient 3 months later and may postpone a decision to treat with an anti-TNF agent. 
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Model 13 also provides argumentation that patient-subgroups that are currently excluded for anti-TNF 
per treatment recommendation should be eligible. Epidemiological data indicates that selection with 
ASDAS>=2.1 rather than BASDAI>=4 would increase the anti-TNFα treatment eligible population with 
about 15% (Figure 53A) (28). Figure 53B shows how the profile of patients selected with ASDAS 
corresponds with a population that is more prone to have good outcomes (55, 56). Approximately 16% 
of patients have a NNT to achieve ASDAS major improvement >12 (corresponding with the darkened 
area in Figure 3B and the red area in Figure 2B). If inclusion of patients with ASDAS>=2.1 is combined 
with exclusion of patients predicted to have NNT>12 on ASDAS major improvement, the return on 
investment in anti-TNF therapy for society would be better with a similar proportion of patients treated.   
 
FIG.3: Patient selection with ASDAS versus BASDAI: comparison of selected populations. The table 
highlights the proportion of patients with high disease activity that are selected with the ASDAS or 
BASDAI instrument from a representative sample of Axial SpA patients followed in rheumatology practice 
in Spain. The figure shows how the newly selected population that includes patients who have 
ASDAS>=2.1 rather than BASDAI>=4 is distributed over the predictor grid. Green triangles highlights sub-
populations that include patients who have ASDAS>=2.1 but BASDAI<4 and who would be selected if the 
selection criterion changes as such. Red triangles highlights sub-populations that include patients with 
ASDAS<2.1 but BASDAI>=4 and who are no longer selected if the selection criterion changes. The shaded 
area represents the area that corresponds with sub-populations that based on the prediction model have 
a NNT to achieve ASDAS major improvement >12. Modified from Reumatol Clin. 2014 Jul-Aug;10(4):204-
9. 
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In addition to clinical examination and CRP, MRI results may be of use to help decide whether initiating 
anti-TNF-alpha therapy is warranted (30, 57). We believe that the clinical prediction models provide the 
context based on which the appropriate place for MRI imaging to help with treatment choice can be 
made.  If clinical characteristics alone indicate that the likelihood of response is really high, MRI 
information may not alter the likelihood of response to that extent that anti-TNFα treatment would 
suddenly no longer be started. Similarly, if the likelihood of response is low based on clinical 
characteristics, MRI results may not dramatically alter this. In the intermediate situation however, MRI 
may help make better decisions. The color coding used in Figure 2B based on the NNTs for the ASDAS 
major improvement prediction model could hypothetically be associated with the following treatment 
recommendations for rheumatologists: RED = ‘Expected benefit of anti-TNF is low, consider alternative 
analgesics’; YELLOW = ‘Perform MRI. If positive consider anti-TNF, if negative consider alternative 
analgesics’; GREEN = ‘Expected benefit from anti-TNF is high’.  While researchers continue their search 
for predictors with new technologies, it should be avoided that this only leads to identifying expensive 
alternatives to what is measured already in practice. The research agenda should therefore continue to 
focus on how novel predictors are complementary to what is readily available.  
6.4.5.4. Conclusions 
Registry-data highlights that baseline disease activity of RA patients receiving an anti-TNF inhibitor has 
changed from high to moderate in the past 15 years (58-60). This coincides with a more than twofold 
increase in remission rates (58, 59) and rates of sustained remission (60) at which time clinicians can 
consider tapering the biological agent (5, 61). Remission rates in early Axial SpA are double of what is 
seen in AS (62-67). A first report of successful treatment-discontinuation in Axial SpA (68) and upcoming 
evidence from stop-studies commended by the European Medicines Agency (49) may help establish 
treatment tapering in this disease as well.  
The RA and Axial SpA recommendations have likely contributed to the significantly changed profile of 
patients currently seen in rheumatology practice versus roughly 15 years ago in Western countries. In 
order to continue to make progress in the coming decades, it is likely that more patients need treatment 
with costly treatments. Scientists continue to search for outcome-predictors to further optimize 
treatment and avoid waste due to non-response. While this continues, the clinical evidence available 
today should already allow improving patient-selection based on anticipated outcomes.  
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Summary 
Prediction models to guide treatment choice in Rheumatoid Arthritis 
Persistence of elevated disease activity and subsequent destruction of peripheral joints leads to 
functional impairment and disability in Rheumatoid Arthritis (RA), which may be irreversible. The 
therapeutic goal in RA is to bring a patient in remission or low disease activity. When that is not 
achieved with a first-line treatment strategy that includes non-biologic Disease Modifying Anti-
Rheumatic Drugs (DMARDs), rheumatologists are recommended to use anti-TNF agents, which have an 
acceptable safety profile and reduce disease activity, improve function and slow radiographic 
progression in DMARD-naïve and DMARD-refractory patients.  
In patients failing DMARDs, presence of poor prognostic factors like elevated serum level of Rheumatoid 
factor, joint-erosions visible on conventional X-rays and elevated disease activity should be weighed in 
when clinicians are considering to start anti-TNF therapy. In the EAP study presented in Chapter 3 of this 
thesis, we investigated which of these characteristics was associated with the decision to increase the 
dose of an anti-TNF agent. This showed that the Disease Activity Score based on a 28 tender and swollen 
joint count (DAS28) best discriminates the decision of the rheumatologist to take anti-TNF related 
decisions. Other poor prognostic factors did not contribute too much. This nicely highlights the 
usefulness of the DAS28 score in clinical practice. The results also show that higher disease activity 
increases the likelihood that a physician will increase the dose of an anti-TNF agent. This is not a big 
surprise; it may even be obvious that a physician would use more intensive treatment options in 
patients who are more severely ill. However, in a situation where resources are scarce, one may wonder 
which patients should be treated so that the return on value for the investment (e.g. reimbursement of 
a treatment by health authorities) is maximized. Since the most severe patients are not necessarily the 
ones that benefit most from the envisioned treatment, the question becomes whether physicians 
should reserve more effective and frequently more expensive treatment options for severe patients (for 
example measured with DAS28) or for patients who will have the best outcomes from that medicine? 
A number of studies were initiated with the aim to create user-friendly prediction models of treatment 
outcome that can be used in clinical practice to help rheumatologist understand for which patient 
initiation of anti-TNF therapy would be most valuable. These are included in Chapter 4. The data of 2 
randomized clinical trials (the ASPIRE and ATTRACT studies) was used to create a model that predicts the 
risk of poor prognosis of a potential treatment choice (e.g. a single DMARD or a DMARD in combination 
with an anti-TNF agent) in a specific RA patient. Poor prognosis was defined as progression equivalent to 
destruction of one joint per year or ‘rapid radiographic progression’ and 3 disease characteristics of RA 
(i.e. number of swollen joints, rheumatoid factor level and level of C-reactive protein [CRP]) are used to 
inform a rheumatologist of the likelihood that rapid radiographic progression will occur in a patient 
treated with one DMARD or with combination therapy. For example, patient A with high CRP, high 
swollen joint count and high rheumatoid factor level has a risk of 14% to have rapid radiographic 
progression when treated with combination therapy and 47% if treated with one DMARD; patient B with 
low values for the 3 characteristics has a risk of 4% to have rapid progression when treated with 
combination therapy but 7% risk when treated with one DMARD. For patient A, the incremental value of 
combining DMARD with an anti-TNF to avoid rapid progression (or poor prognosis) is much larger than 
for patient B. The rheumatologist may use this information as support to initiate combination therapy in 
 211  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
patient A but may decide not to use anti-TNF (yet) for the initial treatment strategy of patient B, as the 
relative added benefit may not outweigh the increased costs and/or potential risks. 
Remission is the ultimate goal of treatment in RA, and since it can be assumed that achievement of this 
disease state will also prevent rapid progression from occurring, a second model using data from the 
GO-MORE study was created to predict remission. In this research, 6 characteristics were predicting 
remission: low age, male gender, low number of tender or swollen joints, elevated markers of 
inflammation (CRP or ESR), low disability score and absence of comorbid diseases. Patients who have 
presence of all these characteristics have a chance of 77% to achieve remission, whereas elderly, 
disabled females with comorbid disease, and high disease activity (i.e. high joint counts combined with 
high level of inflammatory markers) have only 4% chance to go in remission with an anti-TNF agent.   
   
Comparing the results of the poor prognosis model for rapid progression with the model predicting 
remission highlights a conflict in the European treatment recommendations for management of RA. 
Namely, that high disease activity predicts rapid radiographic progression or poor prognosis and that it is 
at the same time associated with a lower likelihood of achieving remission. Stratifying the RA population 
based on this characteristic of poor prognosis will thus reduce the likelihood of the selected population 
to achieve the treatment goal with anti-TNF. Suggestions are made in Chapter 6 on how the RA 
treatment recommendations can be refined to avoid this conflict. One way could be to remove high 
disease activity as selection criterion for poor prognosis. Alternatively, it can be considered to remove 
the requirement to stratify the population based on the risk of poor prognosis overall, and move 
towards patient stratification that is aimed at maximizing the likelihood of achieving remission. The 
remission prediction model may come in useful if that would be considered.  
Prediction models to guide treatment choice in Axial Spondyloarthritis 
A treatment goal has not been adopted in the management recommendations for Axial SpA and use of 
outcome-predictors to guide treatment choice is not recommended at this time either. Biological agents 
should be used as second-line agents in this disease when elevated disease activity persists in spite of 
repeated trial with Non-Steroidal Anti-Inflammatory drugs (NSAIDs).  
Rheumatologists who treat Axial SpA patients with anti-TNF agents are recommended to use clinical 
features, serum acute phase reactant levels and imaging results when making a decision to treat. The 
nature of the characteristics and how they should be used is however not specified. Presented in 
Chapter 3, the ASPECT study is one of the few studies that help understand what characteristics are 
really used in the clinic and highlights that disease severity characteristics such as high disease activity, 
worse functional capacity, elevated inflammatory markers, presence of extra-articular manifestations 
and advanced stage of damage visible on conventional X-rays are the main drivers behind initiation of an 
anti-TNF agent in Axial SpA.  
 
Based on the premises that the most severe patients are not necessarily the ones that will do best on 
therapy, we wanted to create a tool that can be used in the clinic to help clinicians understand which 
Axial SpA patients will have the best outcomes with anti-TNF treatment. As presented in Chapter 4, data 
of the ASSERT and GO-RAISE studies was used to show that elevated CRP, HLA-B27 genotype, lower age, 
less functional impairment and lower enthesitis score was associated with higher likelihood of response 
after 3 months and remission after 6 months of treatment. Patients with these characteristics treated 
with anti-TNF had a chance of as high as 93% to have response at 3 months and up to 55% had remission 
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at month 6. Chance of response to NSAIDs in similar patients was never higher than 42% and to 
remission never higher than 7%. Likelihood of response in old, HLA-B27 negative patients with normal 
values for CRP who report very poor function and have a very high enthesitis was 28% when treated 
with an anti-TNF agent and 1% when treated with NSAIDs.  
For the current recommendation to use clinical characteristics, acute phase reactants and imaging it is 
assumed that intuitively experts will use these characteristics in the appropriate way. Taking into 
account what a rheumatologist actually does in practice, we believe our model provides a better 
evidence basis allowing informed decision making in the clinic. Several published reports identified the 
same predictors we did which lends further support to make better use of anti-TNFα outcome-
predictors in treatment guidelines. Also presented in Chapter 4, a study of the characteristics of the 
patient population identified with our prediction tool, allows us to also advocate for a change of the 
disease activity instrument used for selection of Axial SpA patients eligible for anti-TNF treatment. The 
instrument that is advocated for use according to current treatment recommendations excludes a 
number of patients in whom a high likelihood of response and remission can be expected. A recently 
described and validated disease activity instrument would select these patients that are currently not 
elegible for treatment and for which good outcome of therapy can be expected. 
In RA, the practice of tapering or discontinuing an anti-TNF agent, once persistent disease activity 
control is achieved, is already part of treatment recommendations and helps control the cost of RA 
management. Early initiation of effective therapy is a key to success for this. For Axial SpA however, 
studies have shown that discontinuation of anti-TNF in long-standing disease leads to flaring of the 
disease activity. Patients who start an anti-TNF agent (very frequently at a young age) should thus 
continue this treatment for the rest of their life. Recently developed classification criteria of Axial SpA 
allow making an earlier diagnosis and treating the disease at an earlier stage. This new classification was 
used to select patients for treatment in the INFAST study presented in Chapter 5, which showed among 
the highest remission rates ever reported with anti-TNF; 62% patients treated with anti-TNF plus NSAID 
versus 35% treated with NSAID alone had remission after 6 months. When treatment with the anti-TNF 
agent was subsequently discontinued, the disease activity remained fairly controlled up to 6 months in 
the absence of anti-TNF therapy and nearly half of the patients remained in remission. Use of prediction 
models can help identify Axial SpA patients in which remission with anti-TNF and subsequent treatment 
discontinuation may be an attainable goal. In such patients, life-long treatment may not be needed.  
Conclusion 
In this thesis we show that rheumatologists will primarily select the most severe RA and Axial SpA 
patients for treatment with an anti-TNF agent. The prediction analyses we and other groups have done 
however, highlight that the most severe patients do not necessarily have the best anti-TNF treatment 
outcomes. User-friendly prediction models of RA and Axial SpA can assist rheumatologists to select 
patients for treatment with an anti-TNF agent in daily clinical practice based on good outcome of 
therapy. This may improve the outcomes of the treated population. Careful selection will also increase 
the proportion of patients that will achieve remission which allows to tape or discontinue the anti-TNF 
agent without flare of the disease. Aside from avoiding wastage of resources due to treatment of 
patients that turn out to be non-responders, these tools can thus also open the doors to tapering and/or 
discontinuing the anti-TNF agent and thus further reduce the cost of treatment for these diseases.  
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Samenvatting 
Predictiemodellen ter ondersteuning van de therapie-keuze in 
Reumatoide Atritis  
Aanhoudende verhoogde ziekteactiviteit en geassociëerde destructie van de perifere gewrichten leidt 
tot functionele beperkingen en handicap bij reumatoïde artritis (RA), die onomkeerbaar kunnen zijn. Het 
therapeutische doel is om RA patiënten in remissie of lage ziekteactiviteit te brengen. Als dit niet wordt 
bereikt met een eerste-lijnsbehandeling die niet-biologische disease-modifiërende anti-reumatische 
drugs (DMARDs) omvat, wordt reumatologen aangeraden om anti-TNF-middelen te gebruiken. Deze 
medicijnen hebben een aanvaardbaar veiligheidsprofiel, verminderen ziekte-activiteit, verbeteren de 
functie en verhinderen radiografische progressie bij DMARD-naïeve en DMARD-refractaire patiënten.   
Volgens de therapeutische richtlijnen dient voor patiënten bij wie DMARDs falen, de aanwezigheid van 
slechte prognostische factoren zoals aanwezigheid van reumafactor, gewrichtserosies zichtbaar op 
röntgenfoto's en een verhoogde ziekteactiviteit door de rheumatoloog nagegaan te worden vooraleer 
anti-TNF-therapie wordt gestart. In het EAP studie gepresenteerd in Hoofdstuk 3 van dit proefschrift 
onderzochten we welke van deze kenmerken werd geassociëerd met de beslissing om de dosis van een 
ati-TNF middel te verhogen. Dit toonde aan dat de Disease Activity Score waarbij 28 gewrichten worden 
geëvalueerd voor zwelling en pijn (DAS28) het best correleerde me de beslissing van de reumatoloog om 
een anti-TNF-gerelateerde beslissingen te nemen. Andere slechte prognostische factoren bleken minder 
belangrijk. Dit benadrukt enerzijds het nut van de DAS28 score in de klinische praktijk. De resultaten 
tonen anderzijds dat een hogere ziekteactiviteit de kans vergroot dat een arts de dosis van een anti-TNF-
middel zal verhogen. Dit is geen grote verrassing; het lijkt zelfs evident dat een arts intensievere 
behandelingsopties kiest voor patiënten met meer ernstig ziekte. In een situatie waarin middelen 
schaars zijn echter,  kan men zich afvragen welke patiënten moeten worden behandeld om de waarde 
van de investeringen (bijvoorbeeld de terugbetaling van een behandeling door de 
gezondheidsautoriteiten) te maximaliseren. Aangezien de meest ernstige patiënten niet 
noodzakelijkerwijs degenen zijn die de beste resultaten hebben van de beoogde behandeling, wordt de 
vraag of artsen doeltreffendere en vaak duurdere behandelingsopties best gebruiken in de meest 
ernstige patiënten (bijvoorbeeld gemeten met DAS28) of in patiënten voor wie de beste resultaten 
kunnen worden verwacht? 
Een aantal studies werden gestart met het doel gebruiksvriendelijke voorspellingsmodellen van 
therapieresultaat te maken die door reumatologen kunnen worden gebruikt om in te schatten voor 
welke patiënt start van anti-TNF therapie het meest waardevol is. Deze werden geincludeerd in 
Hoofdstuk 4. De data van 2 gerandomiseerde klinische trials (de ASPIRE en ATTRACT studies) werd 
gebruikt om een model te creëren dat de kans op een slechte prognose van de potentiële behandeling 
(bijvoorbeeld een DMARD of DMARD in combinatie met een anti-TNF-middel) voorspelt voor een 
specifieke RA patiënt. Slechte prognose werd gedefiniëerd als progressie gelijkwaardig aan vernietiging 
van één gewricht per jaar of ‘snelle radiografische progressie’. Drie ziektekenmerken van RA (het aantal 
gezwollen gewrichten, reumafactor niveau en het niveau van C-reactieve proteïne [CRP]) worden 
gebruikt om een reumatoloog te informeren over de kans op snelle radiografische progressie bij een 
patiënt behandeld met één DMARD versus combinatietherapie. Bijvoorbeeld, een patiënt met hoge CRP, 
veel gezwollen gewricht en hoge waarde voor reumafactor heeft een kans van 14% op snelle 
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radiografische progressie wanneer zij wordt behandeld met combinatietherapie en 47% wanneer zij 
wordt behandeld DMARD; patiënt B met lage waarden voor de drie kenmerken heeft een kans van 4% 
op snelle progressie wanneer behandeld met de combinatietherapie en 7% wanneer behandeld met één 
DMARD. De meerwaarde van combinatietherapie met DMARD én anti-TNF om snelle progressie (of 
slechte prognose) te vermijden is veel groter bij patiënt A. De reumatoloog kan deze informatie 
gebruiken als ondersteuning om combinatietherapie te initiëren bij patiënt A. Hij kan beslissen (nog) 
geen anti-TNF te gebruiken voor de eerstelijns-behandeling van patiënt B, vermits het relatieve voordeel 
mogelijks niet opweegt tegen de hogere kosten. 
Remissie is het uiteindelijke doel van de behandeling in RA, en het kan worden aangenomen dat het 
bereiken van remissie ook zal voorkomen dat er snelle radografische progressie optreedt. Met behulp 
van gegevens uit de GO-MORE studie werd daarom een tweede model gemaakt voor predictie van 
remissie. In dit onderzoek werden zes kenmerken weerhouden die remissie voorspellen: lage leeftijd, 
mannelijk geslacht, een laag aantal pijnlijke of gezwollen gewrichten, verhoogde acute fase reagentia 
(CRP of sedimentatie), betere score voor functie en de afwezigheid van comorbiede ziekten. Patiënten 
met deze eigenschappen hebben een kans van 77% om remissie te bereiken. Oudere vrouwen met 
comorbiede ziekten, een hoge ziekteactiviteit (dwz hoge gewrichten in combinatie met het hoge niveau 
van acute fase reagentia) en die minder goede scores voor functie hebben hebben slechts 4% kans om in 
remissie te gaan met een anti-TNF-middel. 
Vergelijking tussen de resultaten van het predictie model voor slechte prognose of snelle radiografische 
progressie met het model ter voorspelling van remissie wijst op een conflict in de Europese 
behandelingsaanbevelingen voor de behandeling van RA. Een hoge ziekteactiviteit voorspelt namelijk 
snelle radiografische progressie en is tevens geassociëerd met een lagere kans op het bereiken van een 
remissie. Stratificatie van de RA populatie op basis van deze eigenschap van slechte prognose zal dus de 
waarschijnlijkheid verminderen om in de geselecteerde populatie met anti-TNF behandeling remissie te 
bereiken. Dit proefschrift bevat in Hoofdstuk 6 suggesties om de aanbevelingen te verfijnen en dit 
conflict te vermijden. Eén manier zou kunnen zijn om een hoge ziekteactiviteit te verwijderen als 
selectiecriterium voor slechte prognose. Als alternatief kan het worden overwogen om de RA populatie 
niet langer op basis van het risico voor slechte prognose te stratifiëren maar de stratificatie te richten op 
het maximaliseren van de kans om remissie te bereiken. Het model voor voorspelling van remissie zou 
handig kunnen zijn om dit in de kliniek te implementeren. 
Predictiemodellen ter ondersteuning van de therapie-keuze in Axiale 
Spondyloartritis 
Een behandelingsdoel is nog niet gespecifieerd in de aanbevelingen voor management van axiale SpA en 
het gebruik van de therapieuitkomst-voorspellers ter ondersteuning van de behandelingskeuze wordt 
momenteel ook niet aangeraden. De richtlijn is aldus om biologische middelen voor deze aandoening te 
gebruiken in de tweede lijn, wanneer verhoogde ziekteactiviteit blijft bestaan ondanks herhaalde proef 
met niet-steroïdale anti-inflammatoire geneesmiddelen (NSAID's).  
Reumatologen die overwegen om anti-TNF-middelen bij axial SpA patiënten te starten wordt 
aanbevolen om klinische kenmerken, niveaus van acute fase reagentia en beeldvormingsresultaten in 
acht te nemen bij het nemen van een beslissing. De aard van de eigenschappen en hoe ze dienen te 
worden gebruikt wordt echter niet vermeld. De ASPECT studie gepresenteerd in Hoofdstuk 3 is een van 
de weinige studies die helpt begrijpen hoe deze kenmerken werkelijk worden gebruikt in de praktijk en 
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toont aan dat de ziekte-ernst (hoge ziekteactiviteit, erger functionele capaciteit, verhoogde 
inflammatoire markers), de aanwezigheid van extra-articulaire manifestaties en een gevorderd stadium 
van ankylose (aantoonbaar met conventioneel röntgenonderzoek) de belangrijkste drijfveren zijn tot het 
starten van een anti-TNF middel in axiale SpA. 
Op basis van de veronderstelling dat in de meest ernstige patiënten niet noodzakelijkerwijs de beste 
resultaten worden bereikt, wilden we een instrument maken dat reumatologen in de kliniek duiding 
geeft over welke axiale SpA patiënten de beste resultaten met anti-TNF behandeling hebben. Gegevens 
van de ATTRACT en GO-RAISE studies werden in Hoofdstuk 4 gebruikt en toonden dat verhoogde CRP, 
HLA-B27 genotype, lagere leeftijd, minder functionele beperkingen en lagere enthesitis score 
geassocieerd waren met een hogere kans op respons na 3 maanden en remissie na 6 maanden 
behandeling. In patiënten met deze kenmerken behandeld met anti-TNF was de kans op response tot 
93% en remissie werd gezien bij 55% van dergelijke patiënten. Kans op respons bij vergelijkbare 
patiënten behandeld met NSAID's was nooit hoger dan 42% en remissie nooit hoger dan 7%. De 
waarschijnlijkheid van respons in oudere, HLA-B27 negatieve patiënten met normale waarden voor CRP 
die zeer slecht functioneren en met zeer hoge enthesitisscores was 28% wanneer behandeld met een 
anti-TNF middel en 1% behandeld met NSAIDs.  
De huidige aanbeveling om klinische kenmerken, acute fase reagentia en beeldvorming te gebruiken 
gaat ervan uit dat deze karakteristieken intuitief op de juiste manier door de expert wordt gebruikt. We 
geloven dat ons voorspellingsmodel een beter basis (‘evidence basis’) is om een geïnformeerde 
beslissing te maken in de kliniek. Verschillende gepubliceerde rapporten hebben gelijkaardige 
associaties aangetoond van predictors met therapieuitkomst. Dit levert ondersteuning voor een 
gefundeerd gebruik van voorspellers van anti-TNF resultaat in behandelrichtlijnen. Een in deze thesis 
beschreven studie die de kenmerken van de patiëntenpopulatie vergelijkt op basis van voorpellers van 
goede therapie-uitkomst, laat ook toe te pleiten om het instrument ter bepaling van de ziekte-activiteit 
voor de selectie van Axial SpA-patiënten voor anti-TNF behandeling te veranderen. Het instrument dat 
volgens de huidige richtlijnen wordt aanbevolen sluit namelijk een aantal patiënten uit bij wie wel een 
hoge waarschijnlijkheid van de respons en remissie kan worden verwacht. Een meer recent beschreven 
en gevalideerd instrument voor meting van ziekteaktiviteit zou deze populatie die momenteel 
uitgesloten wordt wel selecteren en een goede therapie-uitkomst kan worden verwacht. Dit werk is ook 
ingesloten in Hoofstuk 4.  
In RA is de praktijk om anti-TNF therapie af te bouwen of te stoppen wanneer de ziekteactiviteit 
langdurig is gecontrolleerd al een deel van de aanbevelingen die helpt om de kosten van RA 
management onder controle te houden. Vroegtijdige behandeling is hierbij een van de sleutels tot 
success. Bij axiale SpA patienten met lange ziektegeschiedenis leidde stopzetten van anti-TNF 
behandeling tot nog toe altijd tot het opnieuw opflakkeren van de ziekte-activiteit. Axiale SpA patiënten 
bij wie (heel vaak op jonge leeftijd) een anti-TNF middel wordt opgestart, dienen dit dus voor de rest van 
hun leven te blijven nemen. Recent ontwikkelde classificatie-scriteria van axial SpA maken het mogelijk 
de behandeling van de ziekte in een eerder stadium aan te vatten. Deze nieuwe axiale SpA classificatie 
werd gebruikt voor de selectie van patiënten in de INFAST studie, beschreven in Hoofstuk 5. Hierin 
bereikten na 6 maanden 62% van de patiënten behandeld met anti-TNF remissie versus 35% van deze 
behandeld met NSAID. Wanneer de behandeling met het anti-TNF middel vervolgens werd beëindigd bij 
patiënten die in remissie waren, bleef ziekteactiviteit gecontroleerd gedurende 6 maanden en bijna de 
helft van de patiënten bleef in remissie zonder gebruik van anti-TNF. Het gebruik van 
voorspellingsmodellen kan helpen om axial SpA patiënten te indentificeren die in remissie zullen gaan. 
 217  
  
Outcome-Based Anti-TNF Treatment Decisions in RA & Axial SpA 
Dit zijn tevens de patiënten bij wie therapie-afbouw kan overwogen worden. Betere selectie van 
patiënten kan aldus levenslange behandeling onnodig maken. 
Conclusie 
In dit proefschrift tonen we dat de reumatoloog hoofdzakelijk de meest ernstige RA en axial SpA 
patiënten selecteert voor behandeling met een anti-TNF-middel. De analyses die wij en andere groepen 
hebben gedaan, benadrukken echter dat de meest ernstige patiënten niet per se de beste anti-TNF 
behandelingsresultaten zullen hebben. Gebruiksvriendelijke voorspellings-modellen van RA en axial SpA 
laten reumatologen in de dagelijkse klinische praktijk toe om patiënten voor behandeling met een anti-
TNF-middel te selecteren op basis van goede therapie-uitkomst. Dit zou de behandelingsuitkomsten van 
RA en axiale SpA verder kunnen doen verbeteren. Meer zorgvuldige selectie zal ook het aandeel van de 
patiënten die remissie bereiken doen toenemen, welke op zich anti-TNF therapie-afbouw en -stop 
zonder ziekteopflakkering mogelijk maakt in een aantal patiënten. Naast het verminderen van verspilling 
ten gevolge van non-respons, kan dit helpen om de behandelingskosten te drukken. 
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PBO   Placebo 
PGA   Patient Global Assessment 
Phys   Physician 
PhGADA  Physician Global Assessment of Disease Activity 
PPV   Positive Predictive Value 
PRO   Patient Reported Outcome 
Pt   Patient 
PtGADA  Patient Global Assessment of Disease Activity 
QoL   Quality of Life  
RA   Rheumatoid Arthritis 
RANKL Receptor activator of nuclear factor kappa-B ligand 
REGISPONSOR Prospective Epidemiological Cohort Study of Ankylosing Spondylitis in 
Rheumatologist Practice in Spain 
RCT   Randomized Controlled Trial 
ROC   Receiver Operating Characteristics Curve 
ROC-AUC  Area Under the Receiver Operating Characteristics Curve 
RRP   Rapid Radiographic Progression 
SD   Standard Deviation 
SDAI   Simplified Disease Activity Index 
SE   Standard Error 
SEM   Standard Error of the Mean 
SF-36   Short Form 36 quality of life assessment 
SHS   Sharp van Der Heijde Score 
SQRT   Variable normalized by taking the squared root 
SvH   Sharp van Der Heijde Score 
SI   Sacroiliitis 
SJC   Swollen Joint Count 
SJC66   Swollen Joint Count based on the 66 joint count 
SpA   Spondyloarthopathy 
SPSS   Software package for statistical analysis 
SSZ   Sulphasalzine 
SWEFOT Swedish Pharmacotherapy Study: Randomized Controlled Study comparing 
treatment with IFX + MTX  versus DMARD triple therapy in patients who do not 
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TEAE   Treatment-Emergent Adverse Events 
TJC   Tender Joint Count 
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TNF   Tumor Necrosis Factor 
UC   Ulcerative Colitis 
UK   United Kingdom 
ULN   Upper Limit of Normal 
US   United States 
USD   United States Dollars 
VAS   Visual Analogue Scale 
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